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Abstract
Nephropathic cystinosis is a rare autosomal recessive disease characterised
by raised lysosomal levels of cystine in the cells of almost all organs. It is
treated by regular oral and topical administration of the aminothiol,
cysteamine (Cystagon™), which possesses an offensive taste and smell.
The oral form frequently causes emesis, and should be administered every
six hours to be maximally effective. The topical eye drop treatment
requires hourly application to be most effective. In an attempt to reduce
this frequency and improve the treatment, the preparation and evaluation
of three alternative cysteamine containing formulations (suppositories,
long-acting ophthalmic gels and an inhaler) was undertaken.
The physiochemical properties, stability and release profiles of the active
(cysteamine or phe conjugate) from the formulations were evaluated. The
suppositories released cysteamine over a 20-40 minute period with a T75=
10-13 minutes. They were most stable at 4°C. The analysis of the
ophthalmic gels demonstrated that a weak gel network was formed at low
shear stress, the bioadhesion of the gel was increased with inclusion of a
cysteamine derivative (e.g. mean force of 0.067N compared to 0.107N with
compound included) and eight-hour, first order release from the gel was
observed. There was significant adhesion observed between the ophthalmic
gels and bovine corneal tissue. The pulmonary microspheres were spherical
and within the optimum size range for deep lung delivery (1-5 µm).
However, Andersen Cascade Impactor analysis revealed poor deep lung
penetration.
In conclusion, these results demonstrated that more development work was
required to produce a useful pulmonary formulation of cysteamine,
however, formulation of an ocular applicable gel or suppository was readily
5achievable. The suppository preparations may be particularly beneficial for
the treatment of infants, whilst the ophthalmic gel preparations could be
developed for daily or overnight use. With respect to pulmonary delivery,
microspheres in the optimum size range were produced. However, deep
lung targeting was prevented by static agglomeration, which requires
further investigation.
Keywords: Cystinosis, formulation, rectal, ophthalmic, pulmonary,
bioadhesive, gel, polymer, modified release.
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Till a' the seas gang dry, my dear,
And the rocks melt wi' the sun;
And I will luve thee still, my dear,
While the sands o' life shall run.
A red, red rose
Robert Burns
1794
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Preface
This thesis presents and discusses data produced during a pharmaceutics
research project. The project aimed to improve upon the current oral
capsule and eye drop treatments for Nephropathic Cystinosis. This disease,
which affects around 2000 people globally, is characterised by poor growth,
rickets and renal failure in children. If untreated, the disease will cause
death by age twelve. Currently, cystinosis is treated with cysteamine
bitartrate as an oral capsule and topical eye drop. This treatment, in
combination with renal transplantation can improve symptoms and delay
renal failure, allowing patients to conduct normal activities and live into
their 30s or 40s. However, the current treatment cysteamine bitartrate
produces side effects which can be prohibitive to compliance. These include
frequent nausea and vomiting, odiferous breath and sweat and a
challenging dosage regime. This project addressed these issues through
the formulation of three alternative dosage forms, which aimed to reduce or
eliminate these side effects.
Chapter one is an introduction to cystinosis, its symptoms, history and
treatments. Chapter two outlines the analytical methods used in this
project and the preformulation work conducted, including cystamine
derivitisation. Chapter three describes the rectal formulation work and the
subsequent analysis of the forms, including hardness testing, dissolution
and microscope analysis. Chapter four outlines the ophthalmic formulations
developed during the project. Analysis of these forms including dissolution,
rheology and long-term stability tests are described. Chapter five details
the pulmonary delivery work, and analysis of the powders including electron
microscope and impactor work is described. Chapter six is a discussion of
the conclusions of the project, with an exploration of areas for further work.
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For my beloved Stuart.
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Chapter 1 – General Introduction
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Chapter 1 – General Introduction
1.1 Nephropathic Cystinosis
Nephropathic Cystinosis is a rare genetic disease characterised primarily by
extremely high intracellular levels of the amino acid cystine, electrolyte
imbalance, proximal renal tubular dysfunction (Fanconi syndrome) and
general failure to thrive (1,2). The accumulation of cystine as crystals in
most tissues leads to the progressive impairment and dysfunction of
multiple organs, such as the pancreas, brain and thyroid (3). The incidence
of cystinosis is one in 100,000 – 200,000 live births, and affects
approximately 2000 patients in the world, although there are believed to be
many more undiagnosed cases (4). It is reported that some infants will die
due to dehydration and electrolyte imbalance from Fanconi syndrome
without diagnosis (5). In the USA alone there are 500-600 reported cases,
with between 20 and 40 born each year (5). In the US, 1.4% of children on
dialysis have cystinosis, while 2% of paediatric renal transplants are due to
the disease (3).
Cystinosis is categorised as a Lysosomal Storage Disorder (LSD), which is a
group of progressive disorders that share multi-organ failure as an
endpoint, and is notable as the first disease in this group to be treatable
(3,5). As with all LSDs, no signs of abnormality are displayed at birth; the
first symptoms of glomerular dysfunction begin to appear at around 6-12
months of age (2). Without treatment most children will reach end-stage
renal failure by age 9 (5), and grow at 50-60% of the expected rate. By
the age of eight an untreated child with cystinosis will be the height of a
healthy 4-year old (5), and, if non-compliant with treatment, may not reach
four feet in height. Patients with cystinosis have normal intelligence, but
possess extremely poor spatial awareness, and this can cause learning
difficulties in early school life as many tasks such as reading and
mathematics are based on this skill. However, many patients have finished
school and gone into higher education (6).
27
1.2 History of nephropathic cystinosis
One hundred years ago, the disease cystinosis was almost unknown. The
Swiss biochemist Abderhalden first reported the symptoms of cystinosis in a
patient, following an autopsy of a 21-month-old child in 1903. The child
was suspected of suffering from malnutrition, however the autopsy revealed
abnormally high levels of the amino acid cystine accumulated as crystals in
the liver and spleen (7). He recognised that the disease was genetic as five
members of the same family had been afflicted, and called it “Familial
Cystine Diathesis”. There were several similar cases reported around
Europe in the following decades (8,9,10). These cases all bore striking
similarities and showed several common components; rickets, glucosuria
and hypophosphatemia. However, it wasn’t until 1936 that Fanconi realised
there was a link between these cases and renamed the condition
“nephrotic-glucosuric dwarfism with hypophosphatemic rickets”.
Burki, working in 1941, first documented the ocular symptoms of cystinosis
(11). Both the posterior ophthalmic segments such as optic nerve and
retina, as well as anterior portions such as conjunctiva, iris, cilliary body
and cornea were found to accumulate cystine crystals. The crystals deposit
slowly in the cornea through infancy until they become apparent at around
16 months of age (12). Photophobia and, ultimately, blepharospasm affect
the quality of life such that the slightest glimmer of sunlight can be
debilitating (2).
In 1943 three researchers linked hyperaminoaciduria to the disease and, in
combination with an improved qualitative method for detection, this then
became a crucial starting point for future detection and research (8). At
first it was hypothesised that perhaps a low kidney threshold for amino
acids was the cause of high levels being found in the urine, despite normal
levels in the blood. However, in 1952 Bickel realised that the kidneys were
being progressively damaged, and therefore the problem had to lie
elsewhere. Bickel renamed the disease “Lignac-Fanconi’s Disease”, or even
“cystine storage disease with amino-aciduria”, after discovering that cystine
was being accumulated in lympho-glandular tissue and bone marrow (10).
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Three major breakthroughs occurred in cystinosis in the late 1960s. Kidney
transplants became more commonplace, immunosuppressant drugs were
developed and a more sensitive method for the detection of cystine was
developed (13). Schulman, Schneider and Patrick et al discovered that
cystine accumulated within the lysosomes of cells. They began to
investigate several compounds as potential cystinosis treatments. This lead
to the biggest breakthrough in cystinosis to date (14); It was discovered
that the aminothiol cysteamine depleted cystine from cells safely and
effectively (15).
Subsequent clinical trials of cysteamine in a healthy human volunteer
revealed that liver function tests, haematology and electrolyte balance tests
all remained within normal ranges, however an episode of grand mal
seizures in the volunteer lead to the premature cessation of the trial (15).
It was concluded that this was due to the cysteamine directly, as the patient
had been treated with 90 mg/kg cysteamine for 4 weeks. Once treatment
stopped, the seizures did not return. Although these results indicated a
rapid elimination of cystine from the cells, it was concluded that a larger
cohort was needed to fully test the new treatment (15). Cysteamine
therapy was later found to rapidly deplete leukocytes of cystine, with minor
side effects. Almost all of the ocular tissues are treated by the oral
administration of cysteamine apart from the cornea, which remains
unaffected by systemic treatment due to it’s avascular nature (12,16). This
meant a topical treatment was required for the corneal crystals alone. More
details of the ophthalmic symptoms are found in Chapter 4.
Lysosomes were recognised as playing a central role in this disease and, in
1982, Gahl et al and Jonas et al both characterised this further: cystine is
transported out of normal lysosomes by a specific carrier system which is
defective in cystinotic patients (17,18). However, other amino-acid specific
transporters remain intact. Gahl also provided a proof by showing that
heterozygotes for the disease take exactly twice as long to clear cystine
from lysosomes compared to healthy cells (17). Recently, Gahl has
continued this genetic work, and demonstrated that heterozygotes for the
disease carry exactly half the number of cystine carriers (5).
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The exact mechanism whereby cysteamine depletes lysosomes of cystine
was hypothesised by Thoene et al, and finally confirmed in 1985 by Gahl et
al; a cysteine and cysteine-cysteamine mixed disulphide is formed (19).
When administered cysteamine accumulates within the acidic environment
of the lysosome and forms an intracellular mixed disulphide (cysteine –
cysteamine) by a disulphide exchange reaction (figure 1). This molecule
can then exit the lysosome and enter the cytoplasm. As a footnote the
paper cites Pisoni et al’s work of 1985, describing how the mixed disulphide
molecule is structurally similar to Lysine and its corresponding transporter is
intact and recognises the molecule, allowing the passage into the cytoplasm
(20).
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Figure 1. The relationship between cysteine and cystine, and how
cysteamine removes cystine from the lysosome.
Cysteamine eye drops were first documented in 1987, when Gahl et al and
Dufier et al both reported initial findings on its novel use (16,21). To date
the corneal crystals are treated using this topical form of cysteamine eye
drops, which must be administered hourly in addition to the oral capsule to
achieve the maximum benefit.
In 1987 a study was conducted which investigated the treatment of 93
children with cysteamine. This aimed to elucidate the long term effects of
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the drug on the disease and the symptoms, with particular focus on renal
function (22). The findings were supportive of previous work in that
cysteamine was found to be very effective at depleting intracellular cystine.
However this study also revealed the possibility that diligent therapy, if
started early enough, could maintain glomerular function at the same level
or even prevent the need for renal transplantation completely (22). The
study also found an improvement in the growth profiles for the children.
This provided a real impetus to provide early diagnosis and treatment as
well as reiterating the importance of regular and compliant use. This study
concluded that research should continue to develop a more palatable form
of cysteamine, and makes reference to phosphocysteamine, a prodrug
phosphorothioester, where the thiol group was masked in order to reduce or
eliminate the smell and taste.
Phosphocysteamine was investigated for an alternative to cysteamine in
1988, when Gahl et al performed a study comparing the standard treatment
cysteamine with the phosphorothioester (23). The smell and taste was also
improved and the bioavailability maximised due to reduced protein binding.
Phosphocysteamine is a prodrug and therefore it must be de-
phosphorylated to be activated. It was hypothesised that this occurred
intracellularly, thereby directly targeting the stored cystine. It was
concluded that cysteamine and the prodrug, when taken orally, can be
regarded as equivalent and should be equally effective for treating
cystinosis.
Cystinosis patients are now living much longer because of improvements in
treatment, but also have to face the increased likelihood of more varied
complications. In 1987 Broyer et al studied 19 patients aged 15-26 years
with good graft survival following a kidney transplant and noted their extra-
renal complications that have only become apparent recently after an
improvement in treatment. They described blindness, hypothyroidism,
insulin-dependent diabetes, liver enlargement, hypersplenism, repeat gross
epistaxis and encephalopathy, and how these effected the patients (24).
This is an added burden to those with the disease and their carers and
families, increasing the number of medicines to be taken and time spent
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receiving treatment. In 1990 a study revealed the extent of swallowing
dysfunction experienced by cystinotic patients, a late complication
stemming from a build up of cystine crystals within the lysosomes of muscle
cells (25). In a study of 43 patients, 17-79% presented with abnormalities
in swallowing. There is a large variation in the percentage as the patients
were grouped by age and the complications tend to be age dependant.
Difficulties included weakness of the lips and tongue, dysphagia, dry mouth
and dysphonia and at least one patient has been recorded to choke and die
of aspiration. Apart from continuing cysteamine therapy to try to limit the
damage to muscles, the importance of “therapeutic manoeuvres” such as
thickening and pureeing food are emphasised in order to limit these deaths.
The importance of early initiation of cysteamine therapy was again reported
following two studies conducted in the early 1990s (1,26). The findings
showed that in order to prolong life and reduce or avoid complications,
therapy should continue after renal transplantation. These conclusions were
taken a step further when Gahl, Markello and Bernardini reported that
children treated adequately with cysteamine resembled healthy children
with respect to height and, remarkably, renal function (27). Predominantly
this occurs only when therapy is started early in life, as the kidneys go
through a rapid development stage during the first 3-4 years of
development. If the kidneys can be preserved of their function during this
time, then subsequent renal deterioration will be minimised or even
avoided. This of course will only be the case if therapy is administered
every 6 hours, every day, for life. These findings demonstrate that if that
regimen is adhered to, some children might avoid the need for renal
transplantation altogether. The paper concludes with the statement: “Since
irreversible kidney damage before diagnosis limits the ultimate benefit of
cysteamine therapy, early diagnosis and treatment are critical in this
disease”. These researchers all come to the same conclusion: diagnose
cystinosis quickly and treat effectively to ensure the best possible outcome.
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1.3 Genetics
Cystinosis is caused by a defect in the CTNS gene. This is a 12 exon gene
within 23 kb of DNA which codes for a 367-amino acid lysosomal transport
protein called Cystinosin. In approximately 56-76% of white western
patients, 12% of Italian patients and 18% of French Canadians, this defect
is caused by a 57 kb deletion removing the first 10 exons (28), and is
thought to have arisen in Germany in 500 A.D. (29) There are more than
100 known CTNS mutations (5,30). Other originating mutations, W138X
and G339R have been identified amongst French Canadians and Amish
Mennonites in Ontario (5). One in 150 – 200 people in the USA have a
CTNS mutation (5). There are also known genetic clusters in French
Canadians, and Brittany in France reports incidence of the disease at one in
26,000 live births (5). The gene responsible for the disease was discovered
in 1995 and mapped in 1998 to chromosome 17p13 by Antignac et al, and
named CTNS (figure 2) (5,6,31).
Figure 2. Location of chromosome 17p13 (CTNS), the gene deletion
responsible for cystinosis (32).
It was discovered that the locus was deleted in 23 out of 70 patients. This
knowledge gives patients the hope of better diagnosis and a genetic cure in
the future, although for now cysteamine is the best treatment available.
This knowledge also allowed scientists to explore the disease through
artificially created cystinotic mice in labs, probing deeper into the
mechanisms of cell apoptosis and ultimately widening the platform from
which a new treatment or cure will be sought. Prenatal diagnosis is now
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possible, as well as diagnosis of the 57 kb deletion (33). If a child is
diagnosed with cystinosis, subsequent pregnancies can be tested at 8-10
weeks of gestation with tissue, or at 14-16 weeks with amniotic fluid. The
placenta can also be tested at birth for cystine (5).
1.4 Cystinosis pathophysiology
The amino acid cystine should be transported into the cytoplasm of healthy
cells for processing. In cystinosis however, it accumulates inside the
lysosomes to 10-1000 times the level seen in healthy cells where it
crystallises, causing cell death leading to organ failure (34). This
crystallisation is widespread throughout the majority of the tissues and
organs in the body. Initially however, it is most apparent in the kidneys
and eyes as these organs are more sensitive to cystine accumulation (33).
Renal tubules show a characteristic ‘swan-neck’ deformity (figure 3), which
then progresses to interstitial nephritis and necrosis (5).
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Figure 3. Image of dissected nephrons from a cystinosis patient, which
display a marked narrowing at the start of the proximal section (the
characteristic ‘swan-neck’ deformity) (35).
If left untreated symptomatic deterioration leads to death by the second
decade of life (30). At diagnosis, 85% of children with cystinosis are
malnourished and classified as failure to thrive due to frequent emesis and
false satiety. This lack of appetite is caused by poor eating habits and large
liquid intake (5). Table 1 summarises the most frequently seen symptoms,
irrespective of age.
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Table 1. Summary of the most common symptoms of cystinosis (3).
Organ/system Common symptoms
Renal Polyurea
Polydipsea
Renal failure
Hepatic Hepatomegaly
Ocular Photophobia
Visual impairment
Poor visual spatial processing
Blindness
Musculo-skeletal Muscle wasting
Rickets
Swallowing difficulties
Inter-costal muscle weakness
Reproductive Hypogonadism
Azoospermia
Other Short stature
Diabetes
Hypothyroidism
Alzheimer’s disease
Epilepsy
1.5 Cystinosis sub-categories
Cystinosis presents as three different forms with varying levels of severity.
Infantile cystinosis is the most severe, progressive form comprising 95% of
cases. Patients with this form have two severe CTNS mutations (5).
Juvenile cystinosis (also known as intermediate or adolescent) is a milder
form, with diagnosis in the second or third decade of life. Here patients
carry one mild and one severe CTNS mutation (5). Although a milder form,
renal failure still occurs. Ocular cystinosis (also called adult or benign) only
presents as crystals in corneas and bone marrow, and does not progress to
renal failure (5). Patients with ocular cystinosis have one mild and one
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severe CTNS mutation, or two mild mutations. In total there are around 40
patients worldwide who suffer from the milder forms of cystinosis, and
therefore the focus of this project was on the more severe infantile form
(5).
1.6 Cysteamine
Cystinosis is treated by the systemic and topical administration of the
amino-thiol cysteamine (figure 4). Cysteamine, which is used
therapeutically in the bitartrate form as Cystagon™, has been used to great
effect since the 1970s and its introduction has completely altered the
prognosis of the disease. With early and diligent therapy, cystinosis
patients can prevent or delay most of the non-renal complications and
extend their lives into a fourth or fifth decade, live independently and even
have children (5,36). The renal damage is continuous however, and decline
is inevitable (5). The treatment is available as an oral capsule, and also as
a liquid eye drop.
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Figure 4. Cysteamine.
Once absorbed after administration, cysteamine enters the lysosomes of
cells. Due to the compound’s primary amine group and the acidic
environment of the lysosome, cysteamine attracts a positive charge and
concentrates there (5,37). Within the lysosome it reacts with the trapped
cystine, forming a lysine isostere: a mixed cysteine – cysteamine
disulphide, which, due to its structural and spatial similarity to the amino
acid lysine, can exit through the unaltered transport mechanism for lysine
(38) (Figure 1). This mimic can be transported out of lysosomes and into
the cytosol of the cell (39). The monomer cysteine can also exit via its
specific transporter into the cytoplasm. The clinical endpoint and target for
treatment is a blood cystine level of less than 1 nmol per milligram of
protein (40).
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Through strict and regular use this treatment has been reported to remove
up to 95% of the crystallised cystine from cells, and has been known to
slow or, in some cases, prevent the development of renal failure
(5,7,27,41). Many other extra renal symptoms show benefit from regular,
compliant use, such as growth retardation and hypothyroidism (36,42). The
likelihood of complications such as myopathy, neuropathy and diabetes
mellitus occurring are reduced the longer the patient takes cysteamine (36).
The life expectancy of patients who adhere to treatment has now extended
to 20, 30 and even 40 years of age, due to the advent of safer kidney
transplants and powerful immunosuppressant drugs (43). It is not a cure
however; the disease progresses continuously until death, caused in most
cases by sepsis or respiratory problems (5).
Continuation of cysteamine treatment post kidney transplant is vital, as
crystals continue to accumulate in other tissues and organs (3,36).
Although the transplanted kidney would be largely free of cystine crystals,
some do accumulate due to invasion by host macrophages (5). As a result
of life-lengthening improvements in treatment, the crystals now have more
time to accumulate and cause damage in multiple organ systems. Thus a
plethora of previously unproblematic complications are now major factors
on quality of life, such as generalised muscular wasting leading to
swallowing difficulties, corneal and retinal crystals, diabetes, cerebral
degeneration and cardiovascular disease (28,44,45). Once patients enter
their twenties, the central nervous system begins to show signs of
deterioration, and most patients display mental deterioration, pyramidal
signs and extreme loss of short-term visual memory (3).
1.7 Cystamine
Research on cystamine (figure 5), the disulphide form of cysteamine, has
found that it is almost as effective as cysteamine at depleting cystine from
lysosomes, in every tissue apart from the cornea (5,29,37). This is
contradictory to previous reports. Although it is known that cystamine is
reduced to cysteamine in vivo, this cannot happen in the corneal tissues.
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The reason for this is most likely to be extracellular crystals, which may
have become extracellular by extrusion or through cell death. These
crystals do not exist in an acidic environment like those inside lysosomes,
which attract cysteamine, and trap the molecule by addition of a positive
charge (37). Therefore cystamine remains oxidised in the cornea, and also
does not concentrate within a certain organelle.
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Figure 5. Cystamine.
Cystamine also has proven benefits in the treatment of neurodegenerative
diseases such as Parkinson’s, Alzheimer’s and Huntington’s Disease (HD)
(46-49). By converting to cysteamine in vivo, the anti-oxidative properties
have been shown to prolong the life of HD-transgenic mice (50).
1.8 Problems arising from cysteamine treatment
Cysteamine causes a range of side effects, largely due to the high dose
which is required. High blood levels of cysteamine must be achieved as
much of the drug is lost to first-pass metabolism (36). A large proportion of
the administered drug will also bind to circulating proteins and cannot be
absorbed (40,47). Neutral and acidic drugs bind to albumin which is basic,
while basic drugs bind to glycoproteins in the blood.
The cysteamine treatment regime for cystinosis is a lifelong commitment.
Patients should aim to take their oral dose at regular 6-hour intervals for
the treatment to work effectively. The plasma half-life of cysteamine is
1.88 hours (33), with blood levels peaking at 1h, and rapidly declining
thereafter (5). This requires a nightly oral dose, which affects the quality of
life of patients and families (36). The cysteamine eye drops have a very
short residence time and require application every hour whilst awake (51-
53). The drug also has a foul taste and smell akin to rotten eggs, which
regularly induces vomiting after ingestion (36). In approximately 10-15%
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of patients this can be severe enough to halt therapy (5). Cysteamine and
its malodorous metabolites are subsequently excreted in breath and sweat.
This can be a major barrier to compliance, especially when the child enters
education. Cysteamine also has the potential to cause potentially serious
stomach irritations, with 97% of patients reporting gastrointestinal
symptoms (54,55). In many patients this can be severe enough to
significantly limit therapy (56). It is caused by a combination of gastric acid
hypersecretion, reverse peristalsis and bile reflux. These factors, coupled
with delayed gastric emptying and reduced mucus and bicarbonate
production, causes gastric ulcers and nodules (42,57). All of these gastric
symptoms must be treated rigorously with proton pump inhibitors.
Compliance can therefore be a major barrier to effective treatment, leading
to significant morbidity.
1.9 Other barriers to effective treatment
Cystinosis patients receive other medication and electrolyte treatments in
addition to cysteamine therapy. Patients must also receive potassium,
bicarbonate, calcium, vitamin D and phosphate for treatment of rickets and
Fanconi syndrome. Carnitine is frequently deficient in patients with kidney
disease, and is required for muscle function. Sodium excretion is normally
only 2-3 mg/kg/day, but in cystinosis patients this can be as high as 13
mg/kg/day. As a consequence, patients crave salty foods, and should be
allowed free access to these (43). Saline supplements may also be
administered if necessary. Patients with cystinosis frequently receive
Indomethacin, which acts in two ways. By sensitising the kidney to
antidiuretic hormone and thereby lowering the glomerular filtration rate,
water losses can be reduced. Consequently, the urinary losses of salts is
reduced, relieving the polyurea and polydipsea, increasing the appetite,
energy and overall well-being (5). Although this therapy can reduce salt
excretion by 20-30%, these supplements have a strong potential for
causing gastric ulcers (56). Indomethacin and salt administration can be
enough to boost growth after diagnosis; however growth hormone is
frequently administered before patients enter puberty, in an attempt to
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achieve a normal adult height. Sex hormones can also improve height if
administered, in addition to producing secondary sexual characteristics.
Patients must also be encouraged to drink water continually.
Growth in infancy is dependent upon nutrition, and the maximum growth
velocity is seen between birth and 12 months. Parents should therefore be
counselled on diet, and advised to aim for 60% carbohydrates, 10% protein
and 30% lipids with a view to gaining weight (5,6). Anti-rejection
treatments are always given after transplantation, and these can introduce
new problems such as recurrent infections and Cushingoid effects (28).
Studies have shown that 50% of all 10-year old cystinosis patients are
hypothyroid (5).
Compliance with these additional treatments in combination with adequate
cysteamine therapy can lead to a normal growth rate (5). The maintenance
dose of cysteamine for children under the age of twelve or weighing less
than 50 kg is 60-90 mg/kg/day in divided doses, every 6 hours. The typical
adult dose is 500 mg every six hours but can be as much as 750 mg (4).
1.10 Economical considerations
A study was conducted in 1997 to examine the cost-effectiveness of
cysteamine as a treatment for cystinosis (58). As patients requiring
Cystagon™ are few in number, pharmaceutical companies can be reluctant
to pursue a drug which provides little return on their efforts. The American
study reported that cysteamine treated patients have a median renal
survival time of 15 years as opposed to 10 years without the treatment.
However, the levels of compliance with therapy were not taken into account
and so this should be seen as a conservative figure. Patients receiving
therapy before renal failure occurs were found to incur $234,000 of lifetime
costs, while those not receiving treatment were estimated at costing
$238,000 each. The report also produces figures that support the use of
cysteamine post transplant. Additional lifetime costs would be $27,000 at
low levels, and $17,256 at high levels of efficacy in delaying renal failure.
41
The authors of this study admit that these figures are conservative, and yet
still produce a convincing argument for the use of the drug.
1.11 Recent advances
Until recently, the mechanism by which cystine crystal accumulation
resulted in widespread apoptosis and organ failure was unclear. The cause
of such renal sensitivity was also unknown. It is now believed to be caused
by a synergistic failure of intracellular organelles, particularly involving
abnormal mitochondria and elevated Reactive Oxygen Species (ROS)
production, which gives rise to widespread apoptosis (39). Autophagy also
appears inhibited and this, coupled with a lack of ATP production, is thought
to cause particular damage to the kidneys (39). The damaged tissue is
then replaced with fibrous tissue (5).
More recently, it has been demonstrated that early diagnosis and initiation
of confluent therapy can salvage kidney function; for each month of
treatment the patient receives before the age of 2 years approximately 14
months of subsequent kidney function is retained (5), while some later
complications may also be avoided or delayed.
Cysteamine was found to be teratogenic and fetotoxic in 1998, and hence is
not recommended during pregnancy or nursing (33). This is thought to be
due to the generation of hydroxyl radicals (56). Patients hoping to conceive
are advised to suspend cysteamine therapy during gestation and nursing,
which carries risks to the patient.
A new side effect of oral cysteamine has recently been reported, and
appears to be linked with higher than recommended doses when
administered over time. Lesions on the elbows and knees similar to Ehlers-
Danlos syndrome have been reported, as well as bone lesions. This is seen
primarily in patients who are receiving three larger than recommended
doses per day, instead of the typical four times a day regime (59). This is
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frequently done in an attempt to achieve normality and stability in the
patient’s routine. Symptoms always resolve after dosage reduction.
Researchers working at King’s College in London recently made a
breakthrough in renal transplantation. If an organ to be transplanted is
washed out with an engineered drug solution before transplantation, graft
survival time can be doubled (60). Currently, less than half of all
transplanted kidneys are still functioning after ten years. The new drug
solution also maintains the kidney more effectively during transit from
donor to recipient, allowing these kidneys, which would have previously
been disregarded for transplant, to become useable thus increasing the
amount of potential donor organs available. This drug solution is hoped to
reach the market by 2015 (60). Cystinosis patients generally experience
better graft survival compared to primary kidney diseases; after ten years,
90% of transplants are still functioning (27,28).
1.12 Alternative routes
Cysteamine has been used intra-venously for long-term treatment of
cystinosis on only two occasions. Therapeutic levels were established at
6mg/kg every 8 hours, with a maximum of 40 mg/kg in 24 hours (56),
where the typical oral requirements are 60-90 mg/kg a day. It has been
reported that a single IV dose kept cystine levels at a therapeutically
acceptable level for 24 hours (15). This is probably due to the avoidance of
the first-pass effect. This has led researchers in San Diego to develop an
enteric-coated form. This is achieved by spray drying the drug with
vegetable fat. Early in 2007 Schneider and Dohil logged a patent for
“Enterically coated cysteamine, cystamine and derivatives thereof” (61).
This was achieved by coating commercially available cysteamine bitartrate
with the polymer Eudragit®, to allow dispersion only at pH 5.5-6 (36). In
2006 the University of San Diego published findings from research which
formed the foundation for the patent idea in which cysteamine was
administered to three different areas of the gastrointestinal tract via a naso-
enteric catheter (47,62). The small intestine was found to absorb the drug
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in the most effective manner, as well as producing the greatest cystine
depletion when compared to the stomach and colon. After the patent was
logged a one-year trial of the form was commenced.
Trials of this new formulation have demonstrated that the enteric-coated
form has equivalent efficacy to 6-hourly Cystagon™ when given twice a day
(36). In addition, a reduction in dose of 40% was achievable, allowing
relief from side effects. However, some patients experienced erratic cystine
levels, and the cause of this was unclear. A twice-daily administered
capsule at 60% of the current dose has demonstrated efficacy in
maintaining cystine levels at the target level during a small clinical study
involving five cystinosis patients, although two of the children still required
acid suppression therapy (36,63). One patient maintained target cystine
blood levels for 15 hours, while another maintained these levels for 24
hours. The capsules contain coated microbeads, allowing sprinkling onto
food and the avoidance of swallowing large capsules. Phase 3 clinical trials
began in July 2010 and are still ongoing, comparing the new formulation
against Cystagon™, but it is hoped that this new capsule will replace and
improve upon the current oral treatment (36).
Developing a form of cysteamine with a gastro resistant coating may be one
step towards a better side effect profile for the drug, and may relieve some
of the troublesome symptoms associated with it. The researchers believe
that a controlled release preparation targeted directly to the small intestine
will lessen the dosing frequency and thereby improve quality of life. This is
the latest finding in a line of gastric research at the University of California,
San Diego, and will hopefully produce results which are of relevance to this
research project (63).
Bone marrow cell transplantation is used in other LSDs such as Hurler
disease and adrenoleukodystrophy (ADL), to slow or prevent disease
progression, and has recently been investigated for cystinosis (3,64). Post-
transplant, the cystine content in the kidneys was reduced by 70%, with
improved renal function and normal serum urea and creatinine levels. The
transplanted cells were also found in other tissues, including eye, brain and
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liver, and in all organs the cystine content was reduced (3,64). Delivery of
the CTNS gene directly into organs has also been trialled but with limited
success (3). Cystinosin cannot be excreted by cells, and therefore, while
the local delivery of an enzyme can greatly improve other LSDs, cystinosis
requires the integration of cells with the functional protein (3).
Prodrugs have been used effectively for other diseases and are also being
investigated for cystinosis. Prodrugs are inactive upon administration and
become activated once metabolised by the body. Examples include 5-
Fluorouracil and Sulfasalazine. They are particularly effective with foul-
tasting drugs. Researchers at Robert Gordon University and Sunderland
University are developing and testing forms which mask the taste and
increase the potency of the current drug, with a potential reduction in
unpleasant side effects (52,65). In addition, these prodrugs have been
designed to release multiple cysteamine compounds once activated,
allowing lower doses to be administered. These experimental compounds
have proven non-toxic and efficient at depleting cystine (66-68).
1.13 Aims of the project
The current oral and ophthalmic treatment for cystinosis often meets with
resistance from patients. A combination of the drug’s putrid taste and
gastric side effects, as well as a demanding dosage regime results in
frequent non-compliance. A sulphurous body odour post-administration is
also very unpleasant. This is highlighted during infancy and puberty, when
compliance is particularly low (4). A study by the World Health
Organisation has shown that compliance with chronic medication as
prescribed is generally around 50%, regardless of the disease, the age of
the patient or the location in the world (69). Refusal of medication is a
serious barrier to effective treatment and avoidance of morbidity and
mortality. Studies have shown that strict compliance with cysteamine can
drastically improve long-term outcomes, and may delay or prevent the need
for renal transplantation (2,58). This has led to several alternative
therapies being investigated, including IV administration, stem cell and
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bone barrow replacements, pro-drugs and lipophilic derivatives of
cysteamine (42).
Formulation science may provide a way to improve the current medication,
significantly improving the lives of sufferers and those who care for them.
By reducing the taste and frequency of administration through alternative
dosage forms, ease of administration of cysteamine could be improved. The
main aim of this project was to develop alternative formulations of
cysteamine which could reduce or eliminate some of the side effects which
are evident using the current oral capsule and ophthalmic eye drop, thereby
improving the quality of life for those affected.
There were three areas of focus for the delivery of cysteamine; rectal,
ophthalmic and pulmonary. Administration of cysteamine via the rectum
should reduce or eliminate the first-pass metabolism by the liver, allowing a
smaller dose to be given daily. This will eliminate the gastric irritation
currently seen with the oral capsule, avoiding the taste, smell and
subsequently reducing the body odour. It will also be a useful dosage form
in paediatric treatment of cystinosis and when the oral route is
compromised.
By formulating cysteamine as a bioadhesive ophthalmic gel with controlled
drug release, it is hypothesised that administration frequency will be greatly
reduced, allowing once or twice-daily dosing instead of the current hourly
requirement. In addition, the gel will be pH neutral to eliminate the
stinging associated with the current eye drop, and the rheology will alter to
reflect the situation in the eye. This should allow pain-free blinking, without
the gel flowing out of the eye. These formulation changes should reduce
the burden of treatment and improve compliance, producing long-term
prevention of ophthalmic morbidity such as blindness.
Delivery of biodegradable polymer-coated cysteamine microspheres to the
respiratory tract will eliminate the foul taste and smell along with the gastric
symptoms experienced at present. A smaller dose may be permissible due
to the avoidance of the first-pass effect. It may also open the possibility of
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sustained release, allowing a reduction in the six-hourly recommended
dosage with the oral capsule.
The central objective was to improve upon the dosage forms in which
cysteamine is currently administered to infants and young children, and
eliminate or reduce the side effects commonly experienced with the oral
capsule and eye drop. It was hypothesised that these new formulations
might, in turn, lead to increased compliance through puberty and into
adulthood, and subsequently reduce morbidity and mortality in the latter
stages of the disease.
In addition, there may be the possibility of incorporating other drugs into
the ophthalmic gel base, allowing versatility for a range of eye diseases
which require chronic medication such as glaucoma and dry-eye syndrome.
As cysteamine also has a potential benefit in the treatment of Alzheimer’s
and Huntington’s diseases, there may also be a wider-reaching benefit to
those patients in the future.
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Chapter 2 – Analytical methods
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Chapter 2 – Analytical methods
2.1 Introduction
Cysteamine does not possess a UV-active chromophore. Therefore, to
enable UV detection, the molecule requires either derivitisation or to be
tagged by a UV-active agent. Two separate methods were used to detect
cysteamine in this project; conjugation with phenylalanine (derivitisation),
and the use of thiol detector DTNB (tagged). The use of DTNB was
preferable, as the chemical and physical properties of cysteamine were
unaltered.
2.2 Phenylalanine conjugate synthesis
Cysteamine and cystamine do not possess a chromophore and therefore are
UV transparent, thus monitoring their release from formulations is very
difficult. A phenylalanine conjugate (phe conjugate) was developed to
‘light-up’ the molecule, allowing quantitative determination of release of the
active from the dosage form via UV spectroscopy (Figure 6). Cystamine,
the disulphide of cysteamine was used in the synthesis. This was used to
avoid the use of protecting agents for the thiol group and concerns about its
oxidation.
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Figure 6. Phe conjugate
Cystamine dihydrochloride was reacted with two equivalents of 1,8-
diazabicycloundec-7-ene (DBU) in dichloromethane (DCM), converting the
cationic tertiary amino groups to primary amino groups. Two equivalents of
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Boc-L-phe N-hydroxysuccinimide ester (Boc-Phe-OSu) was added to the
stirred solution. The amino terminal is tBoc protected and the carboxy
terminal is activated as the OSu ester. Deprotection was achieved by
stirring in trifluoroacetic acid (TFA). The resultant gum-like solid was
triturated with ethanol, followed by drop wise addition of diethyl ether to
yield the final experimental compound (figure 7). More details can be found
in the experimental section, appendix I.
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Figure 7. Synthesis of the phe conjugate.
The compound was fully characterised by 1HNMR and Mass Spectroscopy.
The presence of a doublet centred at 3.1 ppm represented methylene
protons of the phenylalanine residue. There were also characteristic
aromatic signals centred around 7.35 ppm which corresponded to the
phenyl ring of the phenylalanine residue. The multiplets centred at 2.64
and 3.39 ppm represented the methylenes of the cystamine residue. All
remaining protons were fully assigned (appendix I). The electrospray mass
spectrum had a base peak at m/z 453.2 (100%), which corresponded to the
molecular mass of the phe conjugate.
The UV absorbance lambda max, the wavelength at which most light is
absorbed, was analysed in triplicate, and found to be at 256 nm for the phe
conjugate (figure 8). Using three sets of standards at known
51
concentrations, linear regressions were produced in triplicate and used to
quantify the release from formulations (figure 9).
Figure 8. A scan of UV absorbance highlighting the lambda max for phe
conjugate.
256nm
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Figure 9. Linear regression produced for the phe conjugate, with the
corresponding correlation coefficient.
2.3 Partition coefficient studies
The cornea is composed of three alternating hydrophilic and lipophilic
layers, thus any drug targeting the tissue has to be partially soluble in both.
Three different software applications were used, in triplicate, to calculate
the partition coefficient values for cysteamine and cystamine from the
chemical structure, including Chemdraw software (Chemsoft, Cambridge,
England). The calculated value was found to be -0.47 and -1.59,
respectively (70,71). A partition coefficient value of less than zero is
relatively hydrophilic, while a value of 10 is very hydrophobic (71). These
values indicate suitability for ophthalmic delivery, due to both compound’s
solubility in both oil and water phases.
Using a standard method, the partition coefficients of cysteamine and phe
conjugate were determined experimentally (72). Chloroform was used as
the oil layer instead of Octanol, as it has a much lower boiling point and is
easier to evaporate than Octanol (73). Both water and Simulated
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Lachrymal Fluid (SLF) buffer at pH 7.4 were used as the aqueous layer. The
buffer represented aqueous compartments within the body (74). Each test
was performed in triplicate (table 2). The partition coefficient of cysteamine
was found to be -0.32 for water and -0.47 when buffer was used, which
were both similar to the calculated value. This is an ideal value for
ophthalmic delivery due to the balance between lipophilicity and
hydrophilicity. The partition coefficient for phe conjugate was -1.89 with
water and -0.16 with buffer as the aqueous layer.
Table 2. Summary of the experimentally obtained partition coefficient
values (n = 3).
Drug (aqueous/organic phase)
Average partition
coefficient (± SD)
Cysteamine (water/chloroform) -0.32 (± 0.14)
Cysteamine (buffer/chloroform) -0.47 (± 0.12)
Phe conjugate (water/chloroform) -1.89 (± 0.25)
Phe conjugate (buffer/chloroform) -0.16 (± 0.11)
2.4 Ellman’s reagent
The lack of a chromophore in both cysteamine hydrochloride and
cysteamine bitartrate makes the use of Ellman’s reagent necessary. By
addition of this compound, the release of these drugs from formulations can
be measured. Ellman’s reagent, also known as 5,5'-dithiobis(2-
nitrobenzoate) (DTNB), is a disulphide which readily reacts with free thiols
to form a mixed disulphide (75). The colourless DTNB forms a mixed
disulphide compound with the thiol of interest, cysteamine in this case,
which in turn releases a molecule of thionitrobenzoic acid (TNB) (Figure 10).
Measurement of TNB can be used to assess the quantity of thiol present in a
sample as the stoichiometry is 1:1 (75). The yellow-coloured TNB molecule
has an absorption maximum at 440 nm (76,77).
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Figure 10. The mechanism of TNB release.
By equimolar addition of Ellman’s reagent to the dissolution media, samples
can be analysed in a UV spectrophotometer, and the results inserted into a
linear regression equation (figure 11).
Figure 11. A plot of concentration versus absorbance for a series of DTNB
solutions.
DTNB is sensitive to light, and therefore the reaction was undertaken in a
darkroom. The disulphide is susceptible to photolysis (being broken down
by light) when in solution, particularly when exposed to natural light (78).
The reactive TNB species is unaffected by light however (figure 10).
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Daylight is intense at around 325 nm, a wavelength at which Ellman’s
reagent is particularly sensitive, whereas fluorescent light is less intense at
this wavelength (78). All reactions using DTNB were performed either in a
darkroom devoid of any natural light and with minimal artificial light, or in
low light levels using aluminium foil to fully enclose reaction vessels.
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58
Chapter 3 – Rectal formulations
3.1 Introduction
Suppositories were initially investigated to improve upon the current oral
capsule treatment for cystinosis. Suppositories are frequently overlooked
as a drug delivery system, consisting of around 1% of all formulation types
in both the US and the UK (74,79). However, they can avoid many of the
problems encountered with the oral route of delivery. They may also be
beneficial for treating conditions in infancy, when capsules are difficult to
administer, or when the oral route is compromised.
3.1.1 Suppository history
The earliest recorded use of suppositories was in 1550 BC, which has been
documented in ancient Egyptian papyrus records (79). Local and systemic
conditions were treated, using base ingredients such as wax or lard, very
similar to those used currently. During the early 1700s, the liquid bases
cocoa butter and glycerin were used, introducing a need for suppository
moulds which were first manufactured in 1874. The moulds in general use
today for small batch manufacturing are almost identical to those first
pioneered (79). More recently, suppositories have been manufactured in
plastic moulds, which also functions as packaging (80). Examples of
commonly used suppositories include bisacodyl for constipation,
ondansetron for nausea and vomiting, and diclofenac for pain relief.
3.1.2 Rectal anatomy and first-pass effect
First pass metabolism can greatly reduce the bioavailability of an orally
administered drug, before it reaches the systemic circulation (81).
Enzymes present in the gut and liver metabolise the drug, significantly
reducing the concentration before the systemic system can be reached.
There are several ways to avoid the first pass effect, including the buccal
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and sublingual routes, however the malodorous and irritating nature of
cysteamine makes these routes unsuitable. The rectal route of
administration can largely avoid the phenomenon of first-pass effect. This
results from one of the three rectal veins draining into the hepatic system,
while the middle and lower veins bypass this and drain directly into the
systemic circulation (Figure 12). If the suppository is positioned correctly,
the drug should not be subjected to the first pass effect. This potentially
allows a smaller dose to be administered, thereby reducing or eliminating
some of the unpleasant side effects.
Figure 12. A diagram of the three rectal veins: 1. superior rectal vein, 2.
middle rectal vein, 3. inferior rectal vein (82).
In order to ensure accurate placing within the rectum, patients should be
counselled upon receiving the suppositories. The following instructions are
general for all suppositories:
1. Lie down on the left side, with the upper leg bent.
2. Once the packaging has been removed, moisten the suppository with
water, if required.
3. Gently push the suppository into the rectum a finger’s depth, at an
angle towards the belly button, so that it is directly in contact with
the rectal wall.
60
4. Remove the finger, and hold together the buttocks until the urge to
defecate ceases.
5. Try to retain the suppository for at least 20 minutes after insertion by
limiting mobility (79).
3.1.3 Second-generation suppositories
Suppositories have long been recognised for their advantages over the
more traditional oral route, and this is illustrated to some extent in the
paper by Hermann published in 1995 (83), which reported on the potential
for the sustained release of drugs from suppositories. This research also
demonstrated that suppositories can be extremely useful as a dosage form
and perhaps more beneficial than tablets in certain circumstances.
Unfortunately, due to a cultural reluctance to accept and regularly use these
dosage forms, particularly in Japan and certain Western cultures, potential
benefits are being shunned in favour of an easy-to-swallow tablet or capsule
(74,79). In the USA, less than 1% of drugs are manufactured as
suppositories, whereas in Germany suppositories may make up as much as
5% of the market (79). Rectal formulations are useful tools, particularly in
a case such as this where the taste and side effects renders the task of
swallowing a tablet very unpleasant and foreboding (84,85). This is
especially true if the suppository is modified from a solid to a semi-solid, to
make it even more comfortable and bring even greater advantages to the
patient. Such an improvement exists with in situ gelling forms.
3.1.4 In situ gelling suppositories
Research on the applications and benefits of in situ gelling suppositories
began in the last few years of the 20th Century. Various active compounds
have been used and tested, but the fundamental formulation technology is
consistent. During 1998 and 1999, work undertaken by Kim et al vastly
expanded knowledge of these forms, through tests on propranolol and
acetaminophen in situ gelling mucoadhesive suppositories (84,86-89). The
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research reports on the benefits of these forms when compared to
conventional suppositories; the avoidance of the first pass effect and a
reduction in discomfort (86). However, the work also highlights the
limitations of in situ gelling suppositories such as the possible spread to the
colon leading to drainage into the hepatic portal vein (86). These
suppositories can be modified from a liquid form to an in situ gelling form,
to improve their function further, through the inclusion of a bioadhesive
component (88). The suppository can then be administered as a liquid
which gels with the heat in the rectum, reducing spreading and maximising
bioavailability. This work produced a form which gelled at 37°C, was
retained in the rectum and stayed present for up to 6 hours (88). The in
situ gelling suppository also displayed an appropriate gel strength and
bioadhesive force, demonstrating the potential benefits for human use (87).
Kim et al then incorporated propranolol into the formulation, using the same
liquid suppository technology as before (89), although comparing different
mucoadhesive polymers such as HPC, PVP and sodium alginate. The
preparations which included sodium alginate and polycarbophil
demonstrated a 71% and 68% increase in bioavailability respectively when
compared to conventional suppositories. In addition, some important
findings with regard to rectal irritation by mucoadhesive polymers are
discussed; it was found that sodium alginate, when used alone, did not
irritate the rectal lining, although all others studied were found to increase
the proportion of severely damaged epithelium. This issue is a potential
concern as the form is in constant direct contact with the mucosal
membrane, and is also for a lifelong treatment regime. Kim et al made
strong arguments for the use of the novel systems, and the results further
enhanced their hypothesis (88).
3.1.5 Cysteamine suppositories
Van’t Hoff was the first to deliberate on the possibility of delivering
cysteamine as a rectal formulation for the treatment of cystinosis (90).
Eight patients with cystinosis were each given cysteamine rectally as a gel
in a study conducted at Guy’s Hospital in London in 1991. In three younger
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children the form was well tolerated, although it caused defecation 30
minutes after the dose was administered to three older children. None of
the children suffered diarrhoea, vomiting or rectal bleeding during the
study. There was also a dramatic decrease in the odiferous smell of thiol on
the patient’s breath. After the trial, however, it was reported that two out
of three patients stopped the rectal dose and recommenced the oral form,
one because of diarrhoea and the other experienced minor rectal bleeding.
Other problems were a reduced absorption compared to the oral route and
importantly, no significant effect on the mean cystine leukocyte
concentration. The authors concluded that this was caused by the expulsion
of the doses after 30 minutes (90). However, the parents felt that
compliance, including that for other medications and treatments had
improved, due to less vomiting along with greatly reduced smell and taste.
Van’t Hoff and his team concluded that rectal cysteamine was feasible and
safe (90).
3.1.6 Suppository bases
The ideal suppository base should be: solid at room temperature, rapidly
melting once inserted in the body, compatible with active components, non-
irritating and stable (80). There are several commonly used bases, four of
which were investigated in this project.
3.1.6.1 Polyethylene Glycols
Polyethylene Glycols (PEGs) were introduced in 1937, and are still widely
used today (79). They are water-soluble polymers of ethylene oxide and
water, and are available in a range of molecular weights, each having
corresponding melting points (figure 13). The numerical component of their
name refers to the average molecular weight of the polymer. Lower weight
PEGs such as PEG 100 are clear liquids at room temperature and higher
weights such as 8000 are white, waxy solids. PEGs of different molecular
weights can be blended together to produce a water-soluble suppository
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base with the required physical characteristics, and this makes PEGs a
popular choice for suppositories. When formulated as a suppository, the
PEG base is dissolved into the rectal fluid, allowing the active ingredient to
be released. Diffusion through the rectal epithelium and into the plasma
occurs across the concentration gradient (79).
H O O
n
H
Figure 13. Molecular structure of polyethylene glycol, where n = number of
repeating subunits, e.g. n = 34 would produce PEG 1500.
Local irritation is a potential side effect of chronic suppository use but this
can be reduced by moistening the form with water prior to insertion (79).
Hyperemia has also been reported with the chronic use of PEG-based
suppositories (91).
3.1.6.2 Witepsol
Witepsol is a fatty suppository base, composed of triglycerides of saturated
vegetable fatty acids (C12-C18), with varying proportions of
monoglycerides (79). There are many different grades available. The
grade used in this project is Witepsol W35, which has a melting range of
33.5 - 35.5°C. It is white and odourless. It is used in the manufacture of
Gyno-pevaryl 1® pessaries for the treatment of fungal infections, and
Anodesyn® suppositories for the treatment of haemorrhoids (74).
3.1.6.3 Gelucire
Gelucire is composed of glycerol esters of saturated C12 - C18 fatty acids.
Gelucire is available in a wide range identified by melting point and
hydrophilic-lipophilic balance (HLB). It has many uses depending on these
values, including bioavailability enhancer and controlled-release agent.
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Therefore the grade used in this project Gelucire 39/01 has a melting point
of 39°C and an HLB of 1, which is hydrophobic in nature (92). Gelucire is
sold under the trade name Suppocire® for the formulation of suppositories
(93).
3.1.6.4 Poloxamers
Poloxamers are versatile non-ionic block copolymers, composed of a central
poly(propylene oxide) backbone chain, with a poly(ethylene oxide) chain
down each side. They have been used as surfactants and as cell culture
media (94,95). The Poloxamer grades F68 and F127 were used in this
project; the ‘F’ denotes the form at room temperature (flakes), while the
first two digits, when multiplied by 100, gives the approximate molecular
weight of the poly(propylene oxide) component. The final number, when
multiplied by ten, gives the percentage of poly(ethylene oxide) content.
Poloxamers have been investigated as liquid suppository vehicles for
paracetamol and diclofenac sodium (96,97).
3.2 Materials and methods
3.2.1 Materials
Cysteamine hydrochloride and Polyethylene Glycol grades 400, 600, 1000,
1500, 3000, 4000, 6000, 8000 and 14000 were obtained from Sigma.
Witepsol W35 was obtained from Gattefosse (St-Priest, France). Gelucire
39/01 was purchased from Sasol GmbH (Witten, Germany). Poloxamers
F68 and F127 were purchased from BASF SE (Ludwigshafen, Germany).
DTNB was purchased from Molekula (Gillingham, UK). Tris buffer and
Tween 80 were purchased from Fisher. Phe conjugate was manufactured as
outlined in Chapter 2.
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3.2.2 Suppository manufacture
To allow for wastage, the weight of eight suppositories was calculated for a
six-form, nominal 1g mould. The calibration value was calculated for each
mould, and the displacement value was calculated for each drug. The bases
were weighed out accurately on a Mettler AE50 analytical balance, along
with the active (Ohio, USA). The bases were heated and blended together,
before addition of either cysteamine hydrochloride or phe conjugate. This
mix was then thoroughly stirred. The resultant liquid was poured into the
mould and allowed to cool. The tops were then trimmed with a spatula, and
the final forms removed from the mould, bottled and labelled (74). The
surfactant Tween 80 was used in some formulations to ensure the fatty
bases were sampled accurately from the dissolution media.
The suppository bases gelucire, witepsol, PEG and Poloxamer were
investigated; both lipophilic and hydrophilic bases and also blends were
examined for optimum characteristics. As 10 mg/kg was used for previous
rectal delivery of cysteamine hydrochloride, the concentrations 30 mg and
60 mg were used as nominal values (90). Until further tests are carried out
in vivo, the correct dose cannot be determined. These initial studies
demonstrated that the bases can tolerate varying drug loading. The
characteristics of all suppositories made are summarised in appendix II.
Suppository hardness was tested on an Erweka TBH28 hardness tester
(Heusenstamm, Germany). A result of at least 1.8 – 2 kg is considered
acceptable for suppositories (79). If the inert suppository blend produced
unsatisfactory results, no further testing was performed. The suppositories
with the best characteristics based on appearance, hardness and dissolution
tests were selected for further testing (Table 3). The final three
suppositories selected for further characterisation were blend 17 hereafter
designated “A” (40% PEG 8000, 60% PEG 600), blend 10 [“B”] (40% PEG
14000, 60% PEG 600) and blend 1 [“C”] (PEG 1500). The lipophilic bases
Gelucire and Witepsol demonstrated complete melting within two minutes,
increasing the risk of drug loss through expulsion and were therefore
eliminated from the study.
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Table 3. A summary of the batches made and their characteristics.
Suppository
batch
Composition
(%w/w)
Hardness
without
active
Hardness
including active
(cysteamine
HCl)
Appearance
17
‘A’
PEG 8000 40%
PEG 600 60%
19 N, 1.94 kg 9 N, 0.92 kg Uniform
white
10
‘B’
PEG 14000 40%
PEG 600 60%
17 N, 1.73 kg 12 N, 1.22 kg Uniform
white
1
‘C’
PEG 1500 100% 30 N, 3.06 kg 27 N, 2.75 kg Opaque
3.2.3 Dissolution studies
Dissolution tests were performed in a six-chambered Sotax CH-4123
dissolution tank (Basel, Switzerland). The dissolution test method followed
the standard BP test for suppositories: one suppository in a stainless-steel
basket, rotating at 100 rpm in a 1 L water bath at 37°C, sampling at 5
minute intervals for 1 hour (BP 2005 Edition). The dissolution medium was
altered depending on the active used. At present, there is no simulated
rectal fluid available for in vivo testing (98). However, rectal fluid is known
to possess a pH which is very close to neutral, around 7.2 - 7.4, as well as a
negligible buffer capacity. The release was measured by UV spectrometry,
and the samples were returned to the tank after analysis.
Suppositories containing the phe conjugate as the active were initially
tested. The absorbance for each sample was measured at 256 nm, the
corresponding λmax of the phe conjugate.  Deionised water was used as the
dissolution medium.
Cysteamine hydrochloride was then used as the active, as this is the drug
used in the treatment of cystinosis. It was established that the release of
cysteamine could be measured quantitatively via free sulphhydryl
concentration through the use of DTNB (figure 11). Studies were performed
which demonstrated that linearity was achievable, allowing accurate
concentrations to be calculated from an unknown sample. Absorbance was
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measured at 440nm. The dissolution medium was 90% v/v deionised water
and 10% v/v 1 M Tris buffer solution at pH8, as DTNB is water insoluble.
An equimolar weight of DTNB to cysteamine was dissolved in each
dissolution tank. For the reasons described in Chapter 2, the tank was
surrounded with aluminium foil, and the experiment undertaken in a room
void of natural light.
3.2.4 Hot-stage microscopy studies of suppositories and excipients
The active and inactive excipients were studied using a hot-stage
microscope, to examine the exact interaction of the suppository ingredients
and their crystalline characteristics. Samples were viewed through a Leica
DM 2500M microscope connected to a Leica DFC 420 camera (Leica
Microsystems GmbH, Germany) for analysis. The microscope was fitted
with 5x, 10x, 20x, 50x and 100x lenses.
Samples were placed within a hot stage, which could be heated to 100°C
and cooled to -50°C using liquid nitrogen (Linkam, Tadworth, UK). The
images were taken with cross-polarising filters in order to distinguish
between crystalline and non-crystalline structures. Thus, all dark areas are
unorganised, non-crystalline structures, and light areas are ordered
crystalline structures.
3.2.5 Cooling profile studies
The cooling profile of a suppository gives a unique thermal history, altering
crystal size and geometry. This affects how the suppository melts and
dissolves once administered. To determine the precise cooling profile of the
forms, an experiment was performed in which a thermal probe was
positioned in the suppository mould, and the molten suppository mixture
poured. This was performed in triplicate.
68
3.2.6 Active dispersion studies
Due to gravitational settling, there is a possibility that the tip might contain
more drug than the rest of the form (79). To ensure uniform drug loading,
three separate areas of the suppository were sampled and compared using
a DSC Q100 Differential Scanning Calorimeter from TA instruments
(Delaware, USA): the side, the middle and the tip (Figure 14). Samples of
uniformly less than 10 mg were placed in a standard aluminium pan for DSC
analysis, and the lid crimped on. The reference pan was empty. The DSC
was set to a heat-cool-heat cycle, where the sample was equilibrated at
0°C, then heated to 100°C at 10°C per minute, equilibrated at 100°C, then
cooled at 10°C per minute to 0°C, before being heated again to 100°C at
10°C per minute. This was undertaken in triplicate. This method of DSC
analysis was identical throughout the project.
Figure 14. Suppository sample points for uniform content studies.
3.2.7 Suppository mould temperature studies
The temperature of the suppository mould may affect the final form’s
characteristics, as differing rates of cooling affect the crystal size, producing
forms with different thermal histories. Suppositories were analysed using
DSC to ensure that the starting temperature of the mould did not affect the
final form. Six batches of suppository blend A, each containing 30 mg of
cysteamine hydrochloride were manufactured, with the mould set at a
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different temperature for each; 28.5, 30.5, 38, 46, 52 and 58°C. Room
temperature was taken as 21°C.
3.2.8 Stability tests
Stability studies were conducted over a 12-month period. Upon
manufacture (T0), the suppositories were stored under three different
environmental conditions in order to analyse their stability; a refrigerator
(4°C), a store containing a desiccator with saturated sodium hydrogen
sulphate solution at 20°C and 52% RH (99), and an Environmental Test
Chamber (ETC) (Copely, Nottingham, England) set at 30°C and 75%
Relative Humidity (74). These conditions were selected to analyse cold
storage, typical home storage and accelerated testing. As the suppositories
had low melting points, it was decided to reduce the commonly used
accelerated temperature from 37°C to 30°C. The temperature in each of the
storage areas was monitored daily. DSC and IR Spectroscopy analysis was
then performed every week for one month, every month for 3 months, and
subsequently every 3 months for 12 months, and compared with the results
from the suppositories at T0 (74). In combination with other techniques,
infrared (IR) spectroscopy was used to monitor changes over time in the
suppositories. IR Spectroscopy of the samples was performed using a
Nicolet IS10 IR from Thermo Scientific (Fisher, UK) with a Smart iTR
attachment and a diamond HATR (horizontal attenuated total reflectance).
It has been used previously with cysteamine (100). Infrared spectroscopy
of a compound produces a spectrum, the patterns and peaks of which relate
to the vibration of the compound’s different molecular bonds caused by the
electromagnetic energy (101). These bonds vibrate upon the absorption of
energy, producing a unique peak or set of peaks on the spectrum which can
therefore be used for identifying the compound. Thiol groups have an IR
sample frequency of between 2600 to 2550 cm-1, while disulphides are
found between 620 and 600 cm-1 (101). A sample of a cysteamine
hydrochloride suppository will only exhibit evidence of a disulphide bond if
oxidation has occurred, highlighting the instability of the formulation. A
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disulphide bond is present in the phe conjugate samples, allowing a
comparison to be made between the two actives.
3.3 Results and discussion
3.3.1 Dissolution studies
The following plot (figure 15) illustrates the release of the active from the
three PEG suppository bases over time. They were undertaken using the
phe conjugate (6) as the active, in PEG blends A, B and C.
Figure 15. Percentage release of the phe conjugate from PEG Blends A, B
and C over time (n = 7, 9 and 6 respectively).
It is evident that there is a large variation in release onset in forms A, B and
C. T100 for PEG blends A, B and C were observed at 20, 45 and 60 minutes
respectively (n = 5-9). PEG blend C released the phe conjugate more
slowly than PEG blends A and B, and this may be due to the greater
hardness of blend C (table 3).
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The fatty bases Witepsol and Gelucire produced a more homogenous blend
and melted instantly (data not shown), whereas the PEG bases produced a
more desirable dissolution profile and dissolved more slowly over time
(Table 4). It was decided to continue studies using PEG bases only, as they
produced a more prolonged release of 40-60 minutes compared to 2
minutes for witepsol and gelucire. This slower dissolution of the PEGs
allows the drug to be in contact with the rectum for longer where it is more
likely to be absorbed into the body, whereas a sudden melt over 2 minutes
increases the chances of drug loss through expulsion.
Table 4. Summary of phe conjugate release studies
Percentage
release
Time to release phe conjugate (minutes)
PEG blend A PEG blend B PEG blend C Gelucire Witepsol
10% 2 2 3 0.5 0.5
25% 5 5 9.5 1 1
50% 7 7.5 12.5 2 2
75% 10 10 17 2.5 2.5
100% 20 45 59 4.5 4.5
The following plot (figure 16) illustrates the release of the active from the
three suppository bases over time. Cysteamine hydrochloride was used as
the active (4), formulated into suppository bases PEG blends A, B and C.
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Figure 16. Percentage release of cysteamine hydrochloride from PEG
Blends A, B and C over time (n = 6, 5 and 5 respectively).
All three PEG blends containing cysteamine hydrochloride as the active
displayed more reproducible profiles than dissolution using the phe
conjugate. The PEG bases should dissolve at the same rate in every
reproduction of the test, therefore this may have been due to non-uniform
drug loading of the phe conjugate. The UV-tagged phe conjugate was
developed initially to monitor release from the forms, as there is a lack of
chromophore in cysteamine. Cysteamine hydrochloride is also a very
difficult drug to formulate. At room temperature it rapidly oxidises to the
disulphide form cystamine, which has been shown to deplete cells of cystine
but which is not licensed to do so (5,15,29). It is also extremely
hygroscopic and deliquescent, absorbing moisture from the air to become a
liquid. As UV-tagging the cystamine chemically alters the drug, a more
suitable method of monitoring release was found with DTNB. Thus, release
could be measured while the structural properties of the active remained
unaltered. Analysis continued using cysteamine hydrochloride as the active.
A summary of the release times are shown in table 5.
73
Table 5. Summary of cysteamine hydrochloride release studies
Percentage
release
Time to release cysteamine hydrochloride (minutes)
PEG blend A PEG blend B PEG blend C
10% 1.75 2.5 1.75
25% 5 6.5 4.5
50% 9 10 7
75% 13 15 9.5
100% 26 26 17
The data produced using Ellman’s reagent to detect the release of
cysteamine hydrochloride demonstrated excellent reproducibility (average
standard error of the mean for PEG Blend: A – 0.39, B – 0.58, C – 0.14).
However, initial studies using Ellman’s Reagent produced results that
showed a distinct decline in absorbance after full release of cysteamine
hydrochloride (average 3-5% reduction after full release). In an attempt to
eliminate this, aluminium foil was used to limit the exposure to natural light
as much as possible. DTNB is known to be photosensitive (75,78). The
results produced in the dark environment showed an elimination of the
decline that was previously seen.
3.3.2 Hot-Stage Microscopy studies
Figures 17 and 18 examine the suppository excipients, along with the
suppository PEG blends A, B and C. Within each image, the dark areas
represent unorganised, non-crystalline structures, whereas the light areas
correspond to crystalline structures.
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Figure 17. Optical micrographs of: A. cysteamine hydrochloride at 25°C, B.
cysteamine hydrochloride at 25°C (heated to melting point then cooled), C.
PEG 8000, D. PEG 8000 at 25°C (heated to melting point (62°C) then
cooled), and E. PEG 600 at 5°C (heated to 50°C and recrystallised).
Cysteamine hydrochloride possesses a triclinic crystal structure (102). This
is an unsymmetrical structure, with the three crystal vectors of unequal
length and non-perpendicular intersection (103). PEG 1500 at 25°C (results
not shown) displayed a tetragonal structure similar to that of PEG 8000,
where one axis is much longer than the other two, forming a cuboid shaped
crystal. Peg 600 is liquid at room temperature, and indeed displayed a
disordered structure with cross-polarised light (results not shown). These
A B
C D
E
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results demonstrated that lower molecular weights of PEG posses a lower
degree of crystallinity below their melting point.
Figure 18. Optical micrographs of, A. PEG 14000 at 25°C (heated to its
melting point (62°C) and cooled), B. PEG blend A at 25°C (suppository), C.
PEG blend B at 25°C (suppository), and D. PEG blend C suppository at
25°C.
Figure 18 shows evidence of homogenous suppository mixes, where the
suppository possesses a uniform appearance. This homogeneity suggested
that cysteamine hydrochloride was well dispersed within the suppository.
The PEG blend C suppositories were the most stable formulation when
observed over time. Both PEG blend A and B displayed a ‘sweaty’
appearance, in that beads of liquid were clearly visible on the surface. This
was more pronounced in PEG blend A. The liquid was viscous and foul
smelling, possibly indicating the presence of cysteamine hydrochloride. If
left in the open for a few hours, the volume of this liquid increased to the
point where the form was completely covered. When this liquid was studied
A B
C D
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on the hot stage microscope, there were no crystals observed. When
cooled to -20°C with liquid nitrogen, a crystal structure did form similar to
the needle crystal structure displayed by cooled PEG 600 (figure 17E).
There was one crystal evident of unknown composition. To determine if
cold storage affected this ‘sweating’ phenomenon, PEG Blend A
suppositories were kept in a freezer for 1 month. When removed, the form
appeared normal, without any ‘sweating’ evident. However, within seconds
a large amount of this liquid was again produced by the suppository.
Cysteamine hydrochloride crystals were also left out in the open, and after
20 minutes had become a viscous liquid. Cysteamine hydrochloride is
known to be extremely hygroscopic. However, if a PEG Blend C suppository
containing 30 mg of cysteamine hydrochloride is exposed to room
temperature for 24 hours, there is no evidence of any ‘sweating’.
From the evidence obtained phase separation is the most likely cause for
this phenomenon. There may be a ‘demixing’ of the PEG and cysteamine
hydrochloride components. Crystal ripening, where the PEG recrystalises
over time to a lower free energy state may also be expelling the cysteamine
hydrochloride from the suppository. This ‘microcrystalline phase separation’
forces the hygroscopic cysteamine hydrochloride to the outside of the
suppository, where it attracts environmental moisture. The deliquescence is
almost instantaneous, where it appears that a liquid is being produced from
the suppository. Thus, the ‘sweat’ observed may be a concentrated
aqueous solution of cysteamine hydrochloride. Table 3 also illustrates that
there has been a large decrease in suppository hardness after cysteamine
hydrochloride addition, particularly in PEG blend A. This is observed to a
lesser degree in PEG blend B, and only slightly in PEG blend C. There may
therefore be an incompatibility between cysteamine hydrochloride and PEG
blends A and B, which manifests as ‘sweating’.
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3.3.3 Cooling profile studies
Each of the three suppository PEG blends A, B and C were monitored for
temperature changes during the cooling period after being poured into
moulds (Figure 19). This cooling profile gives an indication of the individual
thermal history of each form. If cooled quickly, the suppository base would
be composed of small crystals, whereas a faster cool would produce larger
crystals. This difference in crystal size would affect how the suppository
dissolves in the rectum.
Figure 19. Three PEG blend suppositories average cooling profiles, n = 3.
Whilst PEG Blend A and B displayed very similar cooling profiles, the PEG
Blend C suppositories cooled in a very different way. PEG Blends A and B
displayed a sudden drop in temperature as the hot molten mixture hits the
cooler mould, with a plateau after three minutes when the temperature
neither rises nor falls. There is then a gradual temperature decrease,
eventually reaching a point where the mould and form are almost the same
temperature. Blend C also displays the characteristic initial drop, however
this is followed by a large increase in temperature. This exothermic peak is
the heat of crystallisation of the suppository base. There is also a heat of
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crystallisation for PEG blends A and B, however this is much smaller and is
observed as the plateau in temperature. This smaller heat of crystallisation
observed in PEG blends A and B is due to a lower degree of crystallinity
observed in lower molecular weight PEGs.
3.3.4 Active dispersion studies
To ensure cysteamine hydrochloride was evenly dispersed throughout the
suppository, samples were taken from three separate sections of the
suppository (figure 14) and analysed using DSC (Figure 20).
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Figure 20. Section comparison of the melt phase between the tip, middle
and edge areas of the PEG Blend A suppository containing cysteamine
hydrochloride.
It is evident from figure 20 that there is minimal difference between the tip,
edge and middle sections, which is indicative of a uniform crystallinity
within the PEG suppository.
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3.3.5 Suppository mould temperature studies
Suppository mould temperatures were recorded, and the characteristics of
each complete suppository were analysed. Suppository hardness and
appearance remained unaffected by the change in mould temperature, and
the suppositories were analysed further by DSC (table 6).
Table 6. DSC analysis data of the suppositories from six different starting
mould temperatures.
Suppository mould starting
temperature (°C)
Melting onset
temperature
(°C)
Energy of transition
(J/g)
28.5 50.08 76.63
30.5 50.46 76.37
38 50.58 73.54
46 50.81 75.37
52 51.76 75.88
There is a general trend for the melting point of the suppositories to
increase as the mould temperature increases. This is caused by a slower
cooling rate, producing larger crystals of PEG. When PEG is cooled quickly,
the chains are random and unordered. The suppository exists at too high
an energy state for the molecules. Over time, these chains will move to a
state of lower energy, becoming more aligned and increasing the level of
crystallinity. This process is accelerated if heat is supplied to the form. If
PEG is cooled at a slower rate, the chains align in a more linear manner,
and crystal size is increased (104). This produces a more stable
suppository over time, which is less likely to degrade in storage before use.
All of the tested suppositories were manufactured with the same starting
mould temperature, 22°C, and therefore the crystal size are uniform across
the batches manufactured. The energy of transition values decrease as a
function of temperature. This is evidence of a decrease in the degree of
crystallinity in the samples over time, caused by water absorption (‘physical
ageing’). This contradicts the melting point data. The evidence suggests
that two opposing phenomena are competing to both increase and decrease
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the degree of crystallinity, one as a result of ‘crystal ripening’ (increase),
and the other caused by water absorption (decrease). In ‘crystal ripening’,
the larger the crystals are, the lower the free energy that the sample
possesses. This is thermodynamically more desirable than smaller crystals.
It appears that these analyses have measured the ‘net effect’ of these two
phenomena.
3.3.6 Stability tests
The temperature and relative humidity in each of the three storage
chambers were monitored continuously throughout the 12 months. The
average values are shown in Table 7.
Table 7. Average temperatures and relative humidities in each storage
chamber, with standard deviations.
Refrigerator Store ETC
Average temperature 3.7°C (± 0.8) 20.3°C (± 1.9) 29.9°C (± 1.0)
Average relative
humidity
9.2% (± 0.3) 52% 76.4% (± 2.0)
3.3.6.1 DSC results: T0, T6 months, T12 months comparison.
The suppositories were tested by DSC at 6 months and 12 months for
melting point, energy of transition and peak temperature. This data was
compared with the starting point, time zero (T0). Selected analysis data is
presented in table 8 as a percentage increase or decrease in these
parameters over time, as well as two example plots (figures 21 and 22).
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Table 8. DSC analysis data of selected suppository samples over time (n = 3).
Suppository
sample
Time zero
Melting point (°C)
Energy of transition
(J/g)
Peak temperature
(°C)
T 6 months
Melting point (%°C)
Energy of transition
(%J/g)
Peak temperature
(%°C)
T 12 months
Melting point (%°C)
Energy of transition
(%J/g)
Peak temperature
(%°C)
PEG blend A
4°C storage
50.55 0.75↑ 1.84↓
71.84 5.78↑ 13.1↑
56.44 0.5↑ 2.3↓
PEG blend A
21°C storage
50.70 2.25↑ 0.32↓
83.77 10.7↑ 15.91↑
57.71 0.66↑ 0.88↓
PEG blend A
30°C storage
50.52 3.82↓ 11.6↓
75.32 11.74↑ 19.33↑
56.60 1.54↓ 8.98↓
PEG blend B
4°C storage
51.39 1.46↑ 0.6↓
73.44 9.89↑ 12.43↑
57.77 0.17↓ 2.2↓
PEG blend B
21°C storage
50.35 4.61↑ 1.25↑
67.18 28.57↑ 33.94↑
56.65 2.97↑ 0.26↑
PEG blend B
30°C storage
50.73 1.71↑ 1.59↓
80.09 7.6↑ 13.65↑
57.62 0.9↓ 2.92↓
PEG blend C
4°C storage
41.16 3.77↑ 2.33↑
159.4 12.83↑ 16.56↑
50.30 0.6↓ 0.42↓
PEG blend C
21°C storage
41.07 3.63↓ 8.45↓
165.9 3.86↑ 5.42↑
50.27 2.11↓ 5.78↓
PEG blend C
30°C storage
49.97 1.28↓ 30.64↓
164.50 3.71↑ 4.86↓
40.92 5.96↓ 12.95↑
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Figure 21. DSC plot of PEG blend C suppositories over time, stored at 21°C.
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Figure 22. DSC plots of PEG blend C suppositories over time, stored at 4°C.
The melting points of the PEG blend suppositories demonstrated stability
over time, with the exception of PEG blend A stored at 30°C (11.6%
decrease) and PEG blend C stored at 21°C (8.45% decrease). Both the
melting points and peak temperature values have decreased, demonstrating
deterioration of these samples over time. Both of these storage conditions
possess a high relative humidity, and therefore water penetration is
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probably the main reason for deterioration. Cysteamine hydrochloride is
extremely deliquescent, and exposure to water is likely to be the main
factor for the stability of the suppositories. The storage at 30°C and 75%
RH is representative of accelerated stability testing, and therefore PEG
blend A should be stored at 21°C or below, with a low relative humidity.
Over 12 months, the energy of transition of each sample has increased
without exception. This is due to an increase in the crystallinity of the
samples over time, caused by ‘crystal ripening’. When heat is supplied to
the sample, this process of crystal enlargement is accelerated. This is
illustrated in samples PEG blend A stored at 30°C, and PEG blend B stored
at 21°C. Over twelve months, the energy of transition has increased by
19.33% and 33.94% respectively. As discussed previously, the energy
supplied to the forms as heat during twelve months of accelerated storage
testing has altered the thermal energy, aligning the PEG chains in a less
chaotic manner (104). Overall, the DSC analysis over 12 months
demonstrated that the PEG blend C suppositories were most stable when
stored at 4°C. PEG blend A suppositories displayed deterioration when
stored in excessive temperature and humidity conditions.
3.3.6.2 Infrared Spectroscopy after 1 week, 3 months, 6months and
12 months.
Infrared spectroscopy of a chemical produces a spectrum, the patterns and
peaks of which relate to the absorption of the electromagnetic energy by
the chemical’s different molecular bonds (101). These bonds vibrate upon
the absorption of energy, producing a unique peak or set of peaks on the
spectrum which can therefore be used for identifying the compound (table
9). The bonds can vibrate in many specific ways, such as twisting, wagging
or stretching. Each of the suppository samples were, over time, scanned by
IR spectroscopy and added to a compound library. A percentage match was
then performed on each sample (Figure 23 and table 9).
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Figure 23. Regions of the IR spectra used for comparison in this study (PEG
blend C).
Table 9. The group frequencies used for identification of the samples (101).
Group frequency (cm-1) Functional group/assignment
3400-3380 O-H stretch
2600-2550 S-H stretch
710-685 C-S stretch
620-600 S-S stretch
The oxidation of cysteamine to cystamine was the basis of comparisons
made between samples. This would produce a peak in the region of
disulphide bond stretches, i.e. 620-600 cm-1, and allow the identification of
sample degradation.
Each suppository was analysed over time using the IR spectrometer, and
compared to the suppositories at time zero. The results are shown in table
10 (selected examples only).
620-600cm-1
2600-2550 cm-1
O-H stretch
C-S stretch
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Table 10. Suppository stability over time, presented as percentage match
to sample at T0 (selected data only).
Suppository blend/storage conditions Percentage match to sample at T0
PEG blend C, 4°C 99.2% at 3 months
98.84% at 12 months
PEG blend A, 4°C 97.4% at 3 weeks
PEG blend C, 21°C 98.94% at 6 months
PEG blend B, 21°C 97.95% at 12 months
PEG blend C, 30C, 75% RH 98.94% at 6 months
The stability tests using IR analysis demonstrated that PEG blend C is the
most stable in all conditions, with minimal changes over six months at room
temperature and accelerated tests, and up to twelve months stability when
stored at 4° C. PEG blend B shows evidence of stability over twelve months
at room temperature. PEG blend A shows evidence of degradation when
subjected to a range of storage conditions, and therefore is unsuitable for
the rectal delivery of cysteamine.
3.3.6.3 Correlation between DSC plots and IR percentage match
results
The IR percentage match data supports the DSC plots. This is evidence of
correlation between the two methods which allows a more conclusive result
to be produced. For example, PEG blend C stored at 21°C displayed a
98.94% match at 6 months (table 10), and the IR plot illustrated stability
over time (results not shown).
These stability test results support previous results, and indicate that PEG
Blend C was the most stable formulation over a 12-month period. The
suppositories stored at 4°C were generally more stable than those stored at
higher temperatures, although PEG blend C displays long term stability even
at room temperature. PEG blend B suppositories were stable over time at
room temperature. PEG blend A suppositories displayed long term
instability in all storage conditions. There is correlation between the DSC
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and IR results. By utilizing two techniques a comprehensive comparison
can be made. PEG blend C displays ideal stability over time in a range of
storage conditions (refrigerator, room temperature, accelerated stability
tests).
3.4 Conclusions
Various suppository bases were investigated for suitability for the
incorporation of cysteamine hydrochloride and the phe-cystamine
conjugate. Melting point, hardness, stability and appearance were
analysed, and the three suppository bases with the most suitable
characteristics were chosen for further study. PEG Blends A, B and C were
made and characterised. Blend C displayed good qualities (i.e. complete,
reproducible release after 30 minutes, stability over 12 months at 4°C)
required for the delivery of cysteamine hydrochloride to the rectum. DSC
analysis indicated that cysteamine hydrochloride was dispersed uniformly in
the suppositories. Dissolution studies using the phe-cystamine conjugate
revealed 20-60 minute release, while cysteamine hydrochloride as the
active component demonstrated 17-26 minute release on average. The
stability tests indicate that 4°C provided the ideal storage conditions over a
12-month period. Formulation C is the most stable over time, followed by
B. Blend A is the least stable form, and even when stored in the
refrigerator it is subject to degradation. There is also evidence of an
incompatibility between cysteamine hydrochloride and PEG Blends A and B,
and this may be due in part to a ‘demixing’ of the PEG and cysteamine.
There is evidence that crystal ripening over time is forcing the expulsion of
the cysteamine hydrochloride to the outside surfaces of the suppository.
The highly deliquescent cysteamine then quickly dissolves in environmental
moisture, forming droplets of liquid on the surface of the suppositories. For
these reasons, PEG blends A and B would not be suitable for the rectal
delivery of cysteamine. Analysis indicates that PEG blend C would be an
ideal suppository base for the delivery of cysteamine hydrochloride.
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These tests demonstrate that cysteamine hydrochloride can be formulated
as a suppository. This may be of particular benefit when treating cystinosis
during infancy, when swallowing capsules is difficult or when the oral route
is compromised. Future work with the suppositories may involve the
development of in situ gelling forms.
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Chapter 4 – Ophthalmic
formulations
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Chapter 4 - Ophthalmic formulations
4.1 Introduction
The deposition of cystine crystals in the cornea is one of the most
troublesome complications affecting cystinosis patients. The crystals
become noticeable when the entire peripheral stroma and endothelium have
become packed, usually around the age of 6-8 years. However, the crystals
are always present by 16 months (5). Photophobia and, ultimately,
blepharospasm affect the quality of life such that the slightest glimmer of
sunlight can be debilitating (2). Sunglasses are often worn, and lights
dimmed (5). The tissue can become so packed that it causes the Bowman’s
membrane to rupture, causing pain (Figure 24) (6).
Figure 24. Diagram of the cornea.
In addition, the crystals’ accumulation over a period of years can cause
corneal scars and sores, keratitis and cataracts, as well as calcification in
the form of band keratopathies to form, and ultimately corneal breakdown
(45). A study showed that 15% of Cystinosis patients over ten years of age
had corneal ulcerations (23).
Ophthalmic problems are not limited to the accumulation of cystine crystals
in the cornea. Cataracts can be caused by the steroid treatment post-renal
transplant (45). Angle closure glaucoma can also develop (5). Retinal
blindness occurs in 3-5% of untreated adults, with optic nerve swelling
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another potential cause for this (105). Phthysis bulbi, where the body of
the eye shrinks and vision is lost, is a potential endpoint (21).
The oral form of cysteamine treatment can treat most of the ophthalmic
symptoms, but has no effect on depleting corneal crystals due to a lack of
vasculature in the cornea, and therefore cysteamine must be administered
topically in the form of eye drops (21). Corneal transplantation is now an
option, however the transplanted tissue re-accumulates crystals over time,
and so topical treatment is still required (12,37).
Cysteamine is available in an eye drop form and has been shown to work
well. Due to concerns over the formulation’s instability at room
temperature, the FDA required additional efficacy data and has only
recently approved this current treatment (4). It readily oxidises to the
disulphide form cystamine, the efficacy of which is controversial (22,33).
The only way to overcome this problem is to store the drops in a freezer or
remove all oxygen by storing under Argon, which is not commercially or
domestically practical. Researchers are aware of the limitations and
inconvenience of this current eye drop treatment, and attempts have been
made to resolve it (106).
Compliance with the eye drops is a major factor however, as in order to
achieve the maximum benefit these drops have to be routinely inserted
every hour while awake. They also cause some discomfort by stinging (5).
Thus there is a need for a once or twice-daily dosage preparation, to give
relief from these ocular symptoms whilst allowing minimal interference to
everyday life.
4.1.1 History of cysteamine eye drops
Topical cysteamine was first documented in 1987, when Gahl et al and
Dufier et al both reported initial findings on its novel use (16,21). Both
sources were experimental and conducted in a small population. The Dufier
study was conducted over a 26-year follow-up period however, and showed
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promise for the future use of the eye drops. Gahl’s team performed in vitro
studies in rabbits, and subsequently set up a controlled double-blind clinical
trial in two patients under two years of age. Gahl was also the first to try
and explain the reason for the ineffectiveness of systemic cysteamine on
the ophthalmic complications, and hypothesised it was due to the cornea’s
lack of vasculature. Initial findings were encouraging, and the drug’s use in
this way was deemed safe and effective at depleting corneal crystals, at
least in patients under two years of age.
This lead to more in-depth investigations, which tested the eye-drop’s
toxicity and efficacy in different age ranges. Topical cysteamine in the form
of eye drops was repeatedly shown to be safe at a concentration of 0.5%
w/v while side effects were minor and infrequent, and corneal crystals were
effectively depleted to a level which meant normal activities could be
performed (37,105,107,108). The possibility of crystal deposition reversal
was suggested by the results of a 4-year study (108). Noble’s research
from 1991 highlighted the importance of compliance with regard to efficacy
of the drops and even severe prolonged symptoms were shown to benefit
(109). Therefore this new eye drop treatment had the potential to
transform the lives of sufferers.
Since being introduced, many more trials have reiterated the previous
findings that topical cysteamine eye drops are extremely beneficial to those
with this complication. In 1998, Gahl et al compared topical cysteamine
with the disulphide form cystamine, as cysteamine rapidly oxidises to the
disulphide form at room temperature and therefore has special storage
requirements (37). Despite a conclusion of no efficacy of the disulphide
form, the team did discover that the crystals exist extracellularly in addition
to the currently known intracellular crystals. Gahl et al working in 2000
discovered that the extent of crystal accumulation in the cornea, measured
using the standardised Corneal Cystine Crystal Score (CCCS) method is a
direct indication of the course and severity of the disease (12). They
noticed a link between severity of the individual’s CTNS mutations and the
rate of crystal build up. The reversibility of the complication through
compliant use of eye drops was cemented; however this will not be the case
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if a band keratopathy has occurred. Non-compliance is seen as a major
barrier to improvement of symptoms, as the drops require administration 8-
12 times per day in order to be effective. This paper also contemplates on
future studies: could early preventative therapy with the topical formulation
actually prevent ophthalmic complications from occurring?
A more recent study attempted to alter the current eye drops to allow
storage at room temperature (106). This new formulation included
monosodium phosphate and disodium EDTA, however was not as effective
at depleting cystine as the current therapy.
4.1.2 Eye anatomy
The structure and defence mechanisms of the eye make it incredibly difficult
to target therapeutically. The avascular cornea receives nutrients from
lachrymal fluid and aqueous humor (110). Lachrymal fluid constantly
washes the surface, binding proteins and degrading through metabolism,
while eye lids blink out any particles and increase tear production (111).
The cornea has five, hard to penetrate, layers of alternating hydrophilic and
hydrophobic cell types which exhibit tight junctions. The outermost layer is
the epithelium, which is negatively charged and lipophilic, behind which are
the Bowman’s membrane, and the stroma. This layer provides the cornea
with 90% of its thickness, and is composed mainly of water. Below the
stroma is Descemet’s membrane, and finally the endothelium (110) (figure
24).
Of the three distinct corneal layers, the epithelium, the stroma and the
endothelium, the epithelium provides the greatest hurdle as it is lipophilic
and acts as a barrier to ion transport and to the absorption of hydrophilic
drugs such as cysteamine bitartrate. The tight junctions of the corneal
epithelium serve as a selective barrier for small molecules and prevent the
diffusion of macromolecules via the paracellular route (112). Non-corneal
absorption, on the other hand, involves drug penetration across the
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conjunctiva and underlying sclera into the uveal tract and vitreous humor
(112) and is important for the absorption of large, hydrophilic molecules.
Current understanding of ocular pharmacokinetics involves mixing of the
eye drops with lachrymal fluid, produced at a rate of 0.5-2.2 µL/min,
resulting in a short contact time with ocular tissue (113). Subsequent
drainage towards the nasolachrymal duct during blinking results in
extensive elimination of the applied solution and contact times varying from
1-2 minutes (114) to 5 minutes (115) have been reported. This mix of
lachrymal fluid and instilled medication is subsequently absorbed through
the conjunctival bloodstream, and can cause potentially serious side effects
(116). The rapid drainage rate is due to the tendency of the eye to
maintain its residence volume at ~10 µL, while a typical eye dropper
delivers around 30 µl and consequently, the overall absorption and
bioavailability of a topically applied drug is typically less than 5%
(117,118). These barriers make it extremely difficult for the instilled eye
drop to be retained at the eye surface long enough to exert its full
therapeutic effect.
4.1.3 Mucus
The mucus which covers the eye is constantly being produced by goblet
cells within the conjunctiva and then digested, which makes it difficult for
both pathogens and drugs to reach the corneal surface. Pathogens and
drugs must move through the layers of mucus quickly, to reach the
epithelium before they are lost to the nasolacrimal ducts. The mucus also
traps any foreign particle, and wraps it in a thin mucus coat before the
particle is swept away with blinking (119). Mucin is composed of mucin
glycoproteins, lipids, inorganic salts and as much as 95% water (120). The
thickness of the mucus layer ranges from 0.05 to 1.5 µm (121). Mucus is a
negatively-charged, viscoelastic, shear-thinning gel which is replaced every
10 minutes with lachrymal fluid (122). This high turnover rate of tear fluid,
in combination with the other protective mechanisms such as frequent
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blinking and tight cell junctions ensures that the eye remains clear of
pathogens and foreign bodies, and may impair mucoadhesion (123).
4.1.4 Delivery systems for ophthalmic symptoms of cystinosis
The largest improvement upon the poor bioavailability of eye drops can be
achieved by either improving corneal permeability or prolonging the corneal
residence time of the ophthalmic dosage form (124). This project focussed
on extending corneal contact time using ophthalmic gels.
4.1.4.1 In situ gelling polymers
In situ gelling polymers have the potential to improve ophthalmic drug
bioavailability through prolonged contact of the drug with the ocular tissues.
In situ forming hydrogels exhibit the desirable properties of eye drops,
whilst combining the efficacious nature of ophthalmic inserts. Introduced
within the last 20 years and technically more complex than traditional eye
drops, they embody everything necessary in an ophthalmic delivery form;
easy to make and use, liquid until they come into contact with the eye, a
gel once instilled, minimal interference with vision, comfortable, non toxic
and no need for removal (116).
Hydrogels are composed of three-dimensional aqueous gel networks which
swell rapidly to retain large volumes of water within their structure (125).
The gelling process can be triggered in different ways. A rise in
temperature can cause gelation to occur, through the formation of
hydrophobic interactions between polymer chains (125). The chemical class
Pluronics, which are used in multiple applications such as emulsification and
drug delivery are an example of a polymer which gels upon a rise in
temperature. The gelling process can also be triggered by a change in pH,
through the ionisation of particular groups within the polymer chain.
Carbomer, used as a thickening agent and an emulsifier, is an example of
an acrylic acid polymer which gels under rising pH conditions. Ionic
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changes can also initiate gelling, by cross-linking negatively-charged
polymer chains with positive ions (cations) (126). Gellan gum gels in this
manner, making it suitable for ophthalmic applications. When added to
water, these compounds swell and maintain water (125). The gels take 24
hours to fully hydrate and swell, and are left for this period in a refrigerator.
The formed gels have to possess high viscosity when there is little or no
shear stress placed upon them, and low viscosity under high stress
conditions, thus ensuring maximum comfort to the user during blinking and
causing minimal interference with vision. Human lachrimal fluid has been
measured with a viscosity of 0.0006 Pa.s (120), giving an indication of the
level of viscosity acceptable in the eye. There has been much research on
hydrogels undertaken, and the conclusions are similar; well tolerated, non-
toxic delivering effective 8-hour sustained delivery (126-130).
4.1.4.2 Bioadhesive and mucoadhesive polymers
Bioadhesion describes a situation where a material is held onto the surface
of a biological tissue for extended periods (120). Some polymers can bind
to the mucin layer, and are termed mucoadhesive. This is not in fact true
bioadhesion, as the adherence occurs between the polymer and the mucus
layer which covers the eye, allowing minimal disruption to vision (121).
Certain polymers such as carbomer 934 have been shown to bind to corneal
epithelium (bioadhesive), and be retained in the eye for over 2 hours in vivo
(120). In 2001, Pan et al demonstrated that an ion-activated device was
developed from carbomer 934 and Methocel E50LV as a viscosity enhancing
agent, and found to be extremely well tolerated, non-irritant and delivered
the active pharmaceutical ingredient over an 8-hour period (131). A
thermo-activated gel which incorporated a mucoadhesive was also
developed from various poloxamer grades and carbopol, and demonstrated
long retention times and good bioadhesion (95). This technology appears
ideal for the topical treatment of ophthalmic crystals, and may reduce the
dosage frequency required by anchoring the dosage form to the site of
action.
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The mechanisms of bioadhesion and mucoadhesion are debated, but appear
to involve initial surface interaction with the epithelium, where polymers
gather to reduce the surface tension, followed by stabilisation through or via
hydrogen, covalent or ionic bonding, electrostatic or hydrophobic
interactions (121). These bonding mechanisms correspond to six theories
of exact interaction, of which the wetting theory is the most likely
explanation in this case. This applies to liquids, and their ability to spread
over a surface and subsequently adhere to it. Surface tension is involved,
and the energy required to separate the two phases is referred to as the
work of adhesion, WA.
WA = A + B - AB
Where A is the surface energy of the liquid, B is the surface energy of the
solid, and AB is the interfacial energy between the liquid and solid (120).
In mucoadhesion, the more flexible the polymer chains are, the more the
polymer will be able to penetrate the mucin coat, thereby increasing the
adhesive strength (121). There is a link between mucoadhesive strength
and polymer chain length. Complete hydration of the polymer is another
factor, although care has to be taken to avoid over-hydration, as the
polymer network will be weakened and the gel structure lost (120,132).
It is difficult to distinguish between bioadhesion and mucoadhesion,
especially in this case as the eye will always be coated in a mucin layer.
There are references to both with respect to corneal binding; however, for
the purposes of clarity in this project, and because there is likely to be a
combination of effects involved, the two terms will be synonymous after this
point.
Mucoadhesive polymers have been used to promote bioavailability, by
improving drug retention times as well as reducing the rate of drainage
(133). In addition, the non-Newtonian pseudoplastic or ‘shear thinning’
rheology inherent in PAA hydrogels facilitates the process of blinking by
dramatic reductions in apparent viscosity as a function of the high external
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shear stresses applied by the leading-edge and inside surface of the eye-lid
(112). These high shear stresses are associated with equivalent shear rates
of 0 s-1 at rest to 10,000 - 40,000 s-1 when blinking (134). Pseudoplastic
fluids therefore offer significantly less resistance to blinking than Newtonian
liquids of equivalent consistency (‘viscosity’). High apparent viscosities
under zero external stresses result in longer contact times on the surface of
the eye. By allowing intimate contact with mucus and epithelium for
prolonged periods, an improved efficacy and subsequent reduced dosing
frequency may be possible (123). There appears to be no reasonable
objection to this novel pharmaceutical form, and yet there are very few of
them made commercially. The benefits are potentially enormous, and could
revolutionise the way ophthalmic conditions are treated, certainly for
chronic conditions such as glaucoma and cystinosis where the difference in
dosing frequency would be extremely beneficial to the patient (135). Many
trials demonstrate the value of these dosage forms (112,114,118). Three
gums were analysed for suitability to formulate an eye gel; HPMC, xanthan
gum and carbomer. Gellan gum was also investigated, but eliminated after
pre-formulation studies.
4.1.5 Gellan gum
Gellan gum is frequently used in the pharmaceutical industry as a thickener
and emulsifier (74). The gel is also bioadhesive and has been shown to
provide a sustained release, and was initially investigated for use in this
project. However, gellan gum gels in the presence of mono and divalent
cations, and was unsuitable for use with cysteamine hydrochloride as an
active component (136).
4.1.6 Carbomer 934
Carbomer 934 is commonly used for its excellent gelling characteristics and
optimum rheological properties (Figure 25). Its viscosity is pH dependent,
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and to a lesser extent the presence of electrolytes (137). It is a well-
documented mucoadhesive gel (95,129,130,138).
Figure 25. Structural repeating unit of carbomer 934, where n ≈ 2000
(139).
Carbomer 934 is a negatively-charged, high molecular weight synthetic
polymer. It is composed of poly(acrylic acid) (PAA) cross linked with allyl
sucrose. The primary functional group is carboxylic acid, making the gels
hydrophilic and able to form hydrogen bonds. When dry or un-neutralised
in solution, the carbomer chains are coiled and unexpanded. Sodium
hydroxide is added to a carbomer solution to raise the pH, and the
carbomer becomes ionised above its dissociation constant (pKa) of 4.75.
This ionisation is increased the more the pH is raised beyond the pKa value.
The polymer’s carboxylate groups then repel each other, producing a rigid
gel structure (140). A pH of 7 produces a gel with optimum viscosity and
clarity (137). Carbomer can tolerate alcohol, however the gels become
more viscous and opaque (141).
4.1.7 Xanthan gum
Xanthan gum is widely used in both food and pharmaceutical industries. It
is a negatively-charged polysaccharide produced by the bacteria
Xanthamonas campestris (Figure 26). Higher than ambient temperatures
produce a decrease in viscosity and it is known to be bioadhesive (142).
After installation into the eye, xanthan gum is an ordered double-stranded
helix, due to the lachrymal salts (143).
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Figure 26. Structural repeating unit of xanthan gum, n ≈ 500 (144).
4.1.8 Hydroxypropyl methylcellulose (HPMC)
Hydroxypropyl methylcellulose (HPMC) is frequently used in oral and topical
applications within the pharmaceutical industry (Figure 27). Viscosity is
reduced at higher temperatures, although no significant viscosity change is
seen between 30C and 40C (51,145). Water soluble drugs are released
from an HPMC matrix by a combination of diffusion through and dissolution
of the matrix (125). HPMC is neutral.
Figure 27. Structural repeating unit of HPMC, n ≈ 500 (146).
4.1.9 Thiolated polymers
In an attempt to improve the mucoadhesion of the xanthan, HPMC and
carbomer polymers, work has been undertaken in which thiol-containing
compounds have been included in the formulations, including cysteine and
cysteamine (120). Bernkop-Schnurch et al hypothesized that in situ the
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‘thiomer’ gels would form disulphide links not only between the polymer
itself, but also between the polymer and the mucin layer, leading to a
strengthened adhesive joint (147-150).
Thiomers achieve this increase in strength through disulphide bond
formation as they possess thiol-bearing side chains. These side chains form
disulphide bonds with cysteine-rich sub domains of the mucus, which is
present on every mucus membrane in the body (147,149,150). These
polymers can also inhibit enzymes, gel in situ and enhance permeation, and
examples include chitosan, deacylated gellan gum or poly(acrylates).
Bernkop-Schnurch’s research published in 2005 describes how various
different sulfhydryl ligands can be attached to the polymers, such as
cysteine or cysteamine (Figure 28).
COOH COOH
COOH COOH
Polymer
+
NH2
SH
COOH COOH
COOH COOH
Polymer
N
SH
Figure 28. Synthesis scheme for the generation of polymer–cysteamine
conjugates.
Thiomers have been reported as unstable in aqueous solution, although
there are ways to overcome this (148). When formulated into ophthalmic
inserts, the thiomers were well-accepted by volunteers and achieved a drug
concentration on the ocular surface for more than 8 hours (150). It is
unclear if these polymers could be used in this context; by binding to
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cysteine within the mucus, the absorption of the active through the rest of
the cell layers may be inhibited (147).
4.1.10 In Vitro testing
There is no definitive test for bioadhesion. However, the bioadhesion of the
three gels used is well documented (130,140,151,152). Bioadhesion was
measured by two methods: A Texture Analyser (Stable Micro Systems,
Surrey, UK) was used to measure the force required to remove the gel from
an area of bovine cornea (153). Agar was used as a comparison to the
tissue, being itself a known tissue substitute (154).
As a comparison, rheological studies were performed, analysing the effect of
the gels when combined with porcine mucin. It has been proposed that
rheological synergism between the polymer and the mucin, observed
through changes in storage and loss moduli, can be used as a parameter to
measure bioadhesion (155,156). However, Wong et al questioned the
validity of this method due to the lack of biological tissue (157). Freeze-
dried crude mucin from porcine stomach (type II) was combined with the
gels. Ceulmans et al have reported a dispersion of gastric mucin in a salt
solution is a suitable equivalent to ocular mucin (143).
4.2 Materials and Methods
4.2.1 Materials
Carbomer 934 was purchased from Universal Biologicals, UK. Cysteamine,
cysteamine hydrochloride, potassium chloride, sodium chloride, sodium
carbonate, calcium carbonate, magnesium chloride and freeze-dried crude
mucin from porcine stomach (type II) were purchased from Sigma, UK.
Tubing membrane 12-14,000 kDa was purchased from Visking, UK. Agar
No.1 LP0011 was obtained from Oxoid Ltd (Hampshire, UK). All other
chemicals were of pharmaceutical grade.
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4.2.2 Gel manufacture
All gels were made by addition of the respective polymer to Simulated
Lachrymal Fluid (SLF) at pH 7.4 with some modifications.
SLF was used to mimic tear fluid during tests. It was also used in the
production of the ophthalmic gels to provide additional buffering capacity.
The following salts were weighed out and stirred in a 1 L volumetric flask:
potassium chloride 0.179% w/v, sodium chloride 0.631% w/v, sodium
carbonate 0.218% w/v, calcium carbonate 0.004% w/v and magnesium
chloride 0.005% w/v.
Once dissolved, the pH of the carbomer 934, xanthan gum and HPMC
solutions was adjusted to 7.4, which is that of biological tissues, by addition
of 2 M hydrochloric acid or 2 M sodium hydroxide. Distilled water was
added to 85% final volume. The gel was then stored for 24h at 4°C.
Sorensen’s Modified Phosphate Buffer (SMPB) was added, along with either
cysteamine hydrochloride or phe conjugate. Phe conjugate also required
ethanol as a cosolvent. The pH was maintained at 7.4. SLF addition
achieved the final weight. Final gels were allowed to rest at 4°C for 24h
until further testing commenced (94,129,158). Table 11 summarises all
gels tested.
In addition, the HPMC gels were prepared in deionised water, heated to
90°C and stirred vigorously (51). The xanthan gum was prepared in
0.01% w/w benzalkonium chloride solution in deionised water. This was
heated to 40°C for 10 minutes and sonicated for 1 hour (143,159).
Xanthan gum supports bacterial growth easily without a preservative (160).
Multidose ophthalmic preparations must include a preservative to ensure
sterility, as the bottle could receive contamination from contact with eyelids,
lashes or tears (161). The quaternary ammonium preservative
benzalkonium chloride is known to be safe and efficacious in ophthalmic
preparations (162,163), and is the most frequently used (161). It is weakly
allergenic, and has reported drug penetration enhancing effects, through
disruption of the hydrophobic barrier of the corneal epithelium (161).
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Table 11. Summary of all gels tested.
Concentration of
gel
No active Phe
conjugate
0.5% w/w*
Cysteamine HCl
0.5% w/w
Cysteamine
5% w/w
1.0% w/w
carbomer 934

1.0% w/w
carbomer 934

1.0% w/w
carbomer 934

1.0% w/w
carbomer 934

1.0% w/w xanthan 
1.0% w/w xanthan 
1.0% w/w xanthan 
1.0% w/v HPMC 
1.0% w/v HPMC 
1.0% w/v HPMC 
* Phe conjugate requires ethanol as a cosolvent to dissolve.
4.2.3 pH studies
The effect of active addition on pH was measured using a handheld MP120
pH meter from Mettler Toledo (Columbus, Ohio, USA). Measurements were
recorded at 21°C. Gels for this study were neutralised at pH7.4, and the pH
allowed to alter upon addition of the active, with no further addition of
NaOH.
4.2.4 Optical Transmission
The eye gels should be optically clear to allow minimal interference with
vision. The optical transmission of each gel was measured using a Cecil CE
3021 Spectrometer (Cambridge, England). Transmission is the ratio of the
amount of light unabsorbed by the gel to the total amount of light the gel is
exposed to, expressed as a percentage. A transmission of 480 nm was
used, as this is the middle of human light wavelength perception (164).
The gels were measured with a 1cm path length, although in situ they
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would be less than a millimetre thick. The gels were referenced to
deionised water at room temperature, which was taken as 100%. A figure
greater than 90% is classed as transparent, between 10 and 90% as
translucent, and less than 10% as opaque. As a comparison, some
commercial ophthalmic preparations were also measured.
4.2.5 Rheology studies
The rheological properties of the gels were studied using an Advanced
Rheometer AR1000 from TA Instruments (Delaware, USA). A 60 mm, 2°
angle cone geometry was used, with a truncation value of 65 µm. All
measurements were made at 34°C, the temperature at the cornea surface
(165,166). Continuous shear measurements were made initially, using a
linear mode and a continuous ramp of 0-600 s-1, and 600-0 s-1 over 20
minutes, to establish flow types such as Newtonian or plastic.
Oscillatory measurements were performed on the gels to characterise the
linear visco-elastic behaviour and relate the rheological parameters to
molecular structure. A linear mode was used with a frequency of 1-10 Hz,
and 20 sample points. The controlled variable was percentage strain. The
sample volume was approximately 1.5 ml. All tests were performed in
triplicate.
4.2.6 Dissolution studies
4.2.6.1 Phe conjugate (6) studies
Prior to the dissolution studies commencing, tests confirmed that SLF as a
dissolution medium did not alter the lambda max of either the phe
conjugate or cysteamine hydrochloride. A 100 ml round-bottomed flask
with sidearm was held in a water bath, heated to 34°C (166). To the
sidearm, a condenser was attached. 50 ml SLF was added to the flask, and
stirred magnetically using an IKA RET basic hotplate stirrer (Staufen,
Germany). The dialysis membrane (12-14,000 kDa) contained 7 ml of gel
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and, tied in a rod shape (length 2.23 cm; radius 1 cm, average of 3
measurements) to exclude air bubbles, was added at time zero. The
medium was sampled every 2 minutes for the first ten minutes, every 5
minutes for an hour, and every 15 minutes after the first hour.
To allow quantification of the dissolution results, the A11 of the phe
conjugate was determined. Thus, 100% release would be quantifiable.
Samples were analysed at 256 nm, the λ max for phe conjugate, using an 
UV spectrometer from Unicam (Winsford, Cheshire, UK). All experiments
were carried out under sink conditions and triplicates were obtained for
each experiment. The area of each membrane was calculated using:
A = 2r2 + 2rh
Where r = radius and h = height of the membrane cylinder. This was used
in conjunction with the Higuchi equation to determine the rate-order of the
drug release.
Q = AMt
AF.S
Q = kHt1/2
Where Q is the cumulative amount of drug release in mg/cm2, A is the
absorbance, Mt is the total mass of drug in mg, AF is the final absorbance, S
is the surface area in cm2, kH is the Higuchi dissolution constant and t1/2 is
the square root of time in minutes. A value of kH below 0.45 is indicative of
Fickian diffusion (167).
4.2.6.2 Cysteamine hydrochloride studies
Ellman’s reagent was used for analysis of the cysteamine hydrochloride
dissolution tests (168). The setup was similar to that for the phe conjugate
dissolution tests, with some modifications (section 4.2.6). The 50 ml
deionised water also contained 10% Tris buffer, to allow the Ellman’s
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reagent to solubilise. The dialysis membrane contained 0.5 ml of 0.5% w/v
cysteamine hydrochloride in a 1% gel. Samples were scanned on a UV
spectrophotometer from Unicam (Cheshire, UK) at 440 nm, the λmax for
Ellman’s reagent. The Higuchi method was used to analyse the results. All
experiments were carried out under sink conditions and triplicates were
obtained for each experiment.
4.2.7 Bioadhesion studies
Bioadhesion was quantified by two methods: A Texture Analyser (Stable
Micro Systems, Surrey, UK) was used to measure the force required to
remove the gel from an area of bovine cornea (153). Agar was used as a
tissue substitute (154). Fresh bovine eyes were collected immediately after
slaughter, and washed with deionised water. The whole cornea was then
excised and washed in SLF at room temperature. Prior to testing, the
corneas were placed on a tissue to remove excess fluid. Cyanoacrylate glue
was then used to attach a cornea to a 2 cm2 stainless steel plate. Care was
taken not to allow the glue to come into contact with the upper surface of
the tissue. Immediately after this, the steel plates were attached (in pairs)
to the Texture Analyser, one positioned directly above the other. Each gel
sample was placed between the cornea samples and held together for 60
seconds; the force required to separate the plates was then measured
(contact force of 0.05 N, contact time 60 s, probe speed 0.5 mm/s). The
force was plotted against distance; the area under the curve (AUC) being
equal to the work of adhesion (Wad) (123,153). As a comparison, 3 cm
diameter nutrient agar plates were poured, allowed to cool and used in
place of the corneal tissue. All other parameters were identical to the tissue
studies. Each individual test was undertaken nine times. The statistical
significance was determined using a Mann-Whitney test. All outliers and
extreme values were removed. The bioadhesion attachment area was 4
cm2.
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As a comparison, rheological studies were performed, analysing the effect of
the gels when combined with porcine mucin. Mucoadhesion analysis using
this method is well documented (94,140,155,169,170). A range of mucin
concentrations and test conditions were used. Mucin dispersions of 12%
and 20% w/w were made in both simulated lachrymal fluid and deionised
water, and stirred magnetically for 3 hours. The samples were then
homogenised for 10 minutes and sonicated for 45 minutes. They were then
made to pH 7.4 by drop wise addition of 2 M sodium hydroxide, and left in
the refrigerator overnight before use. Oscillatory tests using the rheometer
were performed at 15°C (to minimise sample dehydration and degradation
(171)), and 34°C (the temperature at the cornea surface (165,166)), using
ratios of 50:50 (129), 40:7 (representative of in vivo volumes upon
installation (172)), 4:1 and 1:4. The geometry and parameters used were
identical to those outlined in section 4.2.5.
4.2.8 Stability tests
To determine the long-term stability of each formulation, the gels were
monitored over a 4-month period at 4C. The rheology of each gel was
measured at time zero, and periodically over the subsequent 4 months.
The gels were also monitored visually for any signs of colour change,
turbidity or bacterial growth (173).
4.3 Results and discussion
4.3.1 pH studies
The change in pH of the gel after addition of the actives was noted (table
12).
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Table 12. pH effect on all gels after active addition (n = 3).
Concentration of gel# Active pH after addition of
the active (± SD)
1.0% w/w carbomer 934 Phe conjugate* 7.00 (± 0.09)
1.0 % w/w carbomer 934 Cysteamine HCl 7.20 (± 0.04)
1.0 %w/w carbomer 934 Cysteamine 7.40
1.0% w/w xanthan gum Phe conjugate* 5.31 (± 0.09)
1.0% w/w xanthan gum Cysteamine HCl 5.90 (± 0.08)
1.0% w/v HPMC Phe conjugate* 7.01 (± 0.04)
1.0% w/v HPMC Cysteamine HCl 7.40
* Phe conjugate required ethanol as a cosolvent to dissolve. # Initial pH 7.4
When formulated at a pH of between 4 and 6, PAA solutions act as in situ
forming gels (pH-dependent). When inserted into the eye, these carbomer
colloidal dispersions show a sol to gel transition as the pH is raised to that
of the eye, pH 7.4. In this study, all three of the hydrogels xanthan, HPMC
and carbomer were initially neutralised using sodium hydroxide and the
actives were added subsequently in SMPB (pH=7.4). These carbomer gels
are considered ‘preformed’ as opposed to in situ (112,114,116). It has
been reported that the ocular surface can tolerate a pH range of 6.6-7.8,
beyond this range patients can experience stinging or discomfort (127,174-
176). The inclusion of phe conjugate, cysteamine hydrochloride or
cysteamine to neutralised hydrogels was to cause changes to the pH
dependent on the initial concentration of polymer. All samples qualify as
preformed gels according to the definition used for an in situ gel, with the
exception of the xanthan gels (116). The xanthan gels will become more
viscous when inserted into the eye due to the presence of lachrymal salts,
and therefore are in situ gelling.
4.3.2 Optical Transmission
The optical transmission of the three gels was tested, along with the two
commercial gels Timoptol® and Viscotears® (table 13).
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Table 13. Optical transmission of the three gels and two commercial gels
(n = 3).
Optical Transmission of gels (%) (± SD)
Carbomer 934 Xanthan gum HPMC
No active 9.3 (± 0.16) 3.4 (± 0.35) 98.3 (± 0.06)
Phe conjugate 0.6 (± 0.2) 2.2 (± 0.06) 94.2 (± 0.06)
Cysteamine HCl 5.7 (± 0.18) 4.5 (± 0.36) 97.9 (± 0.12)
Timoptol® LA 95.6 (± 0.15)
Viscotears® Liquid gel 92.7 (± 0.13)
HPMC displayed the most ideal transmission of the three gels, consistently
above 90% with both the phe conjugate and cysteamine hydrochloride as
actives. Both carbomer 934 and xanthan gum showed less than 10%,
which is classed as opaque. In the case of the phe conjugate, this is due to
the presence of alcohol as a cosolvent (137). There may also be
precipitation due to the salt content of the gels causing opacity. The
commercial preparations displayed excellent transmission of light.
Timoptol® LA and Viscotears® liquid gel contain gellan gum and carbomer,
respectively, and are two of a small group of gel-based ophthalmic drops on
the market.
In situ, these gels would be less than a fraction of a millimetre thick, and
thus transmission would be increased greatly. The tear film has a thickness
of 7-8 µm (135). Only through in vivo work will the true transparency of
the gels be demonstrated.
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4.3.3 Rheology studies
4.3.3.1 Carbomer 934 gels
All of the carbomer samples displayed pseudoplastic flow behaviour as
previously reported for PAA hydrogels of this concentration (130)(figure
29). This is thought to occur through Brownian motion, whereby the
polymer chains regroup into positions with lower kinetic energy (177). An
initially high increase in shear stress as a function of shear rate (‘apparent
viscosity’) followed by a more gradual or constant increase can also be
interpreted as an ‘apparent yield stress’. Polymers that form weak gel
networks often display an apparent yield stress at low shear rates and the
elastic component of the viscoelastic behaviour can be quantified using
oscillatory measurements. To measure this component, a small stress, 
(mPa) applied at a frequency,  (rad.s-1) will create a reactionary strain, 
(mPa) with a smaller amplitude and associated phase lag,  (degrees) due
to the non-ideal nature of the gels’ viscoelastic properties (74).
A 1% w/w concentration was considered necessary to produce the
consistency required for a functional eye gel as the initial 0.1% w/w gels
produced were too fluid with viscosities akin to that of water. It has been
hypothesised that a viscosity of 12-15 mPa.s is optimal for ophthalmic
delivery (124,138), demonstrated through in vivo work with rabbits. A
viscosity of around 20 mPa is known to be acceptable to patients (143), and
preparations for ophthalmic instillation such as eye gels should ideally be
less than 30 mPas to maximise patient comfort (135). The power law was
used to quantify the flow type, as there was no apparent yield stress:
 = n
Where  = shear stress (pa),  = viscosity coefficient (Pa.s),  = shear rate
(s-1) and n = the rate index of pseudoplasticity.
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Figure 29. Rheology of 1% w/w carbomer 934 with 0.5% cysteamine
hydrochloride.
Continuous flow measurements with a 1% w/w carbomer 934 gel and
carbomer 934 gels containing cysteamine compounds are represented in
Figure 30. This indicates an increase in consistency with addition of phe
conjugate and cysteamine hydrochloride, and a slight decrease with
inclusion of cysteamine (table 14). As all of the samples are at equal pH
due to the use of SMPB, these differences may be due to strengthened
network interactions for the conjugate and the hydrochloride, and
decreased interactions for the cysteamine. This change in viscosity may
also have been as a result of the salt in the actives causing the side chains
to align against the backbone of the polymer structures, reducing flexibility
(178). The use of ethanol as a cosolvent decreased the viscosity and the
clarity of the gel.
Table 14. Viscosity coefficient values for carbomer 934 gels containing
different cysteamine compounds (n = 3).
Gel active Viscosity coefficient,  (Pa.s) (± SD)
No active 0.095 (± 0.03)
Cysteamine HCl 0.1 (± 0.02)
Cysteamine 0.9 (± 0.01)
Phe conjugate 0.095 (± 0.02)
112
0 100.0 200.0 300.0 400.0 500.0 600.0
shear rate (1/s)
0
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
sh
ea
rs
tre
ss
(P
a)
0
0.5000
1.000
1.500
2.000
2.500
3.000
3.500
4.000
4.500
5.000
viscosity
(Pa.s)
Phenylalanine conjugate
Cysteamine hydrochloride
No active
Cysteamine free base
Figure 30. Continuous flow curves for carbomer 934 gels containing
different cysteamine compounds at 34C.
The oscillatory shear results provide information on the gel structure. When
a stress is applied at a constant frequency, some of the energy is dissipated
in viscous flow and the remainder is stored, which is recovered when the
stress is removed. Viscosity and gel behaviour (viscoelasticity) can be
examined by determining the effect that an oscillatory force has on the
movement of the material. If the strain is within the linear viscoelastic
region, and therefore the yield stress is not reached, then the sample is not
destroyed. The storage modulus, G, is a measure of ‘dynamic rigidity’, the
amount of energy stored and recovered per cycle of deformation. The loss
modulus, G, is a measure of energy dissipated per cycle. A G value
greater than the G value is indicative of secondary bond formation (124).
Tan delta (loss tangent) gives information on the elasticity of a system, and
can be calculated from the ratio:
Tan  = G/G
A Tan  less than 1 indicates a solid, elastic, gel-like network, whereas a
Tan  greater than 1 indicates that the structure is more like that of a liquid
(124). A Tan  value less than 1 is advantageous for mucoadhesive
systems.
113
All of the carbomer 934 gels were found to exhibit a G greater than G, and
a tan  less than 1. This is indicative of secondary bond formation
(74,143). Results from the oscillatory measurements described in figure 31
and table 15 indicate very little effect of cysteamine hydrochloride, phe
conjugate and cysteamine on the loss tangent, suggesting the same degree
of elasticity for all carbomer 934 gels studied. A degree of elastic behaviour
at low shear stress reflects the weak gel properties of these formulations.
This propensity to form a gel under conditions of zero to low shear is
desirable for increased residence on the ocular surface. The oscillatory
results presented clearly indicate that the addition of cysteamine actives
(cysteamine, cysteamine hydrochloride and phe conjugate) to carbomer
934 gels does not appear to destroy these weak gel properties. The results
for the gel where ethanol was used as a cosolvent were comparable to
those with no active.
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Figure 31. 1% w/w carbomer 934 with 0.5% cysteamine hydrochloride
oscillation results.
Table 15. Oscillatory data for carbomer 934 gels (n = 3)(± SD).
Gel G(Pa) G(Pa) Tan 
Carbomer 934 no active 70 (± 1.8) 6 (± 0.5) 0.09 (± 0.02)
Carbomer 934 cysteamine HCL 119 (± 2.1) 10 (± 0.4) 0.09 (± 0.01)
Carbomer 934 phe conjugate 65 (± 1.1) 6 (± 0.6) 0.10 (± 0.02)
Carbomer 934 cysteamine 43 (± 0.7) 4 (± 0.8) 0.09 (± 0.02)
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4.3.3.2 Xanthan gum gels
Xanthan gum also displayed shear-thinning behaviour, with a slight yield
stress. It was also mildly thixotropic as previously reported (179) (Figure
32). These characteristics will be useful in preventing dosage loss during
initial installation into the eye.
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Figure 32. 1% w/w xanthan gum with 0.5% cysteamine hydrochloride.
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Figure 33. Effect of active addition on xanthan gels.
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Table 16. Viscosity coefficient values for xanthan gels containing different
cysteamine compounds (n = 3).
Gel active Viscosity coefficient, ’ (Pa.s) (± SD)
No active 0.05 (± 0.01)
Cysteamine HCl 0.05 (± 0.01)
Phe conjugate 0.05 (± 0.02)
The addition of actives phe conjugate and cysteamine hydrochloride to the
gel base does not alter the consistency of the gels (figure 33 and table 16).
This may be due to strong interactions within the xanthan double helix
structure (143).
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Figure 34. Oscillatory shear data for xanthan gels.
Table 17. Oscillatory data for xanthan gels (n = 3) (± SD).
Gel G(Pa) G(Pa) Tan 
Carbomer 934 no active 27 (± 0.2) 7.9 (± 0.1) 0.29 (± 0.01)
Carbomer 934 cysteamine HCL 28 (± 0.2) 7.5 (± 0.4) 0.27 (± 0.03)
Carbomer 934 phe conjugate 27 (± 0.3) 7.2 (± 0.2) 0.27 (± 0.01)
All of the xanthan gum gels were found to exhibit a G greater than G, and
a tan  less than 1 (figure 34 and table 17). This indicates that very little
change in structure was produced by the addition of actives, and that the
gel network remained intact.
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4.3.3.3 HPMC gels
HPMC at 1% w/v was found to behave as a Newtonian fluid, and had the
appearance of water as previously reported at low concentrations (180)
(Figure 35). There was no yield stress or thixotropy. After installation into
the eye, this gel will most likely be lost through the nasal-lachrymal ducts,
as it is weakly bioadhesive.
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Figure 35. 1% w/v HPMC displayed a Netownian rheology.
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Figure 36. Effect of active addition on the viscosity of HPMC gels.
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The viscosity is almost unchanged upon addition of the actives, with
cysteamine hydrochloride producing a marginal reduction in viscosity (figure
36 and table 18). HPMC is unaffected by pH, temperature or ionic changes.
Table 18. Viscosity coefficient values for HPMC gels containing different
cysteamine compounds (n = 3).
Gel active Viscosity coefficient, ’ (mPa.s)(± SD)
No active 6.5 (± 0.01)
Cysteamine HCl 6.7 (± 0.01)
Phe conjugate 6.6 (± 0.02)
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Figure 37. 1% w/v HPMC with 0.5% cysteamine hydrochloride oscillation
results.
The cross-over observed between G and G in figure 37 is indicative of the
destruction of secondary bonds within the HPMC gel (124). The gel would
lose viscosity in the eye when sheared by the action of the eye lids, allowing
it to flow out of the eye unless the gel network was quickly reformed. The
HPMC gels were found to display neither G greater than G’’, nor a tan  less
than 1, suggesting no secondary bond formation or gel-like networks. The
exception to this was when cysteamine hydrochloride was added, as
demonstrated in figure 37 and table 19.
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Table 19. Oscillatory data for HPMC gels (n = 3) (± SD).
Gel G(Pa) G(Pa) Tan 
HPMC no active 0.05 (± 0.01) 0.07 (± 0.01) 1.48 (± 0.2)
HPMC cysteamine HCL 0.08 (± 0.01) 0.06 (± 0.01) 0.7 (± 0.1)
HPMC phe conjugate 0.005 (± 0.002) 0.05 (± 0.01) 8.9 (± 0.3)
4.3.4 Dissolution studies
4.3.4.1 Phe conjugate as active
Figures 38 to 40 show the percentage release of the phe conjugate from
each gel. The release from the gel was analysed by the Higuchi method
(Table 21). The average area of each membrane rod is shown in table 20.
Table 20. Average membrane rod areas for each gel (n = 3).
Gel Average membrane rod area (cm2)(± SD)
Carbomer 934, phe conjugate 20.32 (± 0.15)
Xanthan gum, phe conjugate 19.97 (± 0.15)
HPMC, phe conjugate 23.45 (± 0.15)
Carbomer 934, cysteamine HCl 6.28 (± 0.12)
Figure 38. Percentage release of phe conjugate from carbomer 934.
On average 95% of the phe conjugate was released from the carbomer 934
gels after 420 minutes.
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Figure 39. Percentage release of phe conjugate from xanthan gum.
The xanthan gum gels released 95% of phe conjugate after 435 minutes on
average. The triplicate results were identical.
Figure 40. Percentage release of phe conjugate from HPMC.
HPMC released 95% of phe conjugate after 390 minutes on average.
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Table 21. Results of the Higuchi model analysis on each of the three gels.
Gel sample time (minutes)
Higuchi model, kH
2 35 75 240 420 540
Carbomer 934, phe conjugate 0.05 0.08 0.08 0.07 0.06 0.04
Xanthan gum, phe conjugate 0.06 0.08 0.09 0.08 0.07 0.07
HPMC, phe conjugate 0.07 0.11 0.12 0.09 0.07 0.07*
Carbomer 934, cysteamine HCl 0.25 0.24 - - - -
*495 minutes
The in vitro release from each gel could be categorised as first-order Fickian
diffusion. This is indicative of reversible interactions between the polymer
matrix and the active and uninterrupted drug release from the gels.
The dissolution tests for the three gels demonstrated that the gels released
the phe conjugate over a prolonged period of time. This is in support of
previous studies which demonstrated sustained drug release over an 8-hour
period from gels for ophthalmic delivery (181). This slow release of drug
may be as a result of ionic interactions between the negatively charged
polymers carbomer and xanthan and the positively charged phe conjugate
(124). Where the constant administration of eye-drops is the routine
method of drug delivery, as is the case with cystinosis, the development of
a controlled release formulation is desirable. These results indicate that this
may be achieved using ophthalmic gels as a vehicle for ophthalmic delivery.
4.3.4.2 Cysteamine hydrochloride as active
Figure 41 shows the release of cysteamine hydrochloride from carbomer
934 gels.
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Figure 41. Percentage release of cysteamine hydrochloride from carbomer
934 gels.
On average, 95% of the cysteamine hydrochloride was released after 30
minutes. This is a faster release than was recorded with the phe conjugate,
although in combination with the bioadhesive properties, this gel should be
a marked improvement over traditional eye drops. The work conducted by
Bozdag et al in 2008 (51), showed an incompatibility between cysteamine
hydrochloride and carbopol. However, they did achieve in vitro release
over 8 hours using HPMC.
It is hypothesised that the faster release rate observed with cysteamine
hydrochloride is due to the smaller, more hydrophilic nature of the drug
when compared to the phe conjugate.
Using both the phe conjugate and cysteamine hydrochloride as actives,
equilibrium solubility has been displayed, where drug particles reach
equilibrium between the gel and the aqueous media. In vivo, the drug
would be absorbed by the cornea or surrounding tissues, and allow more
drug to be released by the gel.
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4.3.5 Bioadhesion studies
PAA has been shown to have excellent bioadhesive properties in comparison
to other gels as reported by Slovin and Robinson (121) and its ability to
increase ocular residence time, relative to traditional eye drops, has also
been reported (182). It should be noted however that the negative charge
on the corneal epithelium (183,184) would be expected to provide a natural
barrier to adhesion of a highly anionic polymer such as PAA. In practice,
the significant yield stress of PAA gels, particularly at a concentration of
1.0% w/v, would appear to counteract this effect causing the gel to remain
on the surface of the corneal epithelium despite microadhesion being weak
or non-existent.
The force required to remove the gels from the tissue corresponds to
secondary, chemical interactions, while the AUC values relate to physical
entanglements between the polymer gel and the tissue (153,169). The
Mann-Whitney analysis reveals significant bioadhesion between the corneal
tissue and the carbomer gels containing both phe conjugate and cysteamine
hydrochloride, although this is not the case for AUC (Table 22). The agar
tests confirm these results to some extent, with cysteamine hydrochloride
gels showing significant bioadhesion for AUC data. Physical entanglements
will probably occur in vivo, due to the presence of mucus.
Table 22. Results of bioadhesion assay for carbomer 934.
Carbomer 934 Force (N) AUC
Tissue vs plain gel 0.067b 0.205b
Tissue vs gel with cysteamine HCL 0.107b 0.177a
Tissue vs gel with phe conjugate 0.107b 0.196b
Agar vs plain gel 0.134 0.29b
Agar vs gel with cysteamine HCL 0.177a 0.35b
Agar vs gel with phe conjugate 0.159a 0.27b
p<0.05 a, p<0.01 b.
The Mann-Whitney analysis of the xanthan gum gels shows significant
bioadhesion for the tissue tests only, while the agar tests are devoid of
bioadhesion (Table 23).
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Table 23. Results of bioadhesion assay for xanthan gum gels.
Xanthan gum Force (N) AUC
Tissue vs plain gel 0.051b 0.091b
Tissue vs gel with cysteamine HCL 0.108b 0.150b
Tissue vs gel with phe conjugate 0.76b 0.145b
Agar vs plain gel 0.276b 0.39b
Agar vs gel with cysteamine HCL 0.242b 0.314b
Agar vs gel with phe conjugate 0.223b 0.28b
p<0.05 a, p<0.01 b.
Analysis of the HPMC gels show bioadhesion between the agar plates and all
gel types. However, the tissue tests show significant bioadhesion only with
cysteamine hydrochloride (force) and the phe conjugate (AUC) (Table 24).
Table 24. Results of bioadhesion assay for HPMC gels.
HPMC Force (N) AUC
Tissue vs plain gel 0.076 0.051b
Tissue vs gel with cysteamine HCL 0.081a 0.048b
Tissue vs gel with phe conjugate 0.065a 0.061b
Agar vs plain gel 0.095b 0.091b
Agar vs gel with cysteamine HCL 0.110 0.098b
Agar vs gel with phe conjugate 0.161 0.113b
p<0.05 a, p<0.01 b.
It has been reported that pH, ionic strength, molecular weight and chain
flexibility all affect the bioadhesive properties of PAA gels (155,185)
however, it appears that the mechanisms of polymer attachment to mucosal
surfaces are still not fully understood (186). There is speculation that
bioadhesion is the net effect of many physicochemical factors that include
attractive forces such as hydrophobic interactions, hydrogen bonding and
van der Waals attraction; physical entanglement of polymer chains via
diffusional processes and electrostatic interaction of an attractive or
repulsive nature all contribute to the bioadhesive process. It appears that
the inherent rheological properties of ophthalmic gels may also have a
decisive role to play with respect to improved residence on the eye. The
precise reasons for the apparent bioadhesiveness of gels requires more
study (121,132).
Carbomer 934 and xanthan gum gels both display excellent bioadhesion,
providing the possibility of sustained release through improved residence
time. HPMC displayed the weakest bioadhesion, possibly due to its low
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viscosity and non-ionic nature. This finding is in agreement with other
studies (138). Carbomer 934 has been shown to be less mucoadhesive
than another carbomer grade, 974, which is manufactured without the use
of benzene (123). While the 934 grade is cross linked with allyl sucrose and
polymerised in benzene, the 974 grade is cross linked with allyl penta
erythritol and polymerised in ethyl acetate.
The presence of thiol groups in cysteamine hydrochloride is likely to aid the
bioadhesion of the gels to the corneal epithelium, by forming disulphide
bonds with the thiols of the lachrymal mucus (133). In addition, tear fluid
contains positive ions (cations) while lachrymal mucus contains negative
ions (anions), allowing various ionic interactions to occur, regardless of the
electric charge on the polymer used (138). These interactions will increase
the corneal residence time, further improving cysteamine bioavailability.
Physical entanglements are also likely to occur between the mucin
glycoproteins and polymer chains in vivo, thereby strengthening the
bioadhesion effect.
4.3.5.1 Oscillation rheology
The absence of rheological synergy, observed as values for G and G
below 100% under all test conditions (table 25), may be as a result of ions
in commercially-prepared mucins (155,156). The ions released through the
extraction process can interfere with and disrupt the gel structure. Mucus
rheology is also affected by the mucins composition and glycosilation,
degree of hydration and ionic composition (123).
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Table 25. Synergy tests using oscillatory rheology (selected data only,
n = 3, ± SD).
Gel/mucus G(Pa) G(Pa) ΔG(Pa) ΔG(Pa)
Carbomer 934 1% w/w no active 118.7 10.15 119.31
(±1.2)
12.94
(± 0.4)Mucus 0.61 2.79
Carbomer gel no active, mucin 50:50 0.88 1.27 0.74% 9.8%
Carbomer gel phe conjugate, mucin 50:50 0.90 1.27 0.75% 9.8%
Carbomer gel no active, mucin 1:4 0.24 1.43 0.2% 11.1%
Carbomer gel no active, mucin 4:1 12.51 3.78 10.49% 29.2%
Close contact between the gel and mucus layer (particularly if the mucus
layer becomes dehydrated) can promote interdiffusion and entanglements
between polymer and mucin chains which can strengthen the mucoadhesive
bond (123). Carboxylic groups along the polymer chain can further
strengthen the mucoadhesive joint by hydrogen bonding with the mucin
layer.
4.3.6 Stability tests
The average storage temperature for all samples over the four-month
stability test period was 4.5°C.
4.3.6.1 Carbomer 934
Figures 42 to 45 show the plots from the rheological tests of the carbomer
gels over time.
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Figure 42. Carbomer 934 gel stability containing no active.
The reduction in viscosity observed between time zero and two weeks is
possibly due to bacterial contamination causing polymer degradation.
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Figure 43. Carbomer gel stability over time containing phe conjugate.
The phe conjugate imparts a greater stability to the gel, observed as a
reduction in viscosity variation over time when compared to carbomer gel
alone (figure 42). This may be as a result of the presence of salts in the
phe conjugate strengthening the polymer structure.
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Figure 44. Carbomer gel stability over time containing cysteamine
hydrochloride.
There has been a decrease in viscosity over time, particularly between 2
weeks and 1 month.
The carbomer 934 gels containing the phe conjugate as the active are the
most stable, with almost no change observed in the rheology over four
months. The gels containing cysteamine hydrochloride appeared stable at 2
weeks, but by 4 weeks the rheology had altered dramatically. This may be
due to the presence of salts in the actives affecting the stability of the gel
structure.
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Figure 45. Carbomer 934 oscillation data over time.
The oscillation results support the continuous shear measurements. All of
the carbomer gels still displayed a G greater than G, and a tan  less than
1 after 12 months, demonstrating that the gel structure was intact.
4.3.6.2 Xanthan gum
Figures 46-48 demonstrate the rheology of the xanthan gum gels over time.
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Figure 46. Effect of time on the viscosity of xanthan gels containing no
active.
This reduction in viscosity over time may be as a result of degradation of
the polymer over time due to hydrolysis.
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Figure 47. The rheology of xanthan gum containing cysteamine
hydrochloride over time.
The reduction in viscosity observed between time zero and two weeks may
be as a result of polymer degradation.
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Figure 48. Oscillatory results for xanthan gum over time.
The lack of a gel network, illustrated by G > G, suggests that the xanthan
gels are instable over time. The presence of benzalkonium chloride may
have destroyed any secondary bonds which were present.
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4.3.6.3 HPMC
Figures 49-51 display the rheology of HPMC gels over time.
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Figure 49. Rheology of HPMC containing no active over time.
There is virtually no change in the rheology of the gels over time,
suggesting that HPMC gels are very stable over four months.
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Figure 50. The rheology of HPMC over time, containing cysteamine
hydrochloride.
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The HPMC gels containing cysteamine hydrochloride appear to be as stable
over time as the gel alone without any active component (figure 49).
Figure 51. Oscillatory data of HPMC gels over time.
There has been a large reduction of G over time, although evidence of a
gel network can still be seen as G > G.
4.4 Conclusion
The gels were formulated to be weakly adherent to the eye tissue and tests
confirmed this for both the carbomer and xanthan gum gels. Carbomer 934
showed statistically significant bioadhesion, against tissue and agar.
Xanthan gum was found to display the most comprehensive and statistically
significant bioadhesion of all three gels, against tissue only. HPMC
displayed the weakest bioadhesion of all three gels, against tissue and agar.
This may be due to a low viscosity. Stability tests show carbomer gels to
be stable without a preservative over 2 weeks, and the gel structure is
intact after 4 months of storage at 4°C. Overall, the carbomer and xanthan
gum gels appear promising for improved performance upon the current eye
drops.
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The results demonstrate that the formulation of cysteamine hydrochloride
as a gel for ophthalmic delivery is achievable. The three ophthalmic gels
were found to possess similar characteristics and exhibit properties
desirable for eye gels. The xanthan and carbomer gels tested formed weak
gel networks at zero to low shear stresses, desirable properties for
increased residence time on the ocular surface. A net bioadhesion and first
order release of the active from the sample matrix was also apparent. On
average the experimental compound was released over an eight-hour
period. The current ophthalmic treatment requires hourly administration
whilst the patient is awake, allowing a treatment-free period overnight. It
is thought that these gels could provide overnight drug treatment, through
prolonged contact and decreased drainage, thereby permitting a decrease in
daytime administration. Furthermore, the addition of cysteamine did not
destroy the gel properties.
These results offer the possibility of a gel formulation of cysteamine, which
would considerably enhance the quality of life for patients with the ocular
complications of cystinosis. They may also be suitable as a base gel for
other ophthalmic drugs.
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Chapter 5 – Pulmonary delivery
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Chapter 5 – Pulmonary delivery
5.1 Introduction
5.1.1 History of respiratory delivery
The lungs have been targeted to treat respiratory disease since the first
century, when Pedanus Discorides, the Greek physician and pharmacologist,
prescribed inhaled fumigation (187). Thomas Clover first described inhalers
for general anaesthesia in Britain in 1877 (187). However, it wasn’t until
the 1940s that nebulisers were first used to treat respiratory diseases. In
1956, MDIs were invented to treat respiratory diseases such as asthma,
while dry powder inhalers have been used since the early 1960s (74).
Some of the most commonly prescribed inhalers are Ventolin® (GSK),
QVAR® (Teva), Serevent® (GSK) and Bricanyl® (AZ), which are all used to
treat asthma.
More recently, the lungs have become a target for systemic treatments. In
2006 the inhaled insulin product Exubera® (Pfizer) was launched for the
treatment of diabetes (188). However, the manufacturers withdrew the
product after 14 months due to poor sales levels (189). It was found to be
equivalent in efficacy to the existing short-acting insulin, meaning at least
one daily injection of insulin was still needed. It was also double the cost of
the existing therapy, leading the National Institute of Clinical Excellence
(NICE) to advise local health boards to prescribe it only for patients with
serious needle phobia, or injection site problems (190). After withdrawal
from the market, a report was published which found an increased risk of
lung cancer in ex-smokers using Exubera® (189). As such, there is
currently only one inhaled drug licensed for systemic treatment. Relenza®
(GSK) was the first inhaled drug to be marketed for systemic treatment
(191). It is used to prevent and treat influenza. Studies have shown that
Relenza® has around a 2% bioavailability, and should be used with caution
in asthmatics and people with respiratory ailments, a patient group
particularly susceptible to the flu (192,193). There are issues over the
drug’s cost, and this further limits its use (194).
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5.1.2 Pulmonary delivery in cystinosis
Despite cystinosis affecting nearly every tissue in the body, lung disease
has not been reported. Evidence suggests that late-stage lung dysfunction
is caused by intercostal muscle impairment, the muscles which power
inhalation, and not lung disease itself (5,195). This complication primarily
affects individuals who have not received oral cysteamine therapy from
infancy. Pulmonary function tests show a 50% reduction in lung volume for
size and age. A cystinosis patient’s chest cavity may also be conical due to
early rickets, lowering inspirational volume (5). The impact of disease
states on the absorptive capacity of the lung is undetermined (196).
There is only one study to date that has examined inhaled cysteamine
(197). Mice were exposed to nebulised cysteamine prior to receiving
chemotherapy, in an attempt to reduce radiation-induced lung damage, i.e.
not for the treatment of cystinosis. They were also given intraperitoneal
doses. Cysteamine is effective for this indication when administered orally.
The aerosol proved to be ineffective however, while the intraperitoneal
doses were effective. It was concluded that the concentration of
cysteamine reaching the peripheral lung was inadequate when delivered by
nebuliser. Aerosol particle size was too large to reach the alveoli, as
medical nebulisers are designed to target the airways and not the alveoli.
The author states that cysteamine is active in the lung, and that future
studies should aim to increase the dose and decrease the particle size
(197).
5.1.3 Lung anatomy
The structure of the lungs is shown in Figure 52. The trachea or windpipe
divides into two branches, called bronchi, where the lungs begin. These
bronchi continue to divide into bronchioles, which lead to alveolar sacs.
These are clusters of alveoli, tightly wrapped in blood vessels. There are
millions of alveoli in each lung. The total alveoli surface area for both lungs
is 100 square meters (198,199), with 70 square meters in contact with
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capillaries (196). The capillaries stretch for 2000 km (200). All of these
factors endow the inhaled route with a potentially high bioavailability (189).
Figure 52. Diagram of particle sizes for lung delivery, with the
corresponding Andersen Cascade Impactor (ACI) stages (201).
Small molecules can be absorbed within seconds of inhalation via this route
(202), either by absorption through epithelial cells or by alveolar
macrophages. Hydrophilic molecules in particular are favoured in lung
epithelial transport (203), and this should maximise the absorption of
cysteamine. Particles of aerodynamic diameter 3 µm are an optimum target
for ensuring drug absorption via alveolar macrophages (204). There is
reduced uptake by alveolar macrophages of particles below 0.26 µm (205).
The epithelium of the airways is lined with tiny hairs called cilia, which carry
any insoluble particles up to the throat for swallowing (74). The mucociliary
pathway carries mucus out of the lungs at an estimated 4 mm/min (206).
Larger particles will be swept away by cilia (188), which particularly affects
the upper airways. Phagocytic activity is more prevalent in the lower
airways (188). Larger particles tend to impact on the back of the throat, or
get swept out of the lungs by cilia, while smaller particles are carried out of
the lungs upon expiration. Another factor leading to large drug absorption
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is the thickness of the epithelium, which can be as much as 60 µm in the
trachea, but as little as 0.2 µm in the alveoli (189,199,202).
The mucus layer in the trachea is thicker than in the lower airways (188).
In addition, an elevated blood flow of 5 L/min ensures rapid drug
circulation. The lungs do not have a low degrading pH or enzymes like the
GI tract, and once absorbed, the drug directly enters the system circulation
and avoids the first pass effect (189,207). This allows a smaller dose to be
given, further reducing the likelihood of side effects.
Lung-Lining fluid (LLF) has several roles, the main one being host defence.
It is also vital for lung structure and function, by providing lubrication to the
pulmonary epithelium, and maintaining fluid surface tension (208). It is
important in gaseous exchange. The volume of the LLF has been calculated
to be 15-70 ml in healthy adults (208,209). LLF is further categorised into
airway surface liquid (ASL), which covers the conducting airways, and
alveolar subphase fluid (ASVF), which is only found lining the alveolar sacs.
ASL is composed mainly of water, with a mucus component of mucin
glycoproteins and proteoglycans, which endow a gel-like structure. The
glycoproteins are present both on the surface of the epithelium and
secreted, the rate of secretion being largely controlled by inflammatory
mediators and neurotransmitters. This is the most likely explanation for
mucus hypersecretion present during airway inflammation (208). ASL
operates in conjunction with the cilia, as particles of diameter 5 µm or
greater are trapped in the ASL, which are then cleared from the lungs via
the mucociliary escalator to the throat for swallowing.
ASL contains lysozymes, lactoferrin, immunoglobins and phagocytes
amongst other antimicrobial factors, which all aid in limiting foreign
particulate invasion (208). These antibacterial molecules also add to the
rheological character, endowing it with increased viscosity and elasticity
(206). It is pH 6.6 during periods of health and non-inflammation, but
becomes more acidic when the person has disease or lung inflammation
(208).
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ASVF is composed of mainly water with a surfactant. It is 0.1-0.2 µm thick,
and is sterile due to the large number of macrophages. It traps particles of
diameter 5 µm or less, which are then taken up by macrophages, and either
carried up to the throat by cilia, or absorbed and released into the blood
stream (208). The surfactant is composed mainly of phospholipids, and
also contains cholesterol and proteins (210).
The humid atmosphere of the lungs has a large impact on the aspirated
particles. Inside the airways it is approximately 99% relative humidity
(RH), compared to the ambient room humidity of around 50% (74). As it
enters the lungs, the particle collects condensation on its surface. The
particle will continue to collect water until equilibrium exists between the
vapour pressures. This way, the inhaled particle will gradually increase in
size, altering the predicted flow into the lungs. This phenomenon can be
avoided by coating the particle with a lipophilic coating (207).
5.1.4 Inhaled bioavailability
The bioavailability of inhaled drugs is reportedly as low as 8%
(200,202,211). The dose which impacts on the throat and upper airways is
subsequently swallowed, and is then available to the systemic circulation
once absorbed from the gut (212). The total percentage which actually
reaches the lungs is typically between 20 and 40% (211,212). The lungs do
not possess degrading enzymes, and also avoid the first pass effect. This
allows a smaller dose to be delivered, and circumvents the issues of low
drug delivery.
5.1.5 Inhaler types
There are three main inhaler types currently available: Metered-Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and nebulisers.
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MDIs
The drug is dissolved or suspended in a liquid propellant, along with
excipients, and sealed in a pressurised canister. Upon actuation, the
patient must inhale simultaneously to avoid the dose being lost (74).
DPIs
The patient inhales the drug in a propellant-free cloud of fine particles.
DPIs are mainly breath-actuated devices, although some modern devices
incorporate a powered system to aid particle break-up. DPIs avoid
problems with the coordination of actuation and inhalation required for
MDIs, and larger doses can be delivered than with an MDI. DPIs also allow
a greater stability for the drug (207).
Nebulisers
The drug is dispersed in an aqueous solution, and fine droplets as a mist are
produced for inhalation. This delivery device is useful if the drug is
unsuitable for MDI or DPI formulation, or if the dose is large. The patient
can also breathe normally, and the drug will be delivered efficiently (74).
A DPI was chosen for the delivery device of the drug, due to practical and
economical factors (213). Formulated powder is filled into hard gelatine
capsules, which are subsequently loaded individually into a Handihaler®
device (Figure 53).
Figure 53. The Handihaler® device used in this project (214).
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Once the capsule has been pierced and air flow is initiated, the capsule
spins within a chamber inside the device, allowing the powder to escape
through a hole at each end. The de-agglomeration of powders is a complex
process involving centrifugal force, fluid mechanics, adhesion, turbulence,
shear forces, impaction, the impact of the capsule with the device, and of
the powder with a grid or mesh. These factors all contribute to the
fluidisation and de-agglomeration of the powder, particularly the mechanical
impaction of the powder with the impact angle on the throat (215). The
free-flowing powder then leaves the device through the mouthpiece, and
into the patient’s lungs.
DPIs are termed ‘passive’ devices, in that the patient’s inspiration alone
operates the device. DPIs require the patient to inhale deeply and with
some force, as particle de-aggregation is dependent on this (216). Inside a
DPI, inhalation flow and the resistance within the inhaler gives rise to
turbulent flow, which leads to flow-dependant dose emission. It is
extremely important that the patient receives counselling on the use of their
inhaler, as poorly de-aggregated particles will impact on the throat and
oropharynx, with a result of the loss of the dose. The strength and duration
of the patient’s breath are therefore critical parameters in the in vitro
testing process. When testing DPIs, both the European and US
Pharmacopoeias state that the flow rate used should produce a pressure
drop across the inhaler of 4 kPa, while the duration of flow should give a
volume of 4 Litres. This is broadly representative of a normal, healthy adult
male of 70 kilos in weight, inhaling ‘as deeply and as hard as possible’
(217). The initial acceleration rate is important to detach the drug
molecules from the carrier particles. Cystinosis patients are generally
underweight, and children will not be able to achieve these values. Most
patients inhale for a period of 2 seconds on average, which is half the
recommended period in the USP. However, as most DPIs deliver their dose
within 100-300 ms of initiation of use, this should not be a problem (218).
Measuring the pressure down-stream of the device, and comparing this with
atmospheric pressure can be used to calculate the pressure drop across the
device. There is a consensus that a flow of 30 L/min should be achieved
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when using a DPI (217). The European and US pharmacopoeias state that
the flow rate should be within +/-5% of the target flow.
The following relationship can be used to calculate the pressure drop across
an inhaler:
R = Q/P
Where R is the resistance, Q is the flow rate in L/min, and P is the
pressure drop (cm H2O) (217). The Handihaler® device has been reported
as having one of the highest resistance values of commonly prescribed
inhalers, which is probably due to the basic nature of the device (217). In
most DPIs, the patient ‘activates’ the dose by twisting the device, or in
some cases just by opening it. This produces a free bolus of drug powder
which can be inhaled with minimal effort. However in the case of the
Handihaler®, the powder remains in a pierced capsule, and it is the patient’s
inhalation alone which liberates it. Nevertheless, a flow of 40.4 L/min has
been shown to produce a 4 kPa pressure drop across the device, and it has
been demonstrated that most patients in a study achieved this, despite
suffering from chronic obstructive pulmonary disease (COPD) (217). This
should give reassurance to critics who may suggest that small, weak
cystinotic children cannot inhale at the flow necessary for successful
respiratory delivery.
5.1.6 Fate of inhaled microparticles
The deposition of powder in the respiratory tract is influenced by particle
size, size distribution, breathing pattern and the delivery device (188),
particle size being the most influential factor in lung targeting efficacy. To
target the lungs efficiently, particles must have an aerodynamic diameter of
1-5 µm (196,207,211,213). Aerodynamic particle size takes into account
the particle’s size, shape and density, and therefore it is widely accepted as
the key parameter in determining lung deposition (219). Particles below 2
µm are perfect for targeting the alveoli (74).
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Once inhaled, aerosols deposit in the airways in three main ways;
gravitational sedimentation, inertial impaction and Brownian diffusion (74).
Gravitational sedimentation
This is the main mechanism of distribution for particles with an aerodynamic
size range of 0.5-5 µm. It is mainly influenced by increasing particle size
and residence time, but decreases as respiration increases. This is the main
factor influencing particles in the small conducting spaces with low air flow
(215).
Inertial impaction
This mainly affects particles with sizes of 5 µm and greater. It is an
important mechanism, particularly affecting the upper respiratory tract and
large conducting airways. The changing physical contours of the throat and
larynx and large flow velocities are responsible for this phenomenon. The
likelihood of impaction increases with increased air flow, rate of breathing
and particle size (216).
Brownian diffusion
This only affects particles with diameters less than 0.5 µm. These micro
particles impact with surrounding air molecules, and tend to migrate to the
vessel walls, especially in areas with low airflow such as alveoli (220).
5.1.7 Microsphere production
There are several techniques available to produce micro particles suitable
for inhalation. Milling, emulsion solvent evaporation (ESE) and spray drying
are the most commonly employed methods (207). Milling has the
advantage of producing solvent-free particles, but allows poor control of
particle size. ESE is much slower than spray drying, in the magnitude of
days compared to minutes, but is excellent for use with thermo labile
compounds. Spray drying is a popular choice due to its numerous
advantages over alternative methods, and was the method chosen for this
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project. None of these methods can precisely control the geometric particle
size distribution (219).
5.1.7.1 Milling
Milling is the traditional method of choice for producing micronised particles.
There are many different types of mills, including ball, colloid, hammer and
jet mills. A jet mill is most commonly used for micronisation of particles for
inhalation (204). Large particles are broken down into smaller particles
through inter-particle collision and attrition. Most of the particles produced
will be within the size range of 1-20 µm, although there is little control over
size, shape or surface properties (204). The particles produced by this
method also tend to be chemically degraded and highly charged due to the
high energy input of the process, which can then lead to static electricity
build up and agglomeration, which can produce instability of the drug.
5.1.7.2 Emulsion solvent evaporation
Microspheres are produced through the evaporation of a constantly-stirring
emulsion mix of drug and excipients. Heat is supplied to accelerate the
process. The significant exposure of the drug to the environment and high
temperatures precluded this method from the study.
5.1.7.3 Spray drying
Spray drying has been used to produce powders for inhalation since the
1980s, to produce uniform particles of microscopic diameter (213,219).
Solvent containing active ingredients and excipients are forced through a
small jet nozzle into a stream of hot air, which vaporises, leaving behind
individual solid particles (74) (Figure 54).
146
Figure 54. Diagram of a typical bench top spray dryer (221).
These particles are typically amorphous hollow spheres, sometimes with a
small hole (219). This is due to the drying process, whereby the outer
surface dries to a crust before the centre, and the liquid centre then
vaporises and escapes through a hole blown in the crust. There are several
advantages of spray drying, including:
1. Rapid, one step process
2. Uniform particles with excellent flow properties
3. Evaporation is extremely quick, thermo-labile drugs can be used
without being destroyed
4. A high yield is achievable
5. Can be used for a wide range of substances, in solution or suspension
(74).
6. Particles are usually organic solvent-free.
The mini (bench top) spray dryer used in this project is useful for initial
stage testing, when only a minimal weight of drug is available. However,
there are some disadvantages of using this system. The drying chamber is
too small, typically less than 10 litres, which makes the drying-gas
residence time less than one second. This limits the drying capacity of the
apparatus, and allows only the smallest droplets to become completely dry,
leaving a larger volume of residual solvent than is desirable. In an attempt
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to offset this effect, a lower flow rate than preferred has been used in the
process (222).
There is an intricate relationship between process variables such as inlet
temperature and flow rate, and feed variables such as concentration and
solvent choice, and these all affect particulate kinetics and morphology
(223). Particle size can influenced within the spray drying technique by
altering the concentration of drug in the feed solution: the lower the
concentration, the smaller the particle size (224). Increasing the
temperature can also reduce the particle size. The molecular weight of the
polymer is also important for successful microsphere formation. A
concentration of between 0.5-2.5% w/v is typically used. Too low a
concentration can result in incomplete microspheres, where too high a
concentration can produce agglomeration (223).
Due to the minute size of the particles produced, static electricity can be a
problem, leading to agglomeration. There can therefore be a poor recovery
rate from the inside walls of the dryer, which may also give poor
aerolisation (220,225). It has also been reported that particles less than 2
µm have low collection efficiencies (204). There is also a high risk of the
pneumatic nozzle clogging. An alternative ultrasonic nozzle may lower the
likelihood of this occurring, as well as producing particles with a more
uniform size distribution (204).
5.1.8 Static electricity and agglomeration
Agglomeration is a problem commonly seen in DPIs (226). The low size
range necessary for optimum lung delivery produces a large surface-area-
to-volume ratio, which favours interparticulate forces over gravity and
aerodynamicity. This gives rise to static electricity problems, where minute
particles aggregate together producing a powder with agglomeration and
poor flow properties (227). DPIs require good flow properties to allow the
patient to breathe in the powder and direct it accurately at the deep lung,
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with minimal losses to the GI tract. Agglomeration due to friction causes
inconsistent drug delivery.
The most common method used to solve the aggregation problem is to
combine the drug molecules in a homogenous blend with an inactive carrier,
such as lactose (224,227). The lactose grade used in this project was α-
lactose monohydrate, which possesses relatively flat particle surfaces (227).
The lactose molecules are much larger than the drug molecules attached to
them (typically 20-100 µm), and therefore the lactose impacts in the
oropharynx, while the drug particles are carried deep into the lungs (228).
There is a fine balance between adhering the drug to the lactose with
enough force to carry the drug to the lungs, but not so strongly that it won’t
disperse upon inhalation (227). The specific force of interaction must be
surpassed to dislodge drug particles (199). There are four main forces
adhering drug particles to carriers:
1. Mechanical adhesion through irregularities on the surface
2. Capillary action from water
3. Static electrical charges
4. Van der Waals forces
These forces prevent adequate aerosol production. Keeping moisture
content at a minimum reduces the capillary forces. Capillary forces are
reciprocally related to surface charge, and develop from the condensation of
water onto particle surfaces. If a large enough volume of water is
condensed, an attractive force is induced. The moisture which condenses
can also produce irreversible aggregation and solid bridge formation, giving
larger particles and poorer lung penetration (199). Therefore, immediate
protection from environmental moisture upon manufacture is extremely
important.
Low deposition efficacy in DPIs is most commonly caused by poor drug
separation from the carrier particle (199), which is governed by drug-drug
and drug-carrier interactions. Interactions which are too weak lead to re-
separation, and interactions which are too strong lead to upper airway
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deposition (229). The balance must be perfect to ensure the drug remains
attached to the carrier during manufacture and transit, but releases upon
inspiration. Separation occurs through three main mechanisms:
1. Shear flow and turbulence
2. Particle-device impaction
3. Particle-particle impaction
For carrier particles with a large surface area and significant asperities, as is
the case in this project, impaction is the predominating mechanism (227).
This occurs when the particle impacts with the device, and is dependent on
momentum. Momentum is related to particle size, therefore the larger
particles will generate larger impaction forces (227). If the surface
roughness of the carrier particle is too great, drug molecules may be
shielded from detachment forces (227), and have areas of higher energy to
attach to. Some strongly adhered particles may not break apart, even after
leaving the device (219).
The optimum impact angle for de-agglomeration is 45 degrees (226).
Higher velocity air flow also improves de-agglomeration, but increases
throat impaction and drug loss. There is a delicate balance between
improved deep-lung penetration and loss to impaction (226). Fine particle
fraction is maximised using a combination of two 45-degree angles, with
minimal loss to impaction. Studies analysing air flow patterns within the
90-degree throat of the ACI show particles initially drop to the bottom of
the throat, accelerate along the throat and are lifted by the airflow. The
centre of the pipe has the maximum velocity, and this reduces gradually to
the slowest, virtually still part nearest the wall of the throat (226).
Surfactants can also be used to de-aggregate particles, but can prematurely
release drug through lowered microsphere/medium interfacial tension
(223).
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5.1.9 Poly(D,L-lactide) (PLA)
Biodegradable polymers are becoming a popular method of ensuring
controlled drug release, through encapsulating drug particles. The higher
molecular weight PLAs are also established as surgical implants and devices
(230,231). Low molecular weight RESOMER
®
R 202s, Poly(D,L-lactide)
(PLA) was chosen for encapsulating cysteamine bitartrate, due to its
biodegradable, biocompatible and non-toxic nature (188,205,231-234)
(Figure 55). Cysteamine bitartrate was used for the respiratory powder
work as it was less deliquescent than the hydrochloride salt (see section
5.2.2). PLA was granted approval by the FDA in 1984 for use in drug
formulations (223). Poly(lactic-co-glycolic acid) (PLGA) was also
investigated for suitability in lung delivery but was found to be extremely
slowly degraded in the lung (205). As this formulation is for the treatment
of a chronic condition, it was eliminated from the study over concerns of
polymer build-up.
Figure 55. Monomeric repeating unit of Poly(D,L-lactic acid), where n ≈
7700 (235)
Biodegradable polymer encapsulation also enhances the stability of the drug
(188). It has been used previously for sustained release to the lungs
(188,210,234,236,237). Recently, it has been used to provide
encapsulation and controlled release for anti-cancer agents (238).
Polymers have also demonstrated an ability to promote the mucus
penetration of coated particles in the lungs (239). Poly(D,L-lactide) is the
racemic polymer of two stereoisomeric forms, D-PLA and L-PLA (230). PLA
is optically inactive. Upon degradation, the Krebs cycle component lactic
acid is liberated, and thus the polymer is atoxic (240). It is also
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amorphous. Poly(D,L-lactide) produces superior particle morphology than
D-PLA and L-PLA, which are liable to exhibit craters, pores and collapsed
particles, possibly due to crystallinity (223). Poly(D,L-lactide) displays
superior film-forming characteristics, and is solubilised under moderate
conditions, which may lead to improved encapsulation (223). To date there
are no sustained release preparations available for targeted lung delivery.
If achieved, duration of action could be improved, along with a reduction of
administration frequency and side effects, which brings improved
compliance and economic viability (210).
Due to the numerous and complex factors affecting dissolution, it can be
difficult to predict how a drug will be released from a microsphere. There
are two main mechanisms involved in drug release from a polymer:
diffusion of the drug, and degradation of the polymer (231).
Biodegradation of poly(D,L-lactide) occurs through hydrolysis (223), by a
mechanism known as ‘homogenous degradation’. Hydrolysis cleaves ester
bonds at random, and any short chain fractions below 15 kD in size are
solubilised, and the mass is gradually broken down (223). There is a
gradual formation of small pores, through which both drug and aqueous
media can penetrate (240).
The rate at which this occurs is largely influenced by environmental pH; the
polymer has been shown to degrade most rapidly and efficiently at pH 9.6,
and slowest and more incompletely at pH 5 (240). PLA degradation is
maximised by hydrophilicity, low crystallinity and low average molecular
weight. The most influential factor is composition of polymer, which affects
hydrophilicity (241). The rate of drug release from microspheres is
influenced by carrier/drug ratio, degree of stabilisation, polymerisation, and
particle size (188).
There has been concern over polymer accumulation within the lungs (204).
Cysteamine bitartrate has a half life of around 1.88 hours, and the
leukocyte cystine content returns to baseline levels after 6 hours, requiring
very accurate, frequent dosing (33). The lung can generally clear particles
easily, therefore a biodegradable polymer should be quickly broken down
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and absorbed. A pulmonary preparation of cysteamine may provide relief
from the punishing oral dosage regime.
5.1.10 In vitro testing
The most commonly used in vitro model for testing the delivery of drugs to
the lungs is the impactor. The impactor used in this project was the
Andersen Cascade Impactor (ACI, Copely Scientific Ltd, Nottingham, UK).
Through a series of eight stages with progressively smaller holes, the
aerodynamic size distribution of the powder is analysed. This defines where
aspirated particles are expected to deposit in the lung. The ACI satisfies the
assessment specifications for inhaled products of both the United States
Pharmacopoeia (USP), and the European Pharmacopoeia (Ph.Eur.). It is
also a widely used technique in quality control analyses. Figure 56 shows a
comparison of the ACI stages with the lungs. The stream of aerosols travel
down through each stage of the ACI, which represent the narrowing airways
within the lungs as larger particles impact on a stage plate, and particles
that are small enough are carried on to the next stage. The particles are
separated according to their mass median aerodynamic diameter (MMAD),
allowing subsequent analysis on size fractions (74). It is the particle’s
inertia that determines at what stage it will impact, and as this is a function
of velocity and aerodynamic particle size, the shape and density of the
particle is not required to be known. The more inertia a particle has, the
more likely it is to impact upon a collection plate, while smaller particles
with less inertia will be carried past the plate by the air stream.
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Figure 56. Detail of the internal structure of the ACI (Copely Scientific Ltd,
Nottingham, UK).
Particle bounce can be a problem; instead of impacting upon a plate,
particles bounce off and continue down the impactor and settle on an
incorrect stage, giving false results (242). In order to lessen this effect,
each plate can be coated with silicon oil, as per the Industry Standard
(GlaxoSmithKline, Ware, UK). The ACI also has the benefit of retaining
100% of the delivered dose for analysis. The operation of the ACI (Copely)
is outlined in the documents received during training on the device at Glaxo
SmithKline’s laboratories in Ware, Hertfordshire (242,243). Measured cut-
off diameters in the ACI stack used for testing are shown in table 26.
154
Table 26. Cut-off diameters in the ACI
ACI
stage
Cut-off diameter at 60 L/min
(µm) a
Cut-off diameter at 28.3 L/min
(µm) b
Stage 0 5.9 9.0
Stage 1 4.1 5.8-9.0
Stage 2 3.2 4.7-5.8
Stage 3 2.1 3.3-4.7
Stage 4 1.4 2.1-3.3
Stage 5 0.62 1.1-2.1
Stage 6 0.35 0.7-1.1
Stage 7 0.15 0.4-0.7
a(244,245), bCopely, usp 601
Cut-off diameters are altered when a 28.3 L/min flow is used, although a
converter kit consisting of additional stages is available, as well as a
formula to calculate the new cut-offs. The cut-offs stated here are taken
from the European Pharmacopoeia (244,245).
The advantages of the ACI method include its well-established and widely
accepted method by regulatory authorities, a choice of construction
materials, conversion kits available for 60 and 90 L/min flow rates allowing
retention of the 28.3 L/min cut-off diameters, small footprint and
attachments available for nasal sprays and nebulisers. However, the ACI
method of in vitro testing has been criticized over its labour-intensive
nature and convoluted analysis, and consequently, large variability in
results (246). Despite this, the technique is the most commonly used,
particularly during the development stage.
The ACI does not allow analysis of formulation biodegradability on, or
permeability or absorption across epithelium. Systems are being developed
which incorporate pulmonary epithelial cells into impactors in an attempt to
rectify this (203).
It is hypothesised that a dry powder inhaler for systemic treatment may
eliminate many of the problems seen with the current oral dose. The
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malodorous nature of the drug may be disguised, allowing easier
administration. It has the possibility of being a simple, portable and
economically viable drug delivery system. It is also a more environmentally
friendly method compared to MDIs. It is hoped that systemic treatment for
cystinosis may become as straightforward as that for asthma and other
respiratory diseases
5.2 Materials and methods
5.2.1 Materials
L-Tartaric acid, cysteamine, ethanol, methanol, DCM, ethyl acetate, hexane,
acetonitrile, acetone, silicon oil and glass microfibre filters were purchased
from Sigma. Tris buffer was purchased from Fisher. Poly(D,L-lactide),
(Resomer R202s) and a Handihaler device were obtained from Boehringer
Ingelheim Pharma GmbH & Co. (Ingelheim am Rhein, Germany). The
spray-dried/USP lactose grade (granulated α-lactose monohydrate) was
obtained from Domo (Goch, Germany). Lactose BP was purchased from
Lactochem (Tamil Nadu, India). The 100 µm lactose was obtained from
DMV International bv (Veghel, Netherlands). Empty gelatine capsules (size
3) were purchased from Davcaps (Hertfordshire, UK). DTNB was purchased
from Molekula (Gillingham, UK).
5.2.2 Cysteamine bitartrate synthesis
During preformulation studies, cysteamine hydrochloride was found to be
unsuitable for use in the spray drier. It is extremely hygroscopic and
deliquesces, and therefore extremely difficult to achieve a dry powder with.
It is also insoluble in most solvents, making a DCM: methanol mix the only
suitable vehicle. There is a reluctance to use DCM as a vehicle for spray-
drying, due to its toxic nature, which the patient may be exposed to if
residual solvent remains (247). It was decided to use cysteamine bitartrate
as an alternative, given that the bitartrate salt is used in the current
medication.
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To a stirring solution of L-tartaric acid (1.5 g, 0.01 moles) in degassed
anhydrous ethanol (200 cm3) at room temperature, cysteamine (0.77 g,
0.01 moles) was added. The precipitate mixture was then stirred
continuously for 5 minutes at room temperature, and filtered under
vacuum. The resultant white powder was then placed in a vacuum oven
overnight at 50C. It was characterised by 1HNMR, and compared with the
commercial preparation of cysteamine bitartrate, Cystagon™ (Appendix III).
5.2.3 Microsphere preparation
Suspensions containing components in varying ratios were prepared and
spray-dried as per table 27. Spray dried microspheres can be hygroscopic.
To avoid uptake of environmental moisture, particles were sealed in a vial
immediately after harvesting from the collection vessel, and stored in a
desiccator at 4°C. Microspheres were stored at different temperatures and
conditions prior to testing, including a desiccator cabinet (Bel-Art Secador,
New Jersey, USA) at 25°C, a desiccator at 4°C and 21°C. The in vitro
deposition of these particles was then compared with that of non-desiccated
microspheres. Microspheres alone and a 50:50 blend with lactose were
tested, and also cysteamine bitartrate which had been micronised for 5
minutes in a ball mill at medium amplitude (AS200 Basic, Retsch GmbH,
Germany). The batch with the most discreet, spherical and non-aggregated
microspheres was selected for further analysis (batch 9). Table 28
describes the final production parameters chosen.
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Table 27. The 10 batches of microspheres were manufactured according to
the conditions shown.
Microsphere
batch
number
Components Spray dryer
conditions
Appearance
1 DCM:Methanol, 9:1,
PLA 3% w/v,
cysteamine HCl 2%
w/v
55C, 700 L/h,
40% pump, 100%
aspirator
Off white, adheres to
jar walls
2 DCM:Methanol, 9:1,
PLA 3% w/v,
cysteamine HCl 2%
w/v
39C, 700 L/h,
40% pump, 100%
aspirator
Off white, some
adherance to jar walls
3 Ethyl acetate, PLA
3% w/v, cysteamine
bitartrate 2% w/v
39C, 700 L/h,
40% pump, 100%
aspirator
White, some
adherance to jar walls
4 Ethyl acetate, PLA
2.5% w/v,
cysteamine bitartrate
1% w/v
39C, 700 L/h,
40% pump, 100%
aspirator
no defined particles
5 Ethyl acetate, PLA
2.5% w/v,
cysteamine bitartrate
2% w/v
39C, 700 L/h,
40% pump, 100%
aspirator
white powder, some
adherance to jar walls
6 Ethyl acetate, PLA
2% w/v, cysteamine
bitartrate 2% w/v
39C, 700 L/h,
40% pump, 100%
aspirator
white powder, some
adherance to jar walls
7 Ethyl acetate, PLA
1.5% w/v,
cysteamine bitartrate
2% w/v
39C, 700 L/h,
30% pump, 100%
aspirator
white powder,
minimum adherance to
jar walls
8 Ethyl acetate, PLA
2.5% w/v,
cysteamine bitartrate
2% w/v
35C, 700 L/h,
30% pump, 100%
aspirator
white powder, lots of
static, difficult to
harvest
9 Ethyl acetate, PLA
2% w/v, cysteamine
bitartrate 2% w/v
35C, 700 L/h,
30% pump, 100%
aspirator
white powder, lots of
static, very difficult to
harvest
10 Ethyl acetate, PLA
1.5% w/v,
cysteamine bitartrate
2% w/v
35C, 700 L/h,
30% pump, 100%
aspirator
white powder, lots of
static, difficult to
harvest
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Table 28. Final spray drying conditions used for optimum microsphere
preparation.
Optimal spray drying conditions
Inlet temperature 35°C
Outlet temperature 27°C
Air flow 700 L/h*
Pump 30%*
Aspirator 100%*
Total solids 4% w/v
*(248,249)
The dose used in DPIs is dependent on four factors:
1. Formulation properties, such as powder flow, particle size, shape and
surface properties and drug carrier interaction
2. Aerosol generation and delivery from the inhaler device
3. Inhalation technique
4. Inspiratory flow rate
Only a few milligrams of drug needs to be delivered into the lungs, therefore
a carrier also provides additional bulk to improve handling and metering of
the drug (199). Generally, excipients contribute 60-99% by weight of the
total dose in respiratory powders (199).
5.2.4 Microscope analysis
Drug particles were viewed through a Leica DM 2500M microscope
connected to a Leica DFC 420 camera (Leica Microsystems GmbH,
Germany) for pre-electron microscope analysis. The microscope was fitted
with 5x, 10x, 20x, 50x and 100x lenses.
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5.2.5 Scanning Electron Microscopy (SEM)
The shape and particle architecture of the microspheres was observed by a
Leo S430 SEM (Leo, UK), with a secondary electron detector. The
microspheres were fixed to the specimen stub using carbon tape and dusted
to remove excess. The stubs were sputter coated in a Polaron SC7640
(Quorum, West Sussex, UK), in a vacuum for 250 s at 100 mTorr. The
photographs were taken at an accelerating potential of 20 kV, beam
diameter of 10 pA and a scan rate of 40 seconds.
5.2.6 Particle size analysis
The particle size and size distribution of the microspheres was analysed by
laser diffraction using a Mastersizer MSS from Malvern (Worcestershire,
UK). Analysis of particle size was performed on batch 9 only, as these were
found to be the most discreet microspheres within the desired size range
(1-5 µm). The microspheres were placed in the dry powder feeder, and
drawn into the Mastersizer by the airflow. Due to the aggregation seen
under the microscope, it was performed 6 times. One sample was mixed
for 30 seconds on a whirlmixer, and then scanned. The other sample was
treated identically, and then sieved through a 45 µm stainless steel mesh
(Retsch GmbH, Germany).
It was noted that agglomeration was more apparent after sieving, and, in
an attempt to eliminate this, a suspension of microspheres were prepared in
triplicate in hexane, acetone and chloroform and sonicated for 1 minute.
The sample was then analysed with a liquid sampling system 6 times (220).
The results are expressed in terms of volume distribution, d[v,0.1],
d[v,0.5] and d[v,0.9] representing the 10th, 50th and 90th percentiles,
respectively. D[4,3] is the mean particle size. D[3,2] is the equivalent
surface area mean diameter. The mass median aerodynamic diameter
(MMAD), defined as the mean geometric aerodynamic diameter, was also
calculated from particle size analysis.
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The distribution of particle diameters is represented by the span, where:
span = (d[v,0.9] - d[v,0.1]) / d[v,0.5]
5.2.7 Moisture content of microspheres
The hygroscopicity of the microspheres was a potential problem as stated in
the introduction. Moisture content analysis was performed on three
identical batches of Batch 9 microspheres, using a TGA Q500 from TA
Instruments (Delaware, USA). Once tared, the titanium pans were loaded
with a uniform covering of sample, and the furnace raised. Using a ramp
mode, the samples were heated at 20°C/min to 250°C, and the percentage
weight loss analysed. The change in moisture content was noted over time.
5.2.8 Drug content of microspheres
To analyse the percentage drug loading of the microspheres, 300 mg of the
blend 9 microspheres were weighed accurately, and dissolved in 5 ml 1M
Tris buffer, pH 8, and deionised water was added to 50 ml. The flask was
then whirl mixed and sonicated. An equimolar weight of Ellman’s reagent
was added to the flask in the absence of light, and the UV absorbance
measured at 440 nm. The absorbance reading was then entered into the
equation of the straight line obtained by the linear regression of a
calibration curve. This was performed in triplicate.
5.2.9 Blend with lactose
The poor flowability displayed by the microspheres, caused by static forces
between the minute particles makes the use of an inert ‘carrier’ particle
necessary. Three different lactose grades were tested: 100 micrometer,
spray dried USP and BP. The carrier generally makes up 60-99% of the
total weight of a dry powder (199,228). As a starting mixture, drug loaded
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microspheres were blended with carrier lactose particles in the ratio 50:50.
Lactose supplied for inhalation is typically below 200 µm (227). The lactose
was sieved through a 90 µm stainless steel mesh, and collected on a 63 µm
mesh (Retch GmbH, Germany) (250,251). The drug-lactose blend was then
mixed on a Denley Spiramix 10 (Thermo Scientific, USA) for 30 minutes,
and subsequently placed on a whirl mixer for 30 seconds (Fisherbrand,
Leicestershire, UK).
5.2.10 In vitro powder aerolisation: Pre-clean
Microsphere aerolisation was analysed using a calibrated Andersen Cascade
Impactor (ACI; Copely Scientific Ltd, Nottingham, UK), attached to a
vacuum pump with a variable free flow rate from 0-133 L/min (Copely,
Nottingham, UK). Before initial use, the whole ACI stack must be
dismantled, sonicated with warm, soapy water for 10 minutes, before being
rinsed in deionised water and acetone and left to air dry. Each ‘o’ ring and
rubber mouthpiece must also be removed, soaked for a minimum of 12
hours in acetonitrile, and a further 12 hours minimum in methanol, before
being rinsed in acetone and left to air dry. Prior to the first run, each stage
and plate must be washed in hexane and rinsed in acetone, and left to air
dry. To eliminate static electricity, no gloves were worn whilst using the
ACI, and the stack was grounded before use.
5.2.11 Andersen Cascade Impactor: Testing
5.2.11.1 ACI Set up
Before each test, the ACI had to be set up as outlined in the Standard
Operating Procedure (GlaxoSmithKline, Ware, UK). Briefly, to minimise any
‘bounce’ between the particles and the plates, the stainless steel collecting
plates were soaked in a 1% w/v silicon oil solution in hexane for 10
seconds, before being removed, placed horizontally and the hexane allowed
to evaporate, leaving a thin film of silicon oil on the surface. The plates
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were then handled with tweezers to ensure the film remained intact, and
the stack reassembled. This included a methanol pre-soaked glass fibre
filter in stage F, and 10 ml of deionised water in the preseparator. When
testing a DPI, a preseparator must be inserted between the throat and
stage 0 of the ACI. This collects the larger inert carrier particles typically
used in DPI formulations, and also removes any particles greater than 10
µm.
The alignment marks were checked for accuracy of the stack assembly. The
stack was attached to the pump, and the flow rate checked using a flow
meter DFM2 from Copely (Nottingham, UK), and adjusted if necessary. A
flow of 60 L/min ± 1.5 L/min is required for DPIs, however flows of
55 L/min and 28.3 L/min were used in this project, as values above this
were beyond the capacity of the vacuum pump.
5.2.11.2 Respiratory powder testing
Powder aliquots (approximately 100 mg) were loaded into size 3 hard
gelatine capsules, and were placed individually into a Handihaler dry
powder device. To test a drug-containing powder, the capsule was pierced
and held firmly against the mouthpiece, ensuring a good seal was made.
The pump was activated for 3 seconds for 55 L/min and 5 seconds for 28.3
L/min using a foot pedal, and the powder drawn through the ACI (table 29).
An airflow of 60 L/min for 3 seconds through the impactor is representative
of the patient inhaling one dose from a DPI, and an airflow of 28.3 L/min is
used for MDIs, although this may be more representative of the patient
group in this study (246,252). Temperature and relative humidity are
important for hygroscopic materials, and were measured before and after
testing using a Rotronic Hygropalm 21 (Bassersdorf, Switzerland).
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Table 29. Summary of the powders tested.
ACI batch, each run at flow rates of 28.3 and 55 L/min
Batch 9 alone, 21C
Batch 9 alone (desiccator, 25C)
Batch 9 alone (desiccator, 4C)
Batch 9 with lactose 50:50, 4C
Batch 9 with lactose 50:50, 21C
Milled cysteamine bitartrate alone, 4C
5.2.11.3 ACI Wash down
The Handihaler® was carefully separated from the mouthpiece of the ACI,
and cleaned with water. The amount of drug deposited in each area of the
ACI stack was then determined, by careful sequential rinsing with deionised
water of the mouthpiece, throat, pre-separator, stages and collection plates
and backup filter into volumetric flasks. Table 30 shows the sizes of flasks
used for the corresponding stages, and the component grouping. Care was
taken at this stage to ensure that no powder was lost.
5.2.11.4 Respiratory powder analysis
To each flask 10% v/v 1M Tris buffer at pH 8 was added, and made up to
the mark with deionised water. The flasks were shaken and sonicated for
10 minutes prior to analysis. Table 30 shows the stages with the
corresponding flask sizes used.
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Table 30. Sequential ACI stages, with corresponding flask size.
ACI stage Corresponding flask
name abbreviation
Flask size
(ml)
Mouthpiece, throat T 250
Lid, pre separator, stage 0, plate 0 P 500
Stage 1, plate 1 1 100
Stage 2, plate 2 2 50
Stage 3, plate 3 3 50
Stage 4, plate 4 4 50
Stage 5, plate 5 5 50
Stage 6, plate 6, stage 7, plate 7, o
ring, filter
6-F 100
Ellman’s reagent was added, and the flasks inverted. Absorbance was
measured at 440 nm in the absence of natural light, and with minimal
artificial light. The resultant readings were inserted into the equation of the
straight line to determine concentration. Stages 1-8 of the impactor contain
the most important size fraction, i.e. below 5 µm.
The fine particle dose (FPD) is defined as the respirable fraction of the
delivered dose, which is the weight of powder less than 5 µm, and was
calculated from the sum of the powder collected on stages 1-7. The fine
particle fraction (FPF) was calculated from the ratio of FPD to total powder
weight. The emitted dose (ED) is the percentage of the total powder mass
in the capsule which exits and deposits in the ACI. The respirable dose
(RD) is the mass of drug recovered from the lower ACI stages (cut off 6.4
µm). The respirable fraction (RF) is the ratio of RD to total loaded dose
(188).
5.2.12 ACI pressure and flow testing
To analyse the pressure drop across the inhaler device produced when a
flow is initiated, a digital Manometer (P200 pressure meter, Digitron,
England) was attached downstream on the ACI (without mouthpiece), in
place of the flow meter. Readings were taken in triplicate at 55.8 L/min for
3 seconds, and 28.3 L/min for 5 seconds, and the results compared to
atmospheric pressure using a calibrated barometer, using the equation:
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R = Q/P’
Where R is the resistance, Q is the flow rate in L/min, and P is the
pressure drop (cm H2O) (217).
5.2.13 Dissolution testing
A 100ml round-bottomed flask with sidearm was held in a water bath, and
was heated to 37°C (body temperature). To the sidearm, a water
condenser was attached. A 10% v/v solution of 1 M Tris buffer in deionised
water was added to the flask (50ml), along with an equimolar weight of
DTNB. The solution was stirred magnetically using an IKA RET basic
hotplate stirrer (Staufen, Germany). At time zero, 50mg of the (50:50
blend) microspheres were added. The medium was sampled every 2
minutes. Samples were scanned on a UV from Unicam (Cheshire, UK) at
440 nm, the λmax for TNB. This was performed in triplicate.
5.2.14 Stability testing
Upon manufacture (T0), the microspheres were analysed by TGA and IR
spectroscopy, and stored under three different conditions in order to
analyse their stability; a refrigerator (4°C) containing a desiccator, a store
at room temperature and an Environmental Test Chamber (Copely,
Nottingham, England) set at 30°C and 75% Relative Humidity (74). These
conditions were chosen to cover cold storage, typical home storage and
accelerated testing. The temperature in each of the storage conditions was
monitored daily. TGA and IR spectroscopy tests were then performed, and
compared with the results from the microspheres at T0 (74). The
microspheres were also checked for any visual changes.
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5.3 Results and discussion
5.3.1 Cysteamine bitartrate synthesis and analysis
Cysteamine bitartrate was synthesised and characterised using 1HNMR and
melting point analysis, the results compared with the commercial
preparation Cystagon™.
The melting point of Cystagon™ was measured at 95°C, 1°C higher than
the melting point of the synthesised cysteamine bitartrate which was
measured at 94°C. It was concluded from these results that cysteamine
bitartrate had been synthesised.
5.3.2 Microscope analysis
Preliminary analysis was performed using a microscope fitted with a 100x
objective lens, using mineral oil (figures 57-58). Although not as detailed
as the SEM, it enabled qualitative assessment of the powders.
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Figure 57. Optical micrographs of the progressing blends, illustrating the
particles becoming more discreet; A. Batch 2, B. Batch 3, C. Batch 8, and
D. Batch 8 showing particles of 3-5 µm.
Figure 58. Optical micrographs illustrating the spherical final particles, A.
Batch 9 particles of 2-3 µm, and B. Batch 9 particles of 2-4 µm.
The particles became more discreet and spherical as testing progressed due
to a reduction in polymer concentration. Batches 8-10 were the most
suitable for further testing, as they existed as discreet, spherical particles
within the desired size range of 1-10 µm, and were fully formed spheres
when viewed by microscope. Initial batches of microspheres (batches 1 - 4)
A B
C D
A B
5 µm
3 µm 3 µm
20 µm10 µm
5 µm
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were found to be highly agglomerated when viewed under the microscope.
This was due to an excessively high polymer concentration, making the
microspheres sticky and adhere together (253), and was confirmed by SEM
analysis. Particle size is controlled by drug and polymer concentration
(254,255). Too high a concentration of either drug or polymer produces a
solution with increased viscosity, which is less readily separated into small
droplets, and hence larger particles are produced. Too low a concentration
gives particles which aren’t fully encapsulated (255). Drug encapsulation is
also influenced by polymer precipitation rate.
Another reason for this ‘clumping’ may have been an excessively high inlet
temperature in the spray dryer. The Glass Transition temperature (Tg) of a
non-crystalline (amorphous) material is a critical point of physical change. If
a polymer is used below it’s Tg, the polymer is described as ‘glassy’ (brittle),
and is not susceptible to molecular change. When used above the Tg,
polymers are soft and flexible (‘rubbery’), allowing molecular change to take
place (256,257). The Tg for PLA is reportedly 45-55°C (data sheet), and 38-
42 °C from Boehringer, therefore a wide temperature range was tested.
5.3.3 Scanning Electron Microscope (SEM) analysis
The ten batches of polymer and drug were sequentially analysed by SEM
(table 27). Spray dryer conditions were altered according to the results,
until microspheres were formed. Initially, too high an inlet temperature and
too high a polymer concentration lead to irregular morphology (figure 59).
By slowly lowering the temperature and polymer concentration, discreet
uniform spheres were formed (figure 60), within the required particle size
range of 1.5 – 5 µm. Batch 9 was found to be ideal (figure 61), displaying
discreet and uniform particles within the desired size range of 1-5 µm. The
magnification used is displayed in the figure headings.
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Figure 59. SEM images showing, A. Batch 2 showing signs of spheres
(x10K), and B. Batch 3 becoming more spherical and displaying hard
bridges between particles (x10K).
Figure 60. SEM images showing, A. Batch 8 showing fully formed
microspheres, with many still connected (x10K), and B. Batch 9 with
complete microspheres within the desired size range (1-6 µm) (x2K).
A B
A B
1 µm 1 µm
2 µm 10 µm
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Figure 61. SEM images of Batch 9, the batch chosen for further analysis
(magnification: A, x5.37K, B, x11.71K, C, x6.28K, D, x8.06K).
The Batch 9 microspheres exist as discreet particles, with smooth
morphology. Batch 10 appeared to have insufficient polymer, as particles
were not fully coated spheres (results not shown). Batch 9 microspheres
were chosen as the particles with the most ideal size and shape, and with
the optimum spray dryer conditions (table 28). SEM analysis gives only a
‘snapshot’ of particle size, therefore the powders were also tested using
laser light scattering.
5.3.4 Particle size analysis
Batch 9 microspheres were prepared in five ways and analysed. The results
are shown in table 31.
3 µm 3 µm
3 µm 3 µm
A B
C D
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Table 31. Summary of the particle size results for Batch 9 microspheres (n
= 3).
Statistics D[v, 0.1] D[v,0.5]
(MMAD)
D[v, 0.9] D[4,3] D[3,2] Span
Batch 9 dry powder
mean (µm)
3.71 25.37 304.49 95.42 8.54 11.86
Batch 9 dry powder
mean sieved (µm)
13.38 200.83 504.76 222.30 39.04 2.45
Batch 9 hexane
solution mean (µm)
5.89 57.09 127.20 87.81 18.42 2.12
Batch 9 acetone
solution mean (µm)
10.25 25.82 54.85 29.65 18.88 1.73
Batch 9 chloroform
solution mean (µm)
10.04 25.64 50.95 28.40 19.24 1.60
D(v, 0.1) is the size of particle for which 10% of the sample is below this
size. D(v, 0.5) is the size of particle at which 50% of the sample is smaller
and 50% is larger than this size. This value is known as the Mass Median
Aerodynamic Diameter (MMAD). D(v, 0.9) gives a size of particle for which
90% of the sample is below this size. D[4.3] is the equivalent volume
mean diameter or the De Broncker mean diameter. D[3,2] is the equivalent
surface area mean diameter or the Sauter mean diameter. Sauter mean
diameter is defined as the diameter of a sphere that has the same
volume/surface area as the particle of interest. The lower the span, the
more homogenous the powder’s particle size distribution (220).
Aerodynamic diameter (dae) particle size (MMAD) is critical for determining
the performance of a particle. It is affected by size, shape and density
(204). This is important to understand how a particle behaves in a moving
air stream, like the respiratory tract, information which diameter alone does
not explain. Therefore for a given density, small particles have lower
aerodynamic diameters compared to larger ones. Porous particles would
have an even lower dae (204).
Scanning electron images show the microspheres to be less than 5 µm in
diameter. However, the particle size results do not support this, which is
probably due to friction agglomeration causing particles to adhere together,
and failing to break up during the analysis. For this reason, microspheres
were subjected to different methods of preparation before analysis,
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including sieving. However, this produced more agglomeration in the
powders. Solubility of the powders in the dispersing agents could cause
agglomeration. Particles should be insoluble in any dispersing agent, and
were found to be insoluble in all three of the solvents used. Wet analysis
confirms that agglomeration is a major problem with these microspheres.
There are reports of correlation between light scattering particle size
measurements and impaction analysis (219). Comparisons between the
results are made in section 5.3.7.
5.3.5 Moisture content of microspheres
The moisture content of the microspheres was analysed by TGA
immediately after harvesting (T0), and at subsequent time intervals for two
weeks. The results are shown in table 32. TGA analyses the mass of the
sample during heating to determine weight change due the loss of volatile
components.
Table 32. Moisture content of Batch 9 microspheres over time (n = 3).
Batch 9 Moisture content (%)(± SD)
T0 0.83 (± 0.04)
T1 day 0.33 (± 0.03)
T2 days 1.23 (± 0.03)
T1 week 0.54 (± 0.04)
T2 weeks 0.70 (± 0.03)
Hygroscopic microspheres are removed from the air stream quicker than
non-hygroscopic particles, as described in the introduction. By coating
cysteamine bitartrate with PLA, the hygroscopic nature of the drug should
largely be avoided. The water content of PLA is reported as being less than
or equal to 0.5% (data sheet), however this is dependent on temperature
and relative humidity. There is no significant absorption of moisture by the
microspheres when monitored over a two-week period.
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5.3.6 Drug content of microspheres
The calibration curve was obtained from UV analysis of a set of standard
solutions containing Ellman’s reagent, producing a curve of absorbance
versus cysteamine bitartrate concentration as follows: y = 1.2808x + 0.05,
where y = absorbance and x = cysteamine bitartrate concentration, with an
excellent correlation coefficient of r2 = 0.9995. Using this method,
calculation of cysteamine bitartrate concentration was made for drug
content, dissolution and ACI analyses. The drug content of the
microspheres was calculated to be 50% (n = 6, SD ± 0.2).
5.3.7 Blend with lactose
The microspheres possessed very poor flow properties, and were subject to
large static forces due to their minute size range (1-5 µm). This was
demonstrated when sieved microspheres were found to be larger than prior
to sieving (table 31). Due to this property, it was unlikely that they would
leave the inhaler and travel through the airways without a carrier particle.
Batch 9 microspheres were combined with three different lactose grades at
1.5%, and viewed using SEM (figures 62 – 64).
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Figure 62. SEM of 100 µm lactose, showing large planar particles with
minor asperities (x4.68K).
Figure 63. The BP lactose grade possesses many areas for drug particle
attachment (x10K).
3 µm
1 µm
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Figure 64. The spray dried/USP lactose has extensive regions for particle
attachment (x10K).
Both the spray dried/USP and BP grades are processed to produce particles
with major asperities, whereas the 100 µm grade is planar with few
asperities. Lactose which has been spray dried can be prohibitive to drug
particle release, producing active areas of high surface energy (roughness)
which the microspheres cannot detach from (227). Therefore, of the three
lactose grades tested, sieved 100 µm grade was selected for further
analysis. The standard lactose blend ratio of 67.5:1 used in some asthma
inhaler powders was difficult to view with the SEM, as the lactose was larger
than the microspheres by a magnitude of approximately fifteen. When
blended in a ratio of 50:50, the microspheres can be seen attached to the
surface of the lactose (figure 65).
2 µm
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Figure 65. SEM of a 50:50 mix of 100 µm lactose with Batch 9
microspheres, with the microspheres clearly attached to the carrier lactose
particles (x2.1K).
Due to the unknown level of metabolism and pharmacokinetics of the
microspheres in the lungs, it was decided to maintain the blend at a 50:50
level for the subsequent tests. The powder characteristics should be
improved at this level, while allowing a larger dose of drug to be loaded into
the capsules if required.
The quantity of lactose present in powders for inhalation is low enough that
even in patients with lactose intolerance there should be no problems (199).
Any lactose which impacts in the upper airways is hydrolysed by enzymes
and swallowed, and that which reaches the deep lung is absorbed and
metabolised.
Recently, studies have been conducted to find alternatives to coarse carrier
particles to improve powder flowability. Incorporating dispersability
enhancers before spray drying has been shown to enhance aerolisation
properties (220).
10 µm
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5.3.8 Andersen Cascade Impactor: Analysis
The temperature and relative humidity were monitored before and after ACI
testing, and the average values are shown in table 33. The powder batches
were analysed by ACI, and the results are summarised in table 34.
Table 33. The average room temperature and relative humidity at ACI
testing, and standard deviation between readings.
Average temperature (°C) 20.9 (± 0.02)
Average RH (%) 35.2 (± 0.36)
Table 34. Summary of the powder batch characteristics (mean, n = 3)
Powder batch FPDa (µg) FPFb (%)
Batch 9, 10%RH 25°C, 55 L/min 25 (± 0.5) 0.0032
Batch 9, 21°C, 55 L/min 33 (± 0.4) 0.042
Batch 9, 4°C, 55 L/min 19 (± 0.5) 0.045
Batch 9, lactose 50:50, 4°C minimal
handling, 55 L/min
72.3 (± 0.3) 0.073
Batch 9, lactose 50:50, 4°C minimal
handling, 28 L/min
62 (± 0.4) 0.051
Batch 9, lactose 50:50, 21°C, 55 L/min 75 (± 0.2) 0.07
Milled cysteamine bitartrate, 4°C, 28 L/min 38 (± 0.3) 0.046
Milled cysteamine bitartrate, 4°C, 55 L/min 47 (± 0.5) 0.043
a Fine particle dose < 5 µm.
b Fine particle fraction, as percentage of total loaded dose (220).
Of the batches tested, the powders which contained lactose produced a
higher FPD, suggesting that the carrier particle has aided the drug further
into the deep lung tissue. Initially, a flow of 55 L/min was used during the
ACI testing. However, poor particle deposition was seen in the critical
stages, i.e. 2-5. A comparative flow of 28.3 L/min was then used, in an
attempt to minimise losses to the throat and preseparator through inertial
impaction. The powders which were tested using a flow of 55 L/min
produced higher FPD values. This could be due to the high resistance of the
inhaler device, requiring more effort to remove the powder. An attempt to
reduce the static agglomeration through minimised contact had minimal
effect. Table 35 shows the percentage deposition on the corresponding
plate of the most successful powder batch (Batch 9, lactose 50:50, 21°C, 55
L/min). Figure 66 compares the effect of storage upon the same powder.
178
Table 35. ACI cut-off diameters and the corresponding powder deposition.
ACI stage Cut-off diameter (µm) a % deposition (± SD)
Stage 1 4.1 2.27 (± 0.3)
Stage 2 3.2 1.42 (± 0.4)
Stage 3 2.1 1.43 (± 0.4)
Stage 4 1.4 1.26 (± 0.3)
Stage 5 0.62 1.60 (± 0.3)
Stage 6 + 7 0.35 – 0.15 3.26 (± 0.2)
a (244,245)
Figure 66. Comparison of storage effects on the most successful powder
blend, T = throat, P = preseparator.
The low in vitro deposition seen is probably due to particulate
agglomeration, which inhibits powder flow from the capsule into the ACI.
This is the most likely cause of large upper airways impaction seen. It is
common to see more than half of a drug powder deposit in the pre-
separator and stage 0 (246), particularly if a carrier particle is employed.
However, the excessively large losses seen here may be due to the carrier
particles failing to release the drug particles. The process of sieving may
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also have increased lactose surface roughness and produced high surface
energy sites, improving the bond between drug and carrier particle (246).
Targeting of the alveolar region is crucial for efficient systemic delivery
(220). Studies have shown that for the granulated lactose, a larger particle
size produces a larger respirable fraction (227). This is corroborated by a
correspondingly low MMAD. A particle size of around 200 µm is ideal; any
larger and the drag forces become prohibitive (227). The powder
developed during this project is therefore unsuitable for deep lung targeting
without substantial further work. The powders may be improved with a
simple change in the carrier particle, or may require a more fundamental
alteration.
5.3.9 ACI pressure and flow testing
The average atmospheric pressure was recorded at 753 mmHg. Resistance
for the device at 55.8 L/min was calculated to be 15.89 kPa, and 25.89 kPa
at 28.3 L/min. In both cases the required minimum pressure drop of 4 kPa
across the device was achieved, satisfying both the European and US
Pharmacopoeias. The predictably high resistance of the Handihaler® device
is important, and produces a good balance between usability and efficiency
(258).
The US and European Pharmacopoeias also recommend that the duration of
flow should give a volume of 4 Litres. Inhalers are usually tested based on
the inspiratory capacity of 3.5 L for men and 2.7 L for women (USP 601).
This is the maximum volume that can be inspired following a normal,
unforced expiration. However, shorter, lighter people will naturally have a
lower lung capacity, and, as most of the cystinosis patients are children or
are short in stature and underweight, these figures are unlikely to be
achieved. Therefore, flow volumes were used which were more
representative of the patient group. A flow of 55.8 L/min for 3 seconds
produced a volume of 2.79 L, while 28.3 L/min for 5 seconds produced a
volume of 2.36 L.
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5.3.10 Dissolution testing
The drug was released almost instantly from the microspheres, and after 8
minutes 100% of the drug had been released (Figure 67). This
measurement was performed four times, and the average release plotted.
Figure 67. Cysteamine bitartrate release from the microspheres over time
(n = 4).
The small size of the particles has a large surface area, and therefore
quicker release. The volume used in this experiment was 50 ml, which is
within lung lining fluid limits, while the weight of microspheres was double
the dose used in the capsules, eliminating concerns of dose accumulation
issues.
5.3.11 Stability tests
TGA analysis was performed at intervals over a two-month period, and IR
analysis for two weeks. At T1week, it was observed that the batch of
microspheres subjected to 30°C and 75% RH had degraded significantly and
irreversibly. The particles had largely dissolved in the high humidity, and
had recrystallised as large agglomerated crystals which had fused to the
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base of the container. The particles stored at 4°C and room temperature
were still present as a white, fluffy powder (Figure 68).
Figure 68. Images of, A. Batch 9 microspheres stored at 4°C for 1 week,
and B. Batch 9 microspheres stored at 30°C, 75% RH for 1 week.
IR analysis showed a 96.78% match of the microsphere batch stored at
30°C and 75% RH after one week (table 36). After two weeks this had
decreased to a 79.19% match with microspheres at time zero, T0. Figure
68 shows evidence of microsphere degradation after only one week of
storage at 30°C. The microspheres stored at 4°C displayed greater stability
over time, as demonstrated by an 11.6% change in percentage match over
seven days, compared to a 19.8% change (21°C storage) and a 17.6%
change (30°C storage)
Table 36. IR analysis of Batch 9 microspheres stored in varying storage
conditions, compared with T0.
Drug powder Percentage overall match to microspheres at T0
T1 week 4°C 98.12%
T1 week 21°C 97.77%
T1 week 30°C 96.78%
T2 weeks 4°C 86.53%
T2 weeks 21°C 77.94%
T2 weeks 30°C 79.19%
TGA analysis showed minor changes in the microspheres over time, with a
consistent 0.5% weight loss at lower temperatures with the loss of water,
A B
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and the beginning of decomposition at around 150°C. Figure 69 is a
representative plot.
80
85
90
95
100
W
ei
gh
t(
%
)
40 90 140 190 240
Temperature (°C)
T1day
T6weeks
Universal V4.5A TA Instruments
Figure 69. TGA plot comparing Batch 9 microspheres from T1 day and T6
weeks, stored at 30°C and at 75% RH.
The amorphous nature of the particles produced by spray drying can
become more crystalline when exposed to high temperatures and/or
humidity (219). This change can have a dramatic effect on particle
deposition, and can lead to strong irreversible bridge formation, through
dissolution in condensed water vapour as capillary forces are strong (246).
Moisture can also act as a plasticiser leading to softening, and as a lubricant
aiding the detachment of drug from carrier particles (246). Relative
humidity should not exceed 55% in any stage of manufacture or storage to
prevent the formation of capillary forces (246).
The microsphere degradation observed when a storage temperature of 30°C
and 75% RH was used (figure 68 and table 36) cannot be explained by an
uptake in moisture as previously hypothesised, as TGA analysis shows
insignificant moisture uptake over time (table 32). Poly(D,L-lactide) is a
thermoplastic polymer. This allows molecular movement within the polymer
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when it is subjected to a temperature around or above its Tg. At 4C, the
polymer is below its glass transition temperature, and is in a glassy state
(240). When the Tg is reached (45 - 55°C), the polymer ‘softens’ at a
molecular level. The rubbery state is at a higher level of free energy than
the glassy state, so the polymer has the potential to be more reactive in
this state. Storage of the microspheres at this elevated temperature and
relative humidity should be avoided to prevent degradation of the polymer
and subsequent loss of activity.
5.4 Conclusion
Cysteamine bitartrate was spray-coated with the polymer PLA to produce
microspheres suitable for delivery to the lungs. The ideal ratios and
solvents required were determined in extensive preformulation tests. Each
batch was analysed by microscope, and the polymer concentration altered
until discreet, spherical particles were produced. Cysteamine hydrochloride
was unsuitable for spray drying due to its hygroscopic and deliquescent
nature, as shown by almost instant uptake of environmental moisture.
Cysteamine bitartrate was synthesised and used as the active component.
Polymer coated microspheres in the size range required for targeted lung
delivery (1-5 µm) were produced and analysed. Drug release from the
microspheres was complete after 8 minutes. Moisture content analysis
revealed minimal moisture absorption over two weeks. Microspheres were
blended in a ratio of 50:50 with a carrier lactose particle. In vitro analysis
revealed a large preseparator loss of microspheres. This could have been
caused by the static agglomeration of particles or the poor separation of
drug particles from the carrier lactose particles. Microspheres stored in the
refrigerator displayed the greatest stability over time.
The PLA-coated cysteamine bitartrate microspheres were developed during
this project as a potential alternative to the current oral capsule treatment
of cystinosis. Analysis of the respiratory powders demonstrated
unsuitability for deep lung targeting without substantial further work. There
was evidence of insufficient powder penetration to the deep lung. This is a
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fundamental requirement for targeted delivery to the lungs, as the lower
airways are mainly involved in drug absorption. The likely cause for this
poor lung penetration is static agglomeration, caused by minute particle
size. The powders may be improved with a simple change in the carrier
particle, or may require a more fundamental alteration (chapter 6). These
results demonstrated that more development work was required to produce
a useful pulmonary formulation of cysteamine bitartrate. Further work on
the respiratory powders was beyond the scope of this project.
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Chapter 6 – General discussion and future work
The purpose of this project was to investigate alternative formulations to
the current oral capsule and eye drop preparations for the treatment of
cystinosis. Rectal, ophthalmic and pulmonary deliveries were investigated.
6.1 Rectal delivery
The side effects and dosage regime of the current oral capsule form of
cysteamine are serious barriers to compliance. Much of the drug is lost to
first-pass metabolism and protein binding, which necessitates a high dose.
The oral treatment for cystinosis causes frequent emesis, and possesses an
offensive taste and smell. It requires strict six-hourly dosing, which
disturbs sleep. As a consequence, compliance can be poor. This limits the
benefits of cysteamine therapy significantly. Early initiation of disciplined
therapy has been demonstrated to improve long-term morbidity and
mortality of cystinotic patients (41,259). Studies have also demonstrated
that diligent therapy, if started early in life, could maintain glomerular
function at the same level or even prevent the need for renal
transplantation completely (22). It is challenging to administer the
currently available capsules to infants (4). A suppository formulation may
allow easier systemic administration of cysteamine to infants and young
children. This would ensure the delivery of the crucial early therapy, with
long-term implications. The avoidance of the GI tract and first-pass effect
will allow a lower dose to be administered, reducing the side effects and
also removing the disagreeable taste and gastric effects currently
experienced with the capsules. This will reduce the fluid and salt losses
through frequent emesis, and in addition may allow relief from the
overnight dose and provide a more stable daily routine for the patients.
Compliance for other treatments is likely to be improved as a result, easing
the burden of care for the patient’s families and carers.
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Various suppository bases were investigated for suitability of delivery of
cysteamine hydrochloride. PEG bases were found to possess the most ideal
characteristics, i.e. compatibility with cysteamine hydrochloride, prolonged
release over time and stability upon handling. Upon subsequent testing and
analysis, the suppositories demonstrated complete cysteamine
hydrochloride release after 40-60 minutes. There was also evidence of
stability over 12 months. In particular, PEG Blend C possessed the most
ideal characteristics of the three suppository bases investigated,
demonstrating long-term stability and ease of manufacturing, handling and
storage when compared to PEG Blends A and B.
Cysteamine hydrochloride was successfully formulated as a suppository.
Further testing of these forms will determine their viability. Future work
should include in vivo testing of the suppositories to investigate their
suitability for the treatment of cystinosis. Only through in vivo studies can
the true efficacy of the forms be determined. There are concerns over the
long-term use of PEG, as the osmotic nature of dissolution can irritate the
rectal mucosa over time. This problem can be avoided by moistening the
suppository prior to insertion, however the hygroscopicity of cysteamine
may lead to drug loss from the suppository. Future studies would
determine the significance of any drug loss due to this practice.
Stability of the forms over time may be improved by a more controlled
cooling rate within the moulds, allowing larger PEG crystals to develop. This
may be achieved by pouring the suppositories into moulds within a
temperature-controlled unit, slowing reducing the temperature over time.
The suppositories could be further developed into in situ gelling forms, with
the incorporation of a gel such as HPMC. This may improve patient comfort
upon administration.
The formulation and characterisation of cysteamine suppositories has
demonstrated that the rectal route of delivery could greatly relieve many of
the side effects currently experienced, thereby improving patient’s
compliance with treatment, quality of life and subsequent morbidity.
Cystamine has demonstrated efficacy in a number of other disease states,
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and therefore there is the potential for a much larger patient population to
benefit (see section 6.4).
6.2 Ophthalmic delivery
The corneal crystals present in cystinosis are treated by the regular
insertion of an eye drop. The oral cysteamine capsules have no effect on
this symptom, as the cornea has no blood supply (21). The current eye
drops sting upon insertion, causing discomfort. They also require hourly
administration to be most effective, as they have a very short residence
time of 1-2 minutes. Compliance with this current medication is poor (106),
leading to severe ophthalmic conditions. Blindness is a potential endpoint.
Ophthalmic gels were investigated as an alternative to the current eye drop
formulation.
Cysteamine hydrochloride was formulated as a bioadhesive eye gel using
three different gel bases (carbomer, xanthan gum and HPMC). Carbomer
gel exhibited ideal properties for a formulation to replace and improve upon
the current eye drop, i.e. pseudoplastic rheology, drug release over 40
minutes and long-term stability. The carbomer gel also displayed
bioadhesion, and this, in combination with increased viscosity, should
improve bioavailability through prolonged contact time with the cornea.
Formulated at pH 7.4 for maximum comfort, the carbomer gels will allow
blinking to occur without interference (112). However, the optical
transmission of the gel was very poor, and would cause blurred vision
unless improved. The high salt content of the gels may be causing
precipitation, which is observed as opacity. Currently, the eye gels would
be useful as an overnight treatment. This may reduce the dosage required
during the day, and allow once or twice-daily dosing. Future work may
improve this factor, and permit daytime administration.
The transmission of light through the gel should be investigated using a
smaller path length such as 1 mm instead of 10 mm, to allow the
190
investigation of a more realistic in vivo situation. Subsequent analysis
should include in vivo testing of the developed ophthalmic forms, allowing
safety analysis to be performed. Rabbits are frequently used as test models
for ophthalmic formulations, due to structural similarities of the rabbit eye
with human eyes, as well as an increased sensitivity to irritants allowing a
conservative result to be obtained (107,113). In combination with this in
vivo work, gamma scintigraphy could be utilised as a method of monitoring
the residence of the instilled eye gel, from installation in the eye to ultimate
metabolism in the liver (138). It allows observation without interference,
and may be a useful tool in the further analysis of the ophthalmic gels.
Future work with the carbomer gels should also involve the incorporation of
a preservative such as benzalkonium chloride. This was previously only
included in the xanthan gels due to the propensity of xanthan gum to
support bacterial growth. The gels should be formulated with cysteamine
bitartrate, and the rheology, bioadhesion and stability analysed.
Incorporating cysteamine bitartrate as the active in comparison to the
hydrochloride form may also bring an improvement to stability over time, as
the bitartrate form is less hygroscopic (260).
Bioadhesive, pseudoplastic, pH neutral, prolonged release hydrogels were
developed for the treatment of the corneal crystals. Full characterisation
demonstrated the suitability of the carbomer gel as a replacement for the
current eye drop. The gel may be useful as an overnight treatment of the
ophthalmic crystals, eliminating the therapeutic break during sleep. This
may also allow for less frequent dosing during the day, thereby increasing
compliance and reducing serious ophthalmic complications such as corneal
rupture. The optical clarity may be improved to permit daytime dosing.
The gel base may also be suitable as a carrier for other ophthalmic
treatments which require chronic application. Drug bioavailability for eye
drops is typically very low, necessitating frequent dosing. Subsequent
compliance for chronic ailments such as for glaucoma can be poor. By
maximising the drug contact time and aiding patient comfort, these gels
may boost compliance by greatly improving the bioavailability, reducing the
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dosage frequency to once or twice a day. This ‘universal gel base’ could
revolutionise ophthalmic treatment, greatly improving a drug’s efficacy and
reducing subsequent health costs. Currently there are very few ophthalmic
gels on the market, however the benefits could potentially be enormous.
6.3 Pulmonary delivery
The delivery of cysteamine to the lungs as a systemic treatment for
cystinosis may allow the avoidance of the first-pass effect, reducing the
dosage required and subsequent side effects. The drug’s foul taste and
smell can also be removed through polymer coating. Cysteamine bitartrate
was spray-coated with a biodegradable polymer (PLA), producing
microsphere-sized particles suitable for respiratory delivery. The polymer
coating was designed to improve the handling and stability and eliminate
the odour of the cysteamine bitartrate. The particles were analysed for size
and morphology by Scanning Electron Microscope and particle size analyser.
The microspheres were found to be spherical and uniform, and within the
size ranges required for optimum deep lung targeting (2-5 µm). The
microspheres were found to release 100% of the cysteamine bitartrate after
8 minutes.
However, much of the drug was lost to the ‘throat’ section of the Andersen
Cascade Impactor in vitro testing apparatus. Deep lung penetration is
critical for successful delivery of drugs to the lungs for systemic treatments.
There are many possible causes for this drug loss, including static
agglomeration, too large particles and poor flowability. The bench-top
spray dryer used in this project also may have contributed to this poor deep
lung penetration, as the drying chamber is too small and may permit
residual solvent. Although these factors were not fully investigated during
the course of these studies due to time constraints, they present
opportunities for further research in the area.
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Significant additional work is required to produce a viable respiratory
dosage form. Deep lung penetration is critical for the dosage form to be
successful. Further studies of the respiratory powder should include testing
with a carrier particle in the size range of 200 micrometers, as this has
recently been demonstrated as an ideal carrier particle size for maximising
deep lung drug delivery (227). This simple adjustment to the formulation
may dramatically improve powder penetration to the lungs. A novel method
of improving powder flowability is to coat the microspheres with magnesium
stearate, which can dramatically improve aerolisation by lowering cohesion
(225). This may be another simple method to improve the deep lung
penetration of the microspheres.
Jet milling the cysteamine bitartrate would produce a powder with a smaller
and more uniform particle size distribution, and may significantly improve
deep lung penetration. Jet milling is the most widely-used method for the
production of microspheres for inhalation (219). However, it is an
expensive method of particle size reduction and also requires large batch
sizes of around 1 kg, which makes it an unsuitable technique for small-scale
research.
Cysteamine absorption in the lung has been demonstrated (197), and
therefore an inhaler could be a useful route of delivery. Patients of all ages
would benefit from the advantages of a dry powder inhaler, except babies
and very young children. This patient group would be more suitable for the
suppository formulation. A DPI would mask the taste of the cysteamine and
allow a lower dose to be administered, further reducing the side effects.
Compliance with the treatment should improve, as administration becomes
easier and less stressful, perhaps in combination with the suppositories.
6.4 Cysteamine bitartrate’s indications in other disease states
Cysteamine bitartrate has demonstrated efficacy in a range of other
conditions such as Huntington’s disease, Parkinson’s disease, Alzheimer’s
disease, malaria, and radiation sickness (2,46,260-263), and is being
investigated as a potential treatment of schizophrenia (264-266).
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Huntington’s disease is much more prevalent than previously thought, and
there are currently 12.4 sufferers per 100,000 population (267). By 2050 it
is estimated that 16 million people in the US alone will be suffering from
Alzheimer’s disease (268). This imparts greater versatility upon the
formulations developed during this project, and potentially allows a much
wider patient population to benefit from the improvements made to the oral
cysteamine bitartrate formulation. Currently there are around 2000
diagnosed cystinosis patients in the world. If cystamine becomes a routine
treatment for these more common diseases, the improvement of efficacy,
side effects and quality of life that the suppository or inhaler forms could
bring over the current oral capsule may be experienced by millions of
patients.
6.5 General conclusion
The aim of this project was to develop alternative formulations of
cysteamine with the potential to reduce or eliminate some of the side
effects which are evident using the current oral capsule and ophthalmic eye
drop, thereby improving the quality of life for those affected. Cysteamine
hydrochloride was successfully formulated as a suppository in a PEG base,
however further work is required to determine the in vivo efficacy and long
term safety of this formulation. It may be a useful dosage form in
paediatric treatment of cystinosis or when the oral route is compromised. A
bioadhesive ophthalmic gel was developed to replace the current eye drop,
and may allow a reduction in administration from 15-times per day to once
or twice daily dosing although currently the optical clarity is extremely poor.
A reduction in salt content may improve this to allow daytime
administration. A dry powder inhaler was also developed, however further
work is required to improve deep lung penetration. It is hypothesised that
further development of these new formulations may lead to increased
compliance through puberty and into adulthood, and subsequently reduce
morbidity and mortality in the latter stages of the disease.
194
References
(1) Almond PS, Matas AJ, Nakhleh RE, Morel P, Troppmann C, Najarian et
al. Renal Transplantation for Infantile Cystinosis: Long-Term Follow-Up.
Journal of Pediatric Surgery. 1993; 28(2):232-238.
(2) Gahl WA, Kleta R. Nephropathic Cystinosis in Adults: Natural History and
Effects of Oral Cysteamine Therapy. Annals of Internal Medicine. 2007;
147(4):242.
(3) Syres K, Harrison F, Tadlock M, Jester JV, Simpson J, Roy S, et al.
Successful treatment of the murine model of cystinosis using bone marrow
cell transplantation. Blood. 2009; 114(12):2542-2552.
(4) Cystinosis Research Network. About Cystinosis. [homepage on the
Internet]. Illinois, USA: Cystinosis Research Network; 2007 cited 2007
20/5/07]. Available from: www.cystinosis.org/aboutcystinosis.html.
(5) Gahl WA. Cystinosis. Pediatric Nephrology. 2009; 6:1019-1038.
(6) Gahl WA, Thoene JG, Schneider JA. Cystinosis. New England Journal of
Medicine. 2002; 347(2):111-121.
(7) Gahl WA, Kleta R. Cystinosis: Antibodies and Healthy Bodies. Journal of
the American Society of Nephrology. 2002; 13:2189-2191.
(8) Williamson DAJ. Cystinosis. British Medical Journal. 1952; 27(134):356-
363.
(9) Fanconi G, Uehlinger E, Knauer C. The Coeliakiesyndrom with congenital
cystic Pankreasfibromatose and bronchiektasien. Viennese Medical Weekly.
1936; 86:753-756.
(10) Tiddens HAWM. The Renal De Toni Syndrome with Dwarfism. [PhD
thesis on the Internet]. 1957: University of Utrecht; 1957 [cited 9/10/07]
Available from:
http://www.urolog.nl/urolog/theses/theses.php?doc=tiddens&profmenu=ye
s.
(11) Burki E. Annales Paediatrici, Basel. 1941; 156:324.
(12) Gahl WA, Kuehl EM. Corneal Crystals in Nephropathic Cystinosis:
Natural History and Treatment with Cysteamine Eyedrops. Molecular
Genetics and Metabolism. 2000; 71:100.
(13) Crawhall J.C, Lietman PS, Schneider J.A, Seegmiller JE. Cystinosis:
Plasma cystine and cysteine concentrations and the effect of D-
penacillamine and dietary treatment. The American Journal of Medicine.
1968; 44(3):330-339.
195
(14) Schneider JA, Schlesselman JJ, Mendoza JA, Orloff S, Thoene JG, Kroll
WA, et al. Ineffectiveness of ascorbic acid therapy in nephropathic
cystinosis. New England Journal of Medicine. 1979; 300:756-759.
(15) Schneider JA, Thoene JG, Oshima RG, Crawhall JC, Olson DL.
Cystinosis. Intracellular Cystine Depletion by Aminothiols In Vitro and In
Vivo. Journal of Clinical Investigation. 1976; 58:180-189.
(16) Gahl WA, Kaiser-Kupfer MI, Fujikawa L, Kuwabara T, Jain S. Removal
of Corneal Crystals by Topical Cysteamine in Nephropathic Cystinosis. New
England Journal of Medicine. 1987; 316(13):775-779.
(17) Gahl WA, Tietze F, Bashan N, Schulman JD, Steinherz R. Defective
Cystine Exodus from Isolated Lysosome-Rich Fractions of Cystinotic
Leucocytes. Journal of Biological Chemistry. 1982; 257(16):9570-9575.
(18) Schneider JA, Jonas AJ, Smith ML. ATP-Dependent Lysosomal Cystine
Efflux is Defective in Cystinosis. Journal of Biological Chemistry. 1982;
257(22):13185-13188.
(19) Gahl WA, Tietze F, Butler JD, Schulman JD. Cysteamine Depletes
Cystinotic Leucocyte Granular Fractions of Cystine by the Mechanism of
Disulphide Interchange. Biochemistry Journal. 1985; 228:545-550.
(20) Thoene JG, Pisoni RL, Christensen HN. Detection and Characterisation
of Carrier-Mediated Cationic Amino Acid Transport in Lysosomes of Normal
and Cystinotic Human Fibroblasts. Journal of Biological Chemistry. 1985;
260(8):4791-4798.
(21) Dufier JL. Ocular Changes in Long-Term Evolution of Infantile
Cystinosis. Ophthalmic Paediatric Genetics. 1987; 8(2):131-137.
(22) Gahl WA, Reed GF, Thoene JG, Schneider JA, Rizzo WB, Schulman JD
et al. Cysteamine Therapy for Children with Nephropathic Cystinosis. New
England Journal of Medicine. 1987; 316(16):971-977.
(23) Smolin LA, Clark KF, Gahl WA, Thoene JG, Schneider JA. A Comparison
of the Effectiveness of Cysteamine and Phosphocysteamine in Elevating
Plasma Cyseamine Concentration and Decreasing Leukocyte Free Cystine in
Nephropathic Cystinosis. Pediatric Research. 1988; 23(6):616-620.
(24) Broyer, Tete MJ, Gubler MC. Late Symptoms in Infantile Cystinosis.
Pediatric Nephrology. 1987; 1(3):519-524.
(25) Gahl WA, Sonies BC, Ekman EF, Andersson HC, Adamson M, Markello
TC et al. Swallowing Dysfunction in Nephropathic Cystinosis. New England
Journal of Medicine. 1990; 323(9):565-570.
(26) Gahl WA, Schneider JA, Adamson M, Reznik VM, Adelman RD, Clark KF
et al. Treatment of Cystinosis with Cysteamine from Early Infancy. Journal
of Pediatrics. 1991; 119(3):491-493.
196
(27) Gahl WA, Markello TC, Bernardini IM. Improved Renal Function in
Children with Cystinosis Treated with Cysteamine. New England Journal of
Medicine. 1993; 328(16):1157-1162.
(28) Gahl WA. Coronary Artery and Other Vascular Calcifications in Patients
with Cystinosis after Kidney Transplantation. Clinical Journal of the
American Society of Nephrology. 2006; 1:555-562.
(29) Skovby F, Kleta R, Anikster Y, Christensen R, Gahl WA. Cystinosis in
Denmark: Mutation analysis and treatment with cystamine, the disulphide
of cysteamine. American Journal of Human Genetics. 2002; 71(4).
(30) Antignac C, Hippert C, Dubois G, Morin C, Disson O, Ibanes S, et al.
Gene Transfer May Be Preventative But Not Curative for a Lysosomal
Transport Disorder. Molecular Therapy. 2008; 16(8):1372-1381.
(31) van't Hoff W, Town M, Jean G, Attard M, Whitmore SA, Broyer M et al.
A Novel gene Encoding an Integral menbrane Protein is Mutated in
Nephropathic Cystinosis. Nature Genetics. 1998; 18:319-324.
(32) US National Library of medicines. CTNS. [homepage on the Internet].
USA: US Department of Health; 2008 [updated February 2008; cited 2011
May 2011]. Available from: http://ghr.nlm.nih.gov/gene/CTNS.
(33) Kleta R, Gahl WA. Pharmacological treatment of nephropathic
cystinosis with cysteamine. Expert Opinion on Pharmacotherapy. 2004;
5(11):2255-2262.
(34) Thoene JG. A Review of the Role of Enhanced Apoptosis in the
Pathophysiology of Cystinosis. Molecular Genetics and Metabolism. 2007;
:1-5.
(35) Chevalier R, Forbes M. Generation and evolution of atubular glomeruli
in the progression of renal disorders. American Society of Nephrology.
2008; 19:197-206.
(36) Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA.
Twice-daily cysteamine bitartrate therapy for children with cystinosis. The
Journal of Pediatrics. 2010; 156(1):71-75.
(37) Gahl WA, Iwata F, Kuehl EM, Reed GF, Kaiser-Kupfer MI, McCain LM. A
Randomised Clinical Trial of Topical Cysteamine Disulfide (Cystamine)
Versus Free Thiol (Cysteamine) in the Treatment of Corneal Cystine Crystals
in Cystinosis. Molecular Genetics and Metabolism. 1998; 64:237-242.
(38) Anderson RJ, Cairns D, Cardwell WA, Case M, Groundwater PW, Hall
AG et al. Design, Synthesis and Initial In Vitro Evaluation of Novel Prodrugs
for the Treatment of Cystinosis. Letters in Drug Design and Discovery.
2006; 3:336-345.
197
(39) Sansanwal P, Yen B, Gahl WA, Ma Y, Ying L, Wong LC, et al.
Mitochondrial autophagy promotes cellular injury in nephropathic cystinosis.
Journal of the American Society of Nephrology. 2010; 21:272-283.
(40) Schneider JA, Belldina EB, Huang MY, Brundage RC, Tracy TS. Steady-
State Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate in
Pediatric Nephropathic Cystinosis Patients. British Journal of Clinical
Pharmacology. 2003; 56:520-525.
(41) Gahl WA, Markello TC, Yang ML, Rose SR, Kimonis VE, Troendle J.
Effects of Early Cysteamine Therapy on Thyroid Function and Growth in
Nephropathic Cystinosis. Journal of Clinical Endocrinology and metabolism.
1995; 80(11):3257-3261.
(42) Lim J, Pellois JP, Simanek EE. A retro-inverso TAT-like peptide
designed to deliver cysteamine to cells. Bioorganic & Medicinal Chemistry
Letters. 2010; accepted manuscript.
(43) Schneider JA. Treatment of Cystinosis: Simple in Principle, Difficult in
Practice. Journal of Pediatrics. 2004; 145(4):436-438.
(44) Elenberg E. Feeding Problems in Cystinosis. Pediatric Nephrology.
1998; 12:365-370.
(45) Gahl WA, Tsilou E, Zhou m, Chan C-C, Sieving PC. Ophthalmic
Manifestations and Histopathology of Infantile Nephropathic Cystinosis:
Report of a Case and Review of the Literature. Survey of Ophthalmology.
2007; 52(1):97-105.
(46) Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson DVW,
Hayden MR, et al. Cystamine treatment is neuroprotective in the TAC128
mouse model of Huntington disease. Journal of Neurochemistry. 2005;
95:210-220.
(47) Schneider JA, Fidler MC, Barshop BA, Deutsch R, Martin M, Dohil R et
al. Pharmacokinetics of Cysteamine Bitartrate Following Gastrointestinal
Infusion. British Journal of Clinical Pharmacology. 2006; 63(1):36-40.
(48) Sun L, Xu S, Zhou M, Wang C, Wu Y, Chan P. Effects of cysteamine on
MPTP-induced dopaminergic neurodegeneration in mice. Brain research.
2010; 1335:74-82.
(49) Gentile V, Cooper AJ. Transglutaminases - possible drug targets in
human diseases. Current Drug Targets - CNS and Neurological Disorders.
2004; 3(2):99-104.
(50) Tarawneh R, Galvin J. Potential future neuroprotective therapies for
neurodegenerative disorders and stroke. Clinics in Geriatric Medicine. 2010;
26(1):125-147.
198
(51) Bozdag S, Gumus K, Gumus O, Unlu N. Formulation and in vitro
evalation of Cysteamine hydrochloride viscous solutions for the treatment of
corneal cystinosis. European Journal of Pharmaceutics and
Biopharmaceutics. 2008; 70(1):260-290.
(52) Cairns D, Anderson RJ, Terry J, Coulthard M. Cystinosis and its
Treatment. Pharmaceutical Journal. 2002; 269:615-616.
(53) Choy YB, Park JH, Prausnitz MR. Mucoadhesive microparticles
engineered for ophthalmic drug delivery. Journal of Physics and Chemistry
of Solids. 2008; 69:1533-1536.
(54) Wenner WJ, Murphy JL. The Effects of Cysteamine on the upper
Gastrointestinal Tract of Children with Cystinosis. Pediatric Nephrology.
1997; 11(5):600-603.
(55) Schneider JA, Dohil R, Newbury RO, Sellers ZM, Deutsch R. The
Evaluation and Treatment of Gastrointestinal Disease in Children with
Cystinosis Receiving Cysteamine. Journal of Pediatrics. 2003; 143(2):224-
230.
(56) Bendel-Stenzel MR, Steinke J, Dohil R, Kim Y. Intravenous delivery of
cysteamine for the treatment of cystinosis: association with hepatotoxicity.
Pediatric Nephrology. 2008; 23:311-315.
(57) Walker WA. The stomach and duodenum. In: Walker WA, editor.
Pediatric gastrointestinal disease: pathophysiology, diagnosis, management,
Volume 1. Fourth ed. USA: PMPH-USA; 2004. p. 516.
(58) Schneider JA, Soohoo N, Kaplan RM. A Cost-Effectiveness Analysis of
the Orphan Drug Cysteamine in the Treatment of Infantile Cystinosis.
Medical Decision Making. 1997; 17:193-198.
(59) electronic Medicines Compendium (eMC). Cystagon 150mg hard
capsules. [homepage on the Internet]. online: Datapharm Communications
Ltd.; 2008 [updated 16/4/08; cited 2010 29/9/10]. Available from:
http://www.medicines.org.uk/emc/medicine/20798/SPC/cystagon%20150
%20mg%20hard%20capsules/.
(60) Amos J.
Protective organ wash engineered. [homepage on the Internet]. London:
BBC; 2010 [updated 15/9/10; cited 2010 15/9/10]. Available from:
http://www.bbc.co.uk/news/science-environment-11322197.
(61) Schneider JA, Dohil R. Enterically Coated Cysteamine, Cystamine and
Derivatives Thereof. [homepage on the Internet]. 9/8/07: WIPO; 2007
[updated 26/1/07; cited 2007 13/12/07]. Available from:
http://www.wipo.int/pctdb/en/wo.jsp?wo=2007089670.
199
(62) Schneider JA, Fidler MC, Barshop BA, Deutsch R, Martin M, Dohil R et
al. understanding Instestinal Cysteamine Bitartrate Absorption. Journal of
Pediatrics. 2006; 148(6):764-769.
(63) Dohil R, Gangoiti JA, Cabrera BL, Fidler M, Schneider JA, Barshop BA.
Long-Term Treatment of Cystinosis in Children with Twice-Daily
Cysteamine. The Journal of Pediatrics. 2010; 156(5):823-827.
(64) Terryn S, Devuyst O, Antignac C. Cell therapy for cystinosis.
Nephrology Dialysis Transplantation. 2010; :1-4.
(65) Cairns D, McCaughan B, Kay G, Knott RM. A Potential New Prodrug for
the Treatment of Cystinosis: Design, synthesis and In-Vitro Evaluation.
Bioorganic & Medicinal Chemistry Letters. 2008; 18(5):1716-1719.
(66) Omran Z, Kay G, Hector EE, Knott RM, Cairns D. Folate pro-drug of
cystamine as an enhanced treatment for nephropathic cystinosis. Bioorganic
& medicinal chemistry letters. 2011; 21(8):2502-2504.
(67) Omran Z, Kay G, Salvo AD, Knott RM, Cairns D. PEGylated derivatives
of cystamine as enhanced treatments for nephropathic cystinosis.
Bioorganic & medicinal chemistry letters. 2011; 21(1):45-47.
(68) Omran Z, Moloney KA, Benylles A, Kay G, Knott RM, Cairns D.
Synthesis and in vitro evaluation of novel pro-drugs for the treatment of
nephropathic cystinosis. Bioorganic & medicinal chemistry. 2011;
19(11):3492-3496.
(69) World Health Organisation. Adherence to Long-Term Therapies:
Evidence for Action. Geneva: WHO; 2003.
(70) Molinspiration. Log P calculator. [homepage on the Internet].
molinspiration; 2008 cited 2008 12/8]. Available from:
www.molinspiration.com/cgi-bin/properties.
(71) Pirika. Log P calculator. [homepage on the Internet]. Pirika; 2008 cited
2008 11/8]. Available from:
www.pirika.com/chem/TCPEE/LOGKOW/ourlogkow.htm.
(72) Europa, European Commission Joint Research Centre. Partition
Coefficient. [homepage on the Internet]. Europa; 2009 [updated 2009;
cited March 2009 Available from:
http://ecb.jrc.ec.europa.eu/DOCUMENTS/Testing-
Methods/ANNEXV/A08web1992.pdf.
(73) Eksterowicz JE, Miller JL, Kollman PA. Calculation of Chloroform/Water
Partition Coefficients for the N-methylated Nucleic Acid Bases. Journal of
Physical Chemistry B. 1997; 101(50):10971-10975.
(74) Aulton M. E. Pharmaceutics. The Science of Dosage Form Design. 2nd
ed. London: Churchill Livingstone; 2002.
200
(75) Black SD. Ellman's Reagent/DTNB (Protocol). [homepage on the
Internet]. Texas: University of Texas Health Centre; 1994 [updated
26/10/94; cited 2008 24/3/08]. Available from:
http://www.bio.net/bionet/mm/methods/1994-October/020180.html.
(76) Lewin A, Crow A, Oubrie A, Le Brun NE. Molecular basis for precificity
of the extracytoplasmic thioredoxin ResA. The Journal of Biological
Chemistry. 2006; 281(46):35467-35477.
(77) Huffman RW, McBride P, Brown DM. On the cleavage of Ellman's
reagent (5,5'-dithiobis(2-nitrobenzoic acid)] by dithonite in the presence of
dioctadecyldimethylammonium chloride [Dodac] surfactant vesicles laced
with cholesterol. Journal of Organic Chemistry. 1994; 59:1633-1637.
(78) Walmsley TA, Abernethy MH, Fitzgerald HP. Effect of Daylight on the
Reaction of Thiols with Ellman's Reagent, 5,5'-(2-Nitrobenzoic acid). Clinical
Chemistry. 1987; 33(10):1928-1931.
(79) Allen LV. Suppositories. first edition ed. 2008: Pharmaceutical Press;
2008.
(80) Coben LJ. Modern Suppository Manufacturing. Drug Development and
Industrial Pharmacy. 1977; 3(6):523-546.
(81) Aungst BJ, Lam G, Shefter E. Oral and rectal nalbuphine bioavailability:
First-pass metabolism in rats and dogs. Biopharmaceutics and Drug
Disposition. 1984; 6(4):413-421.
(82) De Boer AG, De Leede LG, Breimer DD. Drug absorption by sublingual
and rectal routes. British Journal of Anaesthesia. 1984; 56(1):69-82.
(83) Hermann TW. Recent Research on Bioavailability of Drugs from
Suppositories. International Journal of Pharmaceutics. 1995; 123:1-11.
(84) Choi HG, Jung JH, Ryu JM, Yoon SJ, Oh YK, Kim KK. Development of In
Situ-Gelling and Mucoadhesive Acetoaminophen Liquid Suppository.
International Journal of Pharmaceutics. 1998; 165(1):33-44.
(85) Chicco D, Grabnar I, Vojnovic D, Maurich V, Realdon N, Ragazzi E et al.
Correlation of In Vitro and In Vivo Paracetamol Availability from Layered
Excipient Suppositories. International Journal of Pharmaceutics. 1999;
189(2):147-160.
(86) Kim CK, Choi HG, Lee MK, Kim MH. Effect of Additives on the
Physiochemical Properties of Liquid Suppository Bases. International Journal
of Pharmaceutics. 1999; 190:13-19.
(87) Kim CK, Lee SW, Choi HG, Lee MK, Gao ZG, Kim IS et al. Trials of In
Situ-Gelling and Mucoadhesive Acetaminophen Liquid Suppository in Human
Subjects. International Journal of Pharmaceutics. 1998; 174:201-207.
201
(88) Kim CK, Oh YK, Choi HG. In Situ Gelling and Mucoadhesive Liquid
Suppository Containing Acetaminophen: Enhanced Bioavailability.
International Journal of Pharmaceutics. 1998; 165(1):23-32.
(89) Ryu JM, Chung SJ, Lee MH, Kim CK, Shim CK. Increased Bioavailability
of Propranolol in Rats by Retaining Thermally Gelling Liquid Suppositories in
the Rectum. Journal of Controlled Release. 1999; 59:163-172.
(90) van't Hoff W, Baker T, Dalton RN, Duke LC, Smith SP Chantler C et al.
Effects of Oral Phosphocysteamine and Rectal Cyseamine in Cystinosis.
Archives of Disease in Childhood. 1991; 66:1434-1437.
(91) De Muynck C, Cuvelier C, Van Steenkiste D, Bonnarens L, Remon JP.
Rectal Mucosa Damage in Rabbits After Subchronical Application of
Suppository Bases. Pharmaceutical Research. 1991; 8(7):945-950.
(92) Pasquali RS, Taurozzi MP, Bregni C. Some considerations about the
hydrophilic-lipophilic balance system. International Journal of
Pharmaceutics. 2008; 356(1-2):44-51.
(93) Ratsimbazafy V, Bourret E, Duclos R, Brossard C. Rheological behavior
of drug suspensions in Gelucire® mixtures and proxyphylline release from
matrix hard gelatin capsules. European Journal of Pharmaceutics and
Biopharmaceutics. 1999; 48(3):247-252.
(94) Mayol L, Quaglia F, Borzacchiello A, Ambrosio L, La Rotonda MI. A
novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery:
Rheological, mucoadhesive and in vitro release properties. European Journal
of Pharmaceutics and Biopharmaceutics. 2008; 70:199-206.
(95) Chen C, Qi H, Chen W HC, Li L, Wu C. Development of a Poloxamer
Analogs/Carbopol-Based In Situ Gelling and Mucoadhesive Ophthalmic
Delivery System for Puerarin. International Journal of Pharmaceutics. 2007;
337:178-187.
(96) Choi H, Jung J, Ryu J, Yoon S, Oh Y, Kim C. Development of in situ-
gelling and mucoadhesive acetaminophen liquid suppository. International
journal of pharmaceutics. 1998; 165(1):33-44.
(97) Yong CS, Choi JS, Quan Q, Rhee J, Kim C, Lim S, et al. Effect of
sodium chloride on the gelation temperature, gel strength and bioadhesive
force of poloxamer gels containing diclofenac sodium. International journal
of pharmaceutics. 2001; 226(1-2):195-205.
(98) Azarmi S, Roa W, Lobenberg R. Current Perspectives in Dissolution
Testing of Conventional and Novel Dosage Forms. International Journal of
Pharmaceutics. 2007; 328(1):12-21.
(99) O'Brien FEM. The Control of Humidity by Saturated Salt Solutions.
Journal of Scientific Instruments. 1948; 25:73-76.
202
(100) Millot MC, Martin F, Bousquet D, Sebille B, Levy Y. A reactive
macromolecular matric for protein immobilization on a gold surface.
Application in surface plasmon resonance. Sensors and Actuators. 1995;
29:268-273.
(101) Coates J. Interpretation of Infrared Spectra, A Practical Approach. In:
Meyers RA, editor. Encyclopedia of Analytical Chemistry. Chichester: John
Wiley and Sons Ltd; 2000. p. 10815-10837.
(102) Kim CH, Parkin S, Bharara M, Atwood D. Linear coordination of Hg(II)
by cysteamine. Polyhedron. 2002; 21(2):225-228.
(103) Ahmad S, Shaheen MA, Stoeckli-Evans H. A monoclinic polymorph of
cysteamine hydrochloride. Acta Crystallographica Section E; Structure
Reports Online. 2010; 66(1):134.
(104) Li Y, Kaito A. Highly oriented structure formed in a lamella-forming
diblock copolymer with high molar mass. European Polymer Journal. 2006;
42:1986-1993.
(105) Dufier JL. Evolution of Ocular Manifestations in Nephropathic
Cystinosis: A Long-Term Study of a Population Treated with Cysteamine.
Journal of Pediatric Ophthalmology Strabismus. 2003; 40(3):142-146.
(106) Gahl WA, Tsilou E, Thompson D, Lindblad AS, Thoene JG, Schneider
JA et al. A Multicentre Randomised Double Masked Clinical Trial of a New
Formulation of Topical Cysteamine for the Treatment of Corneal Cystine
Crystals in Cystinosis. British Journal of Ophthalmology. 2003; 87:28-31.
(107) Gahl WA, Jain S, Kuwabara T, Kaiser-Kupfer MI. Range of Toxicity of
Topical Cysteamine in Rabbit Eyes. Journal of Ocular Pharmacology. 1988;
4(2):127-131.
(108) Gahl WA, Kaiser-Kupfer MI, Gazzo MA, Kuehl EM, Caruso RC, Datiles
MB. A Randomised Placebo-Controlled Trial of Cysteamine Eye Drops in
Nephropathic Cystinosis. Archives of Ophthalmology. 1990; 108(5):689-
693.
(109) Noble JL, Jones NP, Postlethwaite RJ. Clearance of Corneal Crystals in
Nephropathic Cystinosis by Topical Cysteamine 0.5%. British Journal of
Ophthalmology. 1991; 75:311-312.
(110) Washington University School of Medicine. Cornea Structure and
Function. [homepage on the Internet]. St. Louis: Washington University
School of Medicine; 2010 cited 2010 1/26]. Available from:
http://wuphysicians.wustl.edu/dept.aspx?pageID=17&ID=6.
(111) Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB,
Kristjánsdóttir SS, Bas JF, et al. Cyclodextrin solubilization of carbonic
anhydrase inhibitor drugs: Formulation of dorzolamide eye drop
203
microparticle suspension. European Journal of Pharmaceutics and
Biopharmaceutics. 2010; 76(2):208-214.
(112) Nanjawade BK, Manvi FV, Manjappa AS. In Situ-Forming Hydrogels
for Sustained Ophthalmic Drug Delivery. Journal of Controlled Release.
2007; 122:119-134.
(113) Ahmed I, Patton TF. Disposition of timolol and inulin in the rabbit eye
following corneal versus non-corneal absorption. International journal of
pharmaceutics. 1987; 38(1-3):9-21.
(114) Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R.
Ophthalmic Drug Delivery Systems - Recent Advances. Progress in Retinal
and Eye Research. 1998; 17(1):33-58.
(115) Shell JW. Ophthalmic drug delivery systems. Survey of
Ophthalmology. 1984; 29(2):117-128.
(116) Mali MN, Hajare AA. In situ gel-forming systems for sustained ocular
drug delivery. European Industrial Pharmacy. 2010; (5):17-20.
(117) Saettone MF, Salminen L. Ocular Inserts for Topical Delivery.
Advanced Drug Delivery Reviews. 1995; 16:95-106.
(118) Kaur IP, Kanwar M. Ocular Preparations: The Formulation Approach.
Drug Development and Industrial Pharmacy. 2002; 28(5):473-493.
(119) Cone RA. Barrier properties of mucus. Accepted manuscript ed.
Baltimore: 2008.
(120) Smart JD. The basics and underlying mechanisms of mucoadhesion.
Advanced Drug Delivery Reviews. 2005; 57:1556-1568.
(121) Robinson JR, Mlynek GM. Bioadhesive and phase-change polymers for
ocular drug delivery. Advanced Drug Delivery Reviews. 1995; 16:45-50.
(122) Lai SK, Wang YY, Wirtz D, Hanes J. Micro- and macrorheology of
mucus. Accepted manuscript ed. Baltimore: 2008.
(123) Varum FJO, Veiga F, Sousa JS, Basit AW. An investigation into the
role of mucus thickness on mucoadhesion in the gastrointestinal tract of pig.
European Journal of Pharmaceutical Sciences. 2010; .
(124) Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in
situ gelling systems for ocular drug delivery. Part 1: Physicochemical
characterisation and in vitro release. International journal of pharmaceutics.
2011; 411(1-2):69-77.
(125) Harris P. Food Gels. First ed. London: Elsevier; 1990.
204
(126) Amin PD, Srividya B, Cardoza RM. Sustained Ophthalmic Delivery of
Ofloxacin from a pH Triggered In Situ Gelling System. Journal of Controlled
Release. 2001; 73:205-211.
(127) Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric
platforms for controlled drug delivery. Corrected proof ed. belfast: Elsevier;
2008.
(128) Barbu E, Verestiuc L, Nevell TG, Tsibouklis J. Polymeric Materials for
Ophthalmic Drug Delivery: Trends and Perspectives. Journal of Materials
Chemistry. 2006; 16:3439-3443.
(129) Ceulemans J, Ludwig A. Optimisation of carbomer viscous eye drops:
an in vitro experimental design approach using rheological techniques.
European Journal of Pharmaceutics and Biopharmaceutics. 2002; 54:41-50.
(130) Edsman K, Carlfors J, Harju K. Rheological evaluation and ocular
contact time of some carbomer gels for ophthalmic use. International
Journal of Pharmaceutics. 1996; 137:233-241.
(131) Pan W, Liu Z, Li J, Nie S, Liu H, Ding P. Study of an Alginate/HPMC-
Based In Situ Gelling Ophthalmic Delivery System for Gatifloxacin.
International Journal of Pharmaceutics. 2006; 315:12-17.
(132) Smart JD. Some formulation factors influencing the rate of drug
release from bioadhesive matrices. Drug Development and Industrial
Pharmacy. 1992; 18(2):223-232.
(133) Zambito Y, Colo GD. Thiolated quaternary ammonium–chitosan
conjugates for enhanced precorneal retention, transcorneal permeation and
intraocular absorption of dexamethasone. European Journal of
Pharmaceutics and Biopharmaceutics. 2010; 75(2):194-199.
(134) Bothner H, Waaler T, Wik O. Rheological characterisation of tear
substitutes. Drug Development and Industrial Pharmacy. 1990; 16:615-
616.
(135) Oechsner M, Keipert S. Ployacrylic acid/polyvinylpyrrolidone
bipolymeric systems. I. Rheological and mucoadhesive properties of
formulations potentially useful for the treatment of dry-eye-syndrome.
European Journal of Pharmaceutics and Biopharmaceutics. 1999; 47:113-
118.
(136) Edsman K, Paulsson M, Hagerstrom H. Rheological Studies of the
Gelation of Deacetylated Gellan Gum (Gelrite) in Physiological Conditions.
European Journal of Pharmaceutical Sciences. 1999; 9:99-105.
(137) Osborne DW, Amann AH. Topical Drug Delivery Formulations.
Illustrated ed. London, UK: Informa Health Care; 1990.
205
(138) Rupenthal ID, Green CR, Alany RG. Comparison of ion-activated in
situ gelling systems for ocular drug delivery. Part 2: Precorneal retention
and in vivo pharmacodynamic study. International journal of pharmaceutics.
2011; 411(1-2):78-85.
(139) Medicinescomplete. Carbomer 934 Structural repeating unit.
[homepage on the Internet]. Medicinescomplete; 2009 cited 2009
September 20th]. Available from:
http://www.medicinescomplete.com/mc/excipients/current/images/ExcCarb
omerC001.png.
(140) Tamburic S, Craig DQM. A comparison of different in vitro methods
for measuring mucoadhesive performance. European Journal of
Pharmaceutics and Biopharmaceutics. 1997; 44:159-167.
(141) Kulkarni A. Study of polymers and permeation enhancers effects on
meloxicam gel formulations. [Master of Pharmacy thesis on the Internet].
Bangalore: Rajiv Gandhi University of Health Sciences; 2006 [cited 5/6/11]
Available from:
http://119.82.96.198:8080/jspui/bitstream/123456789/2691/1/Kulkarni%2
0Anant%20Rao.pdf.
(142) Needleman IG, Martin GP, Smales FC. Characterisation of
bioadhesives for periodontal and oral mucosal drug delivery. Journal of
clinical periodontology. 1998; 25(1):74-82.
(143) Ceulemans J, Vinckier I, Ludwig A. The use of Xanthan gum in an
ophthalmic liquid dosage form: Rheological characterization of the
interaction with mucin. Journal of Pharmaceutical Sciences. 2002;
91(4):1117-1127.
(144) Medicinescomplete. Structural unit of Xanthan gum. [homepage on
the Internet]. Medicinescomplete; 2009 cited 2009 September 20th].
Available from:
http://www.medicinescomplete.com/mc/excipients/current/images/ExcXant
hanGumC001.png.
(145) Chiellini E. Biomedical polymers and polymer therapeutics. :
Springer; 2001.
(146) INCHEM. Structural unit of HPMC. [homepage on the Internet].
INCHEM; 2009 cited 2009 September 20th]. Available from:
http://www.inchem.org/documents/jecfa/jecmono/40abcj15.gif.
(147) Bernkop-Schnurch A, Walker GF, Leitner VM. Thiolated Polymers:
Evidence for the Formation of Disulphide Bonds with Mucus Glycoproteins.
European Journal of Pharmaceutics and Biopharmaceutics. 2003;
56(2):207-214.
206
(148) Bernkop-Schnurch A, Kast CE, Richter MF. Improvement in the
mucoadhesive properties of alginate by the covalent attachment of cysteine.
Journal of Controlled Release. 2001; 71:277-285.
(149) Bernkop-Schnurch A, Clausen AE, Hnatyszyn M. Thiolated Poymers:
Synthesis and In Vitro Evaluation of Polymer-Cysteamine Conjugates.
International Journal of Pharmaceutics. 2001; 226:185-194.
(150) Bernkop-Schnurch A. Thiomers: A New Generation of Mucoadhesive
Polymers. Advanced Drug Delivery Reviews. 2005; 57(11):1569-1582.
(151) Singh S, Gajva B, Rawat M, Muthu MS. Enhanced transdermal
delivery of ketoprofen from bioadhesive gels. Pakistan Journal of
Pharmaceutical Science. 2009; 22(2):193-198.
(152) Bilensoy E, Rouf ME, Vural I, Sen M, Hincal AA. Mucoadhesive,
thermosensitive, prolonged-release vaginal gel for clotrimazole: b-
cyclodextrin complex. Pharmaceutical SciTech. 2006; 7(2):54-60.
(153) Thirawong N, Nunthanid J, Puttipipatkhachorn S, Sriamornsak P.
Mucoadhesive properties of various pectins on gastrointestinal mucosa: An
in vitro evaluation using texture analyser. European Journal of
Pharmaceutics and Biopharmaceutics. 2007; 67:132-140.
(154) Madsen EL, Hobson MA, Shi H, Varghese T, Frank GR. Tissue-
mimicking agar/gelatin materials for use in heterogeneous elastography
phantoms. Physics in Medicine and Biology. 2005; 50:5597-5618.
(155) Rossi S, Bonferoni MC, Lippoli G, Bertoni M, Ferrari F, Caramella C, et
al. Influence of mucin type on polymer-mucin rheological interactions.
Biomaterials. 1995; 16:1073-1079.
(156) Rossi S, Bonferoni MC, Lippoli G, Bertoni M, Ferrari F, Caramella C, et
al. A rheological approach. In: Mathiowitze E, Chickering DE, Lehr CM,
editors. Bioadhesive drug delivery systems: fundamentals, novel
approaches and development. First edition ed. New York: Taylor and Francis
(CRC Press); 1999. 3 p. 55-57.
(157) Wong CF, Yuen KH, Peh KK. An in-vitro method for buccal adhesion
studies: importance of instrument variables. International Journal of
Pharmaceutics. 1999; 180:47-57.
(158) Riley RG, Smart JD, Tsibouklis J, Dettmar PW, Hampson F, Davis JA
et al. An investigation of mucus/polymer rheological synergism using
synthesised and charactreised poly(acrylic acid)s. International Journal of
Pharmaceutics. 2001; 217:87-100.
(159) Stewart WC, Sharpe ED, Stewart JA, Hott EC. The safety and efficacy
of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%.
Current Eye Research. 2002; 24(5):387-391.
207
(160) Babbar SB, Jain R. Xanthan gum: An economical partial substitute for
agar in microbial culture media. Current Microbiology. 2006; 52(4):287-
292.
(161) Baudouin C, Labbe A, Hong L, Pauly A, Brignole-Baudouin F.
Preservatives in eye drops: The good, the bad and the ugly. Progress in
Retinal and Eye Research. 2010; :1-23.
(162) Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, et
al. Travoprost 0.004% with and without Benzalkonium chloride: A
comparison of safety and efficacy. Journal of Glaucoma. 2007; 16(1):98-
103.
(163) Marple B, Roland P, Benninger M. Safety review of benzalkonium
chloride used as a preservative in intranasal solutions: An overview of
conflicting data and opinions. Otolaryngology-Head and Neck Surgery.
2004; 130(1):131-141.
(164) Anumolu SS, Singh Y, Gao D, Stein S, Sinko PJ. Design and
evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for
sustained pharmacological response. Journal of Controlled Release. 2009;
137(2):152-159.
(165) Sliney DH. Physical factors in cataractogenesis: ambient ultraviolet
radiation and temperature. Investigative Ophthalmology & Visual Science.
1986; 27:781-790.
(166) Ooi EH, Ng EYK, Purslow C, Acharya R. Variations in the corneal
surface temperature with contact lens wear. Proceedings of the Institution
of Mechanical Engineers, Part H: Journal of Engineering in Medicine. 2007;
221(4):337-349.
(167) Peppas NA, Sahlin JJ. A simple equation for the description of solute
release. III. Coupling of diffusion and relaxation. International Journal of
Pharmaceutics. 1989; 57:169-172.
(168) Riddles PW, Blakeley RL, Zerner B. Ellman's Reagent: 5,5'-
Dithiobis(2-nitrobenzoic Acid)- a Reexamination. Analytical Biochemistry.
1979; 94:75-81.
(169) Thirawong N, Kennedy RA, Sriamornsak P. Viscometric study of
pectin-mucin interaction and its mucoadhesive bond strength. Carbohydrate
Polymers. 2008; 71:170-179.
(170) Hornof M. In Vitro and In Vivo Evaluation of Novel Polymeric
Excipients in the Ophthalmic Field. University of Vienna; 2003 [cited
11/09/2007] .
(171) Madsen F, Eberth K, Smart JD. A rheological examination of the
mucadhesive/mucus interaction: the effect of mucoadhesive type and
concentration. Journal of Controlled Release. 1998; 50:167-178.
208
(172) Qi H, Chen W, Huang C, Li L, Chen C, Li W, et al. Development of a
poloxamer analogs/carbopol-based in situ gelling and mucoadhesive
ophthalmic delivery system for puerarin. International Journal of
Pharmaceutics. 2007; 337:178-187.
(173) Uhart M, Pirot F, Boillon A, Senaux E, Tall L, Diouf E, et al.
Assessment of sodium hyaluronate gel as vehicle for intra camelar delivery
of cefuroxime in endophthalmitis prophylaxis. International Journal of
Pharmaceutics. 2010; in press.
(174) Tang I, Wong DM, Yee DJ, Harris MG. The pH of multi-purpose soft
contact lens solutions. Optometry and Vision Science. 1996; 73(12):746-
749.
(175) Dalton K, Subbaraman LN, Rogers R, Jones L. Physical properties of
soft contact lense solutions. Optometry and Vision Science. 2008; 85:122-
128.
(176) Carney LG, Fullard LG. Ocular irritation and environmental pH.
Australian Journal of Optometry. 1979; 62:335-336.
(177) Lee CH, Moturi V, Lee Y. Thixotropic property in pharmaceutical
formulations. Uncorrected proof ed. Elsevier; 2009.
(178) Oh MH, So JH, Yang SM. Rheological evidence for the silica-mediated
gelation of Xanthan gum. Journal of Colloid and Interface Science. 1999;
216(320):328.
(179) Garcia-Ochowa F, Santos VE, Gomez E. Xanthan gum: Production
recovery and properties. Biotechnology Advances. 2000; 18(7):549-579.
(180) Chen HH. Rheological properties of HPMC enhanced Surimi analysed
by small- and large-strain tests: 1. The effect of concentration and
temperature on HPMC flow properties. Food Hydrocolloids. 2007;
21(7):1201-1208.
(181) Wu H, Liu Z, Peng J, Li L, Li N, Li J, et al. Design and evaluation of
baicalin-containing in situ pH-triggered gelling system for sustained
ophthalmic drug delivery. International journal of pharmaceutics. 2011;
410(1-2):31-40.
(182) Thassu D, Deleers M, Pathak Y. Nanoparticulate drug delivery
systems. Illustrated Edition ed. New York, USA: CRC Press; 2007.
(183) Fitzgerald P, Hadgraft J, Kreuter J, Wilson CG. A γ-scintigraphic
evaluation of microparticulate ophthalmic delivery systems: liposomes and
nanoparticles. International journal of pharmaceutics. 1987; 40(1-2):81-84.
(184) de la Fuente M, Raviña M, Paolicelli P, Sanchez A, Seijo B, Alonso MJ.
Chitosan-based nanostructures: A delivery platform for ocular therapeutics.
Advanced Drug Delivery Reviews. 2010; 62(1):100-117.
209
(185) Park H, Robinson JR. Mechanisms of mucoadhesion of Poly(acrylic
acid) hydrogels. Pharmaceutical Research. 1987; 4(6):457-464.
(186) Salamat-Miller N, Chittchang M, Johnston TP. The use of
mucoadhesive polymers in buccal drug delivery. Advanced Drug Delivery
Reviews. 2005; 57(11):1666-1691.
(187) Dessanges JF. A History of Nebulization. Journal of Aerosol Medicine.
2001; 14(1):65-71.
(188) Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to
the lung. International Journal of Pharmaceutics. 1995; 124:149-164.
(189) Depreter F, Amighi K. Formulation and in vitro evaluation of highly
dispersive insulin dry powder formulations for lung administration. European
Journal of Pharmaceutics and Biopharmaceutics. 2010; 76(3):454-463.
(190) Fleming N. Diabetes fears as inhaled insulin discontinued. [homepage
on the Internet]. London: Telegraph; 2008 [updated 1/14; cited 2010
1/19]. Available from:
http://www.telegraph.co.uk/news/uknews/1575532/Diabetes-fears-as-
inhaled-insulin-discontinued.html.
(191) Home care provider. Relenza (zanamivir for inhalation) receives FDA
approval. Home care provider. 1999; 4(5):174-175.
(192) Mondal D. Zanamivir. In: S.J. Enna, David B. Bylund, editors.
xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier;
2007. p. 1-4.
(193) NICE. Clinical effectiveness and cost effectiveness of zanamivir
(Relenza): translating the evidence into clinical practice, a National Institute
for Clinical Excellence view. Philosophical Transactions of the Royal Society
of London.Series B: Biological Sciences. 2001; 356(1416):1899-1903.
(194) Ewan S. Is flu stronger, or are we weaker? Drug discovery today.
2004; 9(5):200-200.
(195) Anikster Y, Lacbawan F, Brantly M, Gochuico B, Avila NA, Travis W, et
al. Pulmonary Dysfunction in Adults With Nephropathic Cystinosis. Chest.
2001; 119:394-401.
(196) Von Wichert P, Seifart C. The Lung, an Organ for Absorption?
Respiration. 2005; 72:552-558.
(197) Lockhart SP. Inhaled thiol and phosphorothiol radioprotectors fail to
protect the mouse lung. Radiotherapy and Oncology. 1990; 19:187-191.
(198) Brain JD. Respiratory system. [homepage on the Internet]. USA:
Merck; 2006 cited 2010 1/19]. Available from:
http://www.merck.com/mmhe/sec04/ch038/ch038b.html.
210
(199) Pilcer G, Amighi K. Formulation strategy and use of excipients in
pulmonary drug delivery. International journal of pharmaceutics. 2010;
392(1-2):1-192.
(200) Attwood D, Florence AT. Physical Pharmacy. First ed. London, UK:
Pharmaceutical Press; 2008.
(201) Medic. Simulation of the human respiratory system. [homepage on
the Internet]. Revolizer; 2006 cited 2009 11/26]. Available from:
http://images.google.co.uk/imgres?imgurl=http://revolizer.com/in_img/fine
_particle.jpg&imgrefurl=http://revolizer.com/udd.htm&usg=__qxsYmkZgm
B-
cTYV3paErRB7stbI=&h=341&w=550&sz=28&hl=en&start=79&um=1&itbs=
1&tbnid=Pb425JI0pC48QM:&tbnh=82&tbnw=133&prev=/images%3Fq%3Dl
ung%2Bdrug%2Bparticle%26ndsp%3D20%26hl%3Den%26safe%3Dactive
%26sa%3DN%26start%3D60%26um%3D1.
(202) Patton JS, Fishburn CS, Weers JG. The Lungs as a Portal of Entry for
Systemic Drug Delivery. Proceedings of the American Thoracic Society.
2004; 1:338-344.
(203) Hein S, Bur M, Schaefer UF, Lehr C. A new Pharmaceutical Aerosol
Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug
absorption for metered dose dry powder formulations. European Journal of
Pharmaceutics and Biopharmaceutics. 2011; 77(1):132-138.
(204) Shoyele SA, Cawthorne S. Particle engineering techniques for inhaled
biopharmaceuticals. Advanced Drug Delivery Reviews. 2006; 58:1009-
1029.
(205) Dailey LA, Jekel N, Fink L, Gessler T, Schmehl T, Wittmar M, et al.
Investigation of the proinflammatory potential of biodegradable nanoparticle
drug delivery systems in the lung. Toxicology and Applied Pharmacology.
2006; 215:100-108.
(206) Widdicombe JH, Widdicombe JG. Regulation of human airway surface
liquid. Respiration Physiology. 1995; 99:3-12.
(207) Telko MJ, Hickey AJ. Dry Powder Inhaler Formulation. Respiratory
Care. 2005; 50(9):1209-1227.
(208) Ng AW, Bidani A, Heming TA. Innate host defence of the lung: Effects
of lung-lining fluid pH. Lung. 2004; 182:297-317.
(209) Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin
PG, et al. Estimation of volume of epithelial lining fluid recovered by lavage
using urea as marker of dilution. Journal of Applied Physiology. 1986;
60:532-538.
211
(210) Cook RO, Pannu RK, Kellaway IW. Novel sustained release
microspheres for pulmonary drug delivery. Journal of Controlled Release.
2005; 104:79-90.
(211) Lipworth BJ. Pharmacokinetics of inhaled drugs. British Journal of
Clinical Pharmacology. 1996; 42:697-705.
(212) Rohatagi S, Rhodes GR, Chaikin P. Absolute Oral Versus Inhaled
Bioavailability: Significance for Inhaled Drugs with Special Reference to
Inhaled Glucocorticoids. Journal of Clinical Pharmacology. 1999; 39:661-
663.
(213) Chougule MB, Padhi BK, Jinturkar KA, Misra A. Development of Dry
Powder Inhalers. Recent Patents on Drug Delivery and Formulation. 2007;
1:11-21.
(214) PharmQD. Spiriva Handihaler. [homepage on the Internet].
PharmQD; 2010 [updated 15/1; cited 2011 9/7]. Available from:
http://www.pharmqd.com/pharmacy-news/fda-updates-earlier-guidance-
respiratory-treatment-spiriva-handihaler.
(215) Zhou QT, Armstrong B, Larson I, Stewart PJ, Morton DAV.
Understanding the influence of powder flowability, fluidization and de-
agglomeration characteristics on the aerosolization of pharmaceutical model
powders. European Journal of Pharmaceutical Sciences. 2010; 40(5):412-
421.
(216) Nadarassan DK, Assi KH, Chrystyn H. Aerodynamic characteristics of
a dry powder inhaler at low inhalation flows using a mixing inlet with an
Anderson Cascade Impactor. European Journal of Pharmaceutical Sciences.
2010; .
(217) Al-Showair RAM, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all
patients with COPD use the correct inhalation flow with all inhalers and does
training help? Respiratory Medicine. 2007; 101:2395-2401.
(218) Harris D. Testing inhalers. [homepage on the Internet]. UK:
Pharmaceutical Technology Europe; 2007 [updated 30/9; cited 2010 5/6].
Available from:
http://www.camcon.co.uk/downloads/articles/PTE_Testing_Inhalers.pdf.
(219) Taki M, Marriott C, Zeng X, Martin GP. The production of
‘aerodynamically equivalent’ drug and excipient inhalable powders using a
novel fractionation technique. European Journal of Pharmaceutics and
Biopharmaceutics. 2011; 77(2):283-296.
(220) Rabbani NR, Seville PC. The influence of formulation components on
the aerolisation properties of spray-dried powders. Journal of Controlled
Release. 2005; 110:130-140.
212
(221) CHEC research centre. Research. [homepage on the Internet].
Denmark: Denmark Technical University; 2007 [updated 26/3/2007; cited
2011 7/7/11]. Available from:
http://www.chec.kt.dtu.dk/Research/Chemical%20Product%20Design/Parti
cle%20technology/Research.aspx.
(222) Bögelein J, Lee G. Cyclone selection influences protein damage during
drying in a mini spray-dryer. International journal of pharmaceutics. 2010;
401(1-2):68-71.
(223) Bain DF. Development and characterization of biodegradable
microspheres containing selected antimycobacterials. [PhD thesis on the
Internet]. Aberdeen: RGU; 1998 [cited 2010] .
(224) Kawakami K, Sumitani C, Yoshihashi Y, Yonemochi E, Terada K.
Investigation of the dynamic process during spray-drying to improve
aerodynamic performance of inhalation particles. International journal of
pharmaceutics. 2010; 390(2):250-259.
(225) Zhou QT, Qu L, Larson I, Stewart PJ, Morton DAV. Improving
aerosolization of drug powders by reducing powder intrinsic cohesion via a
mechanical dry coating approach. International journal of pharmaceutics.
2010; 394(1-2):50-59.
(226) Adi S, Tong Z, Chan HK, Yang R, Yu A. Impact angles as an
alternative way to improve aerolisation of powders for inhalation? European
Journal of Pharmaceutical Sciences. 2010; in press.
(227) Donovan MJ, Smyth HDC. Influence of size and surface roughness of
large lactose carrier particles in dry powder inhaler formulations.
International journal of pharmaceutics. 2010; 402(1-2):1-9.
(228) Watling CP, Elliott JA, Scruton C, Cameron RE. Surface modification of
lactose inhalation blends by moisture. International journal of
pharmaceutics. 2010; 391(1-2):29-37.
(229) Cline D, Dalby R. Predicting the quality of powders for inhalation from
surface energy and area. Pharmaceutical Research. 2002; 19(9):1274-
1277.
(230) Engelberg I, Kohn Joachim. Physico-mechanical properties of
degradable polymers used in medical applications: a comparitive study.
Biomaterials. 1991; 12(3):292-304.
(231) Zhou S, Song B, Li X. In vitro degradation and release profiles for
poly dl-lactide film containing paracetamol. Journal of Material Science.
2007; 18:1623-1626.
(232) Kim SY, Lee YM, Kang JS. Indomethacin-loaded methoxy
poly(ethylene glycol)/poly(D,L-lactide) amphiphilic diblock copolymeric
213
nanospheres: Pharmacokinetic and toxicity studies in rodents. Journal of
Biomedical Materials Research. 2005; 74(4):581-590.
(233) Kontio R, Suuronen R, Konttinen YT, Hallikainen C, Kommonen B,
Kellomaki M, et al. Orbital floor reconstruction with poly-L/D-lactide
implants: clinical, radiological and immunohistochemical study in sheep.
International Journal of Oral and Maxillofacial Surgery. 2004; 33:361-368.
(234) Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. Development of
copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar
carriers of paclitaxel. Colloids and Surfaces B: Biointerfaces. 1999; 16:161-
171.
(235) Gander B, Johansen P, Nam-Tran H, Merkle HP. Thermodynamic
approach to protein microencapsulation into poly(D,L-lactide) by spray
drying. International Journal of Pharmaceutics. 1996; 129:51-61.
(236) Zhang X, Jiang X, Hu J, Fu C. Rifampicin polylactic acid microspheres
for lung targeting. Journal of Microencapsulation. 2000; 17(6):785-788.
(237) Selek H, Sahin S, Ercan MT, Sargon M, Hincal AA, Kas HS.
Formulation and in vitro/in vivo evaluation of terbutaline sulphate
incorporated in PLGA (25/75) and L-PLA microspheres. Journal of
Microencapsulation. 2003; 20(2):261-271.
(238) Liu Y, Pan J, Feng S. Nanoparticles of lipid monolayer shell and
biodegradable polymer core for controlled release of paclitaxel: Effects of
surfactants on particles size, characteristics and in vitro performance.
International journal of pharmaceutics. 2010; 395(1-2):243-250.
(239) Yang M, Lai SK, Wang Y, Zhong W, Happe C, Zhang M, et al.
Biodegradable Nanoparticles Composed Entirely of Safe Materials that
Rapidly Penetrate Human Mucus. Angewandte Chemie International Edition.
2011; 50(11):2597-2600.
(240) Belbella A, Vauthier C, Fessi H, Devissaguet JP, Puisieux F. In vitro
degradation of nanospheres from poly(D,L-lactides) of different molecular
weights and polydispersities. International Journal of Pharmaceutics. 1996;
129:95-102.
(241) Ravelingien M, Mullens S, Luyten J, D’Hondt M, Boonen J, De
Spiegeleer B, et al. Vancomycin release from poly(d,l-lactic acid) spray-
coated hydroxyapatite fibers. European Journal of Pharmaceutics and
Biopharmaceutics. 2010; 76(3):366-370.
(242) Hammer A and Luciani F. Compendium of analytical procedures -
Anderson Cascade Impactor Test. Hertfordshire: GSK; 2005.
(243) Hammer A. Equipment used for the determination of the particle size
distribution by inertial impaction, excluding NGI - maintenence, calibration
and use, PD Global. Hertfodshire: GSK; 2007.
214
(244) Nichols SC. Andersen Cascade Impactor; calibration and mensuration
issues for the standard and modified impactor. Pharmeuropa. 2000;
12:598-602.
(245) Council of Europe. Preparations for inhalation: aerodynamic
assessment of fine particles. European Pharmacopoeia. Strasbourg, France:
European Pharmacopoeia Convention; 2003. p. 209-219.
(246) Podczeck F. Optimization of the operation conditions of an Anderson-
Cascade impactor and the releationship to centrifugal adhesion
measurements to aid the development of dry powder inhalations.
International Journal of Pharmaceutics. 1997; 149:51-61.
(247) Bain DF, Munday DL, Smith A. Solvent influence on spray-dried
biodegradable microspheres. Journal of Microencapsulation. 1999;
16(4):453-474.
(248) Naraharisetti PK, Lew MDN, Fu YC, Lee DJ, Wang CH. Gentamicin-
loaded discs and microspheres and their modifications: characterisation and
in vitro release. Journal of Controlled Release. 2005; 102:345-359.
(249) Wang FJ, Wang CH. Sustained release of etanidazole from spray dried
microspheres prepared by non-halogenated solvents. Journal of Controlled
Release. 2002; 81(3):263-280.
(250) Zeng XM, Martin GP, Tee SK, Ghoush AA, Marriott C. Effects of
particle size and adding sequence of fine lactose on the deposition of
salbutamol sulphate from a dry powder formulation. International Journal of
Pharmaceutics. 1999; 182:133-144.
(251) Lucas P, Anderson K, Staniforth JN. Protein Deposition from Dry
Powder Inhalers: Fine Particle Multiplets as Performance Modifiers.
Pharmaceutical Research. 1998; 15(4):562-569.
(252) Weda M, Zanen P, de Boer AH, Barends DM, Frijlink HW. An
investigation into the predictive value of cascade impactore results for side
effects of inhaled salbutamol. International Journal of Pharmaceutics. 2004;
287:79-87.
(253) Giunchedi P, Conte U. Spray-drying as a preparation method of
microparticle drug delivery systems: an overview. STP Pharma sciences.
1995; 5(4):276-290.
(254) Grandfils C, Flandroy P, Nihant N, Barbette S, Jerome R, Teyssie P, et
al. Preparation of poly (D,L) lactide microspheres by emulsion-solvent
evaporation, and their clinical applications as a convenient embolic material.
Journal of Biomedical Materials Research. 2004; 26(4):467-479.
(255) Conte U, Conte B, Giunchedi P, Maggi L. Spray dried polylactide
microsphere preparation: Influence of the technological parameters. Drug
Development and Industrial Pharmacy. 1994; 20(3):235-258.
215
(256) Migahed MD, Fahmy T. Structural relaxation around the glass
transition temperature in amorphous polymer blends: temperature and
composition dependence. Polymer. 1994; 35(8):1688-1693.
(257) Liu A, Wang X, Wang L, Wang H, Wang H. Prediction of dielectric
constants and glass transition temperatures of polymers by quantitative
structure property relationships. European Polymer Journal. 2007;
43(3):989-995.
(258) Selvam P, McNair D, Truman R, Smyth HDC. A novel dry powder
inhaler: Effect of device design on dispersion performance. International
journal of pharmaceutics. 2010; 401(1-2):1-6.
(259) Gahl WA. Early Oral Cysteamine Therapy for Nephropathic Cystinosis.
European Journal of Pediatrics. 162; 1:S38-S41.
(260) Min-Oo G, Fortin A, Poulin JF, Gros P. Cysteamine, the molecule used
to treat cystinosis, potentiates the anti-malarial efficacy of artemisinin.
Antimicrobial Agents and Chem. 2010; in press check name of j.
(261) Ambroz HB, Kornacka EM, Przybytniak GKGK. Influence of cysteamine
on the protection and repair of radiation-induced damage to DNA. Radiation
Physics and Chemistry. 2004; 70(6):677-686.
(262) Braun JEF, Sarquis F, Lafleur MVM, Retèl J. Effect of the sulfhydryl
compound cysteamine on gamma-radiation-induced mutations in double-
stranded M13 DNA. Mutation Research/DNA Repair. 1996; 364(3):171-182.
(263) Inoue M, Church CC, Brayman A, Miller MW, Malcuit MS. Confirmation
of the protective effect of cysteamine in in vitro ultrasound exposures.
Ultrasonics. 1989; 27(6):362-369.
(264) Douglas A, Hamlyn A, James O. Controlled Trial of Cysteamine in
Treatment of Acute Paracetamol (Acetomenophen) Poisoning. The Lancet.
1976; 307(7951):111-115.
(265) Prescott LF, Swainson CP, Forrest ARW, Newton RW, Wright N,
Matthew H. Successful Treatment of Severe Paracetamol Overdosage With
Cysteamine. The Lancet. 1974; 303(7858):588-592.
(266) Pae C, Lee C, Paik I. Therapeutic possibilities of cysteamine in the
treatment of schizophrenia. Medical hypotheses. 2007; 69(1):199-202.
(267) Wexler A. Stigma, history, and Huntigton's disease. The Lancet.
2010; 376(9734):18-19.
(268) Alzheimer's Association. Facts and Figures Factsheet. [homepage on
the Internet]. USA: Alzheimer's Association; 2011 [updated March 2011;
cited 2011 May 2011]. Available from:
http://www.alz.org/documents_custom/2011_Facts_Figures_Fact_Sheet.pdf
.
216
(269) Safety Officer in Physical Chemistry at Oxford University. Safety data
for cysteamine. [homepage on the Internet]. Oxford UK: Oxford University;
2006 [updated 11/9/06; cited 2011 8/7/11]. Available from:
http://msds.chem.ox.ac.uk/CY/cysteamine.html.
217
Appendix I
Phe conjugate synthesis
To a stirring solution of cystamine dihydrochloride (1g, 0.00444 moles) in
anhydrous dichloromethane (20 cm3) at room temperature, 1,8-
diazabicycloundec-7-ene (1.33 ml, 0.0089 moles) was added. The reaction
mixture was then stirred continuously for 60 minutes at room temperature.
To this was added butoxycarbonyl-L-phenylalanine N-hydroxysuccinimide
ester (3.22 g, 0.0089 moles). After thin layer chromatographic (TLC)
analysis confirmed that there were no starting materials left the solution
was then partitioned between dichloromethane (20 cm3) and water at room
temperature. The dichloromethane extracts were then washed with water
(3 x 50 cm3), dried with magnesium sulphate, filtered and evaporated to
near dryness. The solution was applied to a silica gel chromatography
column (4 x 30 cm3) prepared with dichloromethane. The column was
initially eluted with the same solvent until all front running impurities had
eluted (monitored by TLC). The eluent was then changed to
dichloromethane : methanol (9:1) and the major product was eluted, this
was monitored and confirmed by TLC analysis, UV visualisation at 254 nm.
The protected compound was dissolved in trifluoroacetic acid (5 cm3) at
room temperature. After 3.5 hours, the resulting solid was washed in
ethanol (3 x 20 cm3), and the trifluoroacetic acid and ethanol removed by
evaporation. Addition of diethyl ether gave an off a white precipitate that
was filtered and dried at 50°C. The solid was analysed by mass
spectroscopy.
Mass spectroscopy method
All analyses were undertaken using a 1200 Series Mass Spectrometer from
Agilent Technologies (Berkshire, UK). The small sample of crystal was
placed into a vial, and chloroform added. The vial was then sealed and
shaken. The sample was selected by the auto sampler and 10.00 µl was
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injected into the Mass Spectrometer. The liquid phase was composed of 5%
of 0.2% formic acid in methanol and 95% of 0.1% formic acid in water.
Found:
Mass spectroscopy: m/z 453.2 (m + 0) (100%), 447.1 (m – 6.1) (90%),
431.4 (m - 21.8) (75%), 469.1 (m + 15.9) (60%), 306.3 (m – 146.9)
(10%). M: C22H22N4S2O2; Exact Mass: 453.2.
NMR: All analyses were undertaken using a Bruker Topspin Ultrashield
400MHz (Massachusetts, USA). The 1HNMR spectrum (CD3OD) (400MHz)
had : 2.64 (d, CH2S, 4H); 3.1 (d, CH2, 2H); 3.39 (d, NCH2, 4H); 4 (m, ,
H); 7.35 (m, C6, 6H); 8.4 (m, NH3, 6H); 8.9 (m, NH, H).
Melting point: 164°C
Yield: 42%
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Appendix II
Table 37. A summary of the suppository batches made and their
characteristics.
Suppository
batch
Composition
(% w/w)
Hardness
without active;
observations
Hardness
including
active
(Phe conjugate)
Appearance
1 (C) PEG 1500 100% 30N, 3.06 kg 27N, 2.75 kg Opaque
2 Witepsol W35 100% 23N, 2.35 kg 20N, 2.04 kg Uniform white
3 Gelucire 39/01
100%
28N, 2.86 kg 26N, 2.65 kg Uniform white
4 PEG 1500 30%
PEG 8000 70%
Brittle
23N, 2.35 kg
- Mottled
5 PEG 8000 20%
PEG 600 80%
Very soft
15N, 1.53 kg
- Uniform white
6 PEG 14000 20%
PEG 600 80%
Extremely soft
12N, 1.22 kg
- Mottled white
7 PEG 600 30%
PEG 4000 70%
Brittle
28N, 2.86 kg
- Mottled
8 PEG 8000 60%
PEG 1500 40%
Slightly brittle
46N, 4.69 kg
- Mottled
9 Witepsol W35 98%
Tween 80 2%
Extremely hard
55N, 5.61 kg
- Uniform white
10 (B) PEG 14000 40%
PEG 600 60%
17N, 1.73 kg 13N, 1.33 kg Mottled white
11 PEG 8000 30%
PEG 600 70%
Firm, melts
easily
7N, 0.714 kg
- Mottled white
12 PEG 14000 30%
PEG 600 70%
Firm, melts
easily
- Mottled white
13 PEG 14000 25%
PEG 600 75%
Soft, melts easily - Mottled white
14 Poloxamer F68 3%
F127 97%
Extremely hard
30N, 3.06 kg
- White, air
bubbles
15 PEG 8000 39%
PEG 400 59%
Tween 80 1%
14N, 1.43 kg - Mottled white
16 PEG 6000 50%
PEG 1500 30%
PEG 400 20%
26N, 2.65 kg Firm
27N, 2.75 kg
Mottled white
17 (A) PEG 8000 40%
PEG 600 60%
19N, 1.94 kg 10N, 1.02 kg Uniform white
18 PEG 1000 100% Firm
319N, 32.54 kg
- Uniform white
19 PEG 1000 75%
PEG 4000 25%
Brittle
43N, 4.39 kg
- Mottled
20 PEG 1000 96%
PEG 4000 4%
72N, 7.34 kg - Uniform
opaque
white
21 PEG 1000 75%
PEG 3000 25%
Brittle
46N, 4.69 kg
- Mottled
22 PEG 1000 95 %
PEG 3000 5%
Brittle
46N, 4.69 kg
- Mottled
opaque
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Appendix III
Cysteamine bitartrate synthesis
Found:
NMR: The 1HNMR spectrum (MeOD) (400MHz) had : 2.79 (CH2S, 2H, t);
3.14 (CH2N, 2H, t); 4.42 (CHbitar, 2H, S)
Melting point: 94°C
Yield: 67%
Cystagon™ analysis
Found:
NMR: The 1HNMR spectrum (MeOD) (400MHz) had : 2.79 (CH2S, 2H, t);
3.14 (CH2N, 2H, t); 4.42 (CHbitar, 2H, S)
Melting point: 95°C (269)
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